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A critical event in apoptosis is the release of intermembrane space proteins from 
mitochondria following mitochondrial outer membrane (MOM) permeabilization 
(MOMP).  The Bcl-2 family of proteins regulates MOM integrity and includes pro- and 
anti-apoptotic members, like Bax and Bcl-xL respectively.  Preceding MOMP, the MOM 
becomes enriched with the sphingolipid, ceramide, which can self-assemble to form 
ceramide channels, contributing to MOMP.  
 Bax and ceramide channels were found to act synergistically in the generation of 
MOMP and a direct interaction between these was observed in phospholipid membranes.  
The apparent affinity of activated Bax for ceramide channels increases with ceramide 
channel size, consistent with an induced fit mechanism; Bax drives the enlargement of 
ceramide channels to an optimum fit for the Bax binding site.  A ceramide channel 
specific inhibitor prevented the enhanced MOMP in the presence of Bax and ceramide 
indicating ceramide channels were the primary permeabilizing entity. 
	  
	  
 Analogs with changes to all the major structural features of ceramide were used to 
assess the molecular basis of stability of ceramide channels.  Methylation of the C1-
hydroxy group abrogated channel formation in mitochondria.  Methylation of the amide 
nitrogen or a change in chirality at C2, which influences the C1-hydroxy group 
orientation, greatly reduced channel-forming ability whereas other changes were well 
tolerated.  Competition experiments between ceramide and analogs resulted in synergism 
or antagonism, depending on compatibility of the analog structure with the ceramide 
channel model.  The results provide evidence for ceramide channels being highly 
organized structures, stabilized by specific inter-molecular interactions.  
 Analogs that retained channel-forming ability were used to assess the structural 
features of ceramide channels required for regulation by Bcl-2 family proteins.  The 
stereochemistry of the ceramide head group and access to the amide nitrogen is 
indispensible for regulation by Bax, implicating the polar portion of the channel as the 
Bax binding site. Bcl-xL’s ability to disassemble ceramide channels depends on the 
length of the hydrophobic chains of ceramide. Specific Bcl-xL inhibitors reveal that Bcl-
xL binds ceramide channels through its hydrophobic groove and this is supported by 
simulated docking.  The opposite effects of pro-and anti-apoptotic proteins are achieved 
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 This dissertation presents my research on ceramide channels and the important 
role they play in mitochondrial outer membrane permeabilization during apoptosis. Dr. 
Marco Colombini discovered ceramide channels just before the turn of the 21st century. 
When I joined his lab, I was presented with the opportunity to expand upon the 
foundational work conducted on ceramide channels by Dr. Leah Siskind and other former 
students. Thus, my quest for the past 5 years has been to understand the mechanisms 
behind the regulation of ceramide channels. What I discovered was that the molecular 
control of these novel lipid channels stems not only from the molecular identity of the 
molecules that comprise the channel, but from the interaction of the channel with specific 
protein modulators.  
 Chapter one is a general introduction, which begins by describing the process of 
apoptosis and its dependence on mitochondrial outer membrane permeabilization 
(MOMP). Also described are the Bcl-2 family of proteins, which regulate MOMP, and 
the research conducted on ceramide channels thus far.  
 Chapter two is a compilation of the major techniques and research tools used to 
accomplish this work. Provided for each method is a conceptual overview and detailed 
description of the specific conditions used with each technique.   
 The specific structural components of ceramide that contribute to channel 
formation and stability were explored in chapter 3. Ceramide analogs were provided by 
our collaborators: Dr. Leah Siskind, Dr. Alicja Bielawska, Dr. Zdzislaw Szulc from the 
Medical University of South Carolina and Dr. Robert Bittman from Queens College in 
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New York. This work was completed in collaboration with Vidyaramanan Ganesan and 
we discovered that some structural components of the ceramide channel are indispensible 
for channel formation while changes to other regions of the molecule were well tolerated. 
Combination experiments between natural ceramide and analogs reinforced previous data 
in support of ceramide channels being highly rigid and ordered structures; ceramide 
channels can be destabilized by the introduction of incompatible monomers, can tolerate 
compatible monomers and can be enhanced by the introduction of monomers that 
promote stability. This work was published in journal Biochimica et Biophysica Acta in 
2012. This project demonstrates an additional layer of ceramide channel regulation: the 
cell has enzymes that generate the specific ceramide monomers that have the propensity 
for channel formation.  
In chapter 4, the interaction of Bax and ceramide channels was explored. We 
discovered that Bax and ceramide together could induce a synergistic enhancement of 
MOMP. Further study revealed that the enhanced permeabilization was due to a direct 
interaction between ceramide and Bax that did not require other mitochondrial proteins or 
specialized lipids. The data is consistent with an induced fit mechanism: the binding of 
Bax to a ceramide channel induces the enlargement of the channel so that the binding site 
of Bax has an optimal fit. Vidyaramanan Ganesan and I worked together on this project, 
which was published in the journal Apoptosis in 2010.  
 Chapter 5 grew from my interest to understanding how two proteins of the same 
family, Bax and Bcl-xL, can have opposite regulatory effects on the same channel; Bax 
enhances ceramide channels and Bcl-xL disassembles them. Using the analogs that retain 
channel formation, I discovered that Bax binds the polar region of the channel while Bcl-
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xL binding is dependent on the hydrophobic region of the channel embedded within the 
phospholipid membrane. Using known inhibitors of Bcl-xL that bind to the hydrophobic 
groove of Bcl-xL, I discovered that Bcl-xL binds the ceramide channel through its 
hydrophobic groove. Dr. Yuri K. Peterson ran molecular docking simulations that 
revealed possible binding modes of ceramide to the hydrophobic groove of Bcl-xL. This 
work culminated in a publication in the Biochemical Journal in 2012.  
 In the final chapter, a brief discussion including ideas on the direction of future 
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Apoptosis is a form of programmed cell death that is vital to the survival of 
multicellular organisms. It is a beneficial process by which unwanted cells are eliminated 
for the greater good of the organism. Apoptosis is found to occur naturally in all stages of 
life, from embryonic development, where the digits of the hands and feet are sculpted to 
remove webbing, to adult tissue homeostasis, where cell death offsets mitosis to maintain 
a constant amount of cells. Importantly, this process of “cell suicide” is also initiated to 
prevent the perpetuation of a defective cell when that cell senses it is irreparably 
damaged. Such deleterious change can originate from within the cell, in the form of DNA 
damage resulting from mutations, aging, overproduction of reactive oxygen species 
(ROS), or exposure to cytotoxic agents and harmful conditions, e.g. toxins, viral 
pathogens, chemicals, UV light, heat-shock, ischemia and others. Thus, apoptosis is a 
process that is vital to the survival of an organism; however, it is potentially lethal if not 
scrupulously regulated. Indeed, alterations to the apoptotic machinery causing a shift in 
balance of when apoptosis is appropriate, leading to either too much or too little 
apoptosis, often result in pathogenesis.  Autoimmune diseases, and cancers are examples 
of the kinds of diseases that result when a cell is rendered unable to initiate or execute 
apoptosis, leading to uncontrolled proliferation and accumulation of unwanted cells. 
However, when excessive apoptosis ensues, following only mild stimuli, it can lead to the 
elimination of cells that are necessary for the health and survival of an organism. 
Neurodegenerative diseases, like Alzheimer’s disease and Parkinson’s disease, and 
inflammatory diseases like multiple sclerosis and ischemic injury (i.e. stroke or heart 
attack), are a few examples of when cell death is undesirable and can have dire 
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consequences. Therefore, the study of apoptosis and how it is regulated is fundamental to 
understanding the development of a myriad of diseases and finding their cure. 
1.1.1 Morphological and Biochemical Characteristics of Apoptotic Cells.  
When a cell chooses to undergo apoptosis, a series of events are “programmed” to 
be executed in an active (energy requiring) and controlled manner: the cell expends 
energy to ensure cellular contents are systematically degraded and carefully packaged so 
they may phagocytosed and eliminated without contaminating the extracellular space. 
Apoptosis is distinguished from other forms of cell death by specific morphological and 
biochemical changes. Kerr and associates described the distinct morphological changes 
that take place in apoptotic cells using electron microscopy (EM) (Kerr et al., 1972).  
These morphological changes (DNA fragmentation, chromatin condensation, plasma 
membrane (PM) blebbing, phosphatidylserine externalization to the outer leaflet of the 
PM, cytoplasmic condensation, and the packaging of cellular contents into apoptotic 
bodies) are now considered to be indicative of the late stages of apoptosis. Interestingly, 
organelles of apoptotic cells such as mitochondria and lysosomes retain their normal 
ultrastructure with minimal to no swelling (Kerr et al., 1972) and the integrity of the 
plasma membrane is maintained.  The resulting apoptotic bodies are neatly engulfed by 
macrophages or proximal cells, which then degrade and recycle the ingested contents. As 
an active process, functional mitochondria are required to maintain ATP levels, and 
consequently mitochondrial transmembrane potential, until late apoptosis. Depending on 
the apoptotic stimulus, the mitochondrial outer membrane may be permeabilized, leading 




When traumatic injury to a cell results in the loss of ATP synthesis and the 
method of cell death is “passive” or energy-independent, termed oncosis (Majno & Joris, 
1995), this will result in a necrotic morphology, termed primary necrosis. It is important 
to note that apoptosis typically confers an advantage to an organism and affects only a 
single cell or small group of cells. On the contrary, necrosis does not confer an advantage 
and is characteristic of large-scale damage to cells and tissues in a particular area as in the 
case of gangrene. Morphologically, necrosis is characterized by swelling of the cell and 
its organelles and the loss of membrane integrity (Searle et al., 1982). Permeabilization of 
the mitochondrial inner membrane (MIM) leads to the loss of the transmembrane 
potential required for the generation of ATP; and mitochondrial swelling can lead to the 
rupture of the mitochondrial outer membrane (MOM), leading to caspase activation. Loss 
of lysosomal membrane integrity results in the release of harmful enzymes into the 
cytoplasm and nuclear membrane disintegration can lead to the breakdown of DNA and 
RNA. Ultimately the cell contents are spilled into its surroundings initiating an 
inflammatory response.  
There is evidence in some cases of a shift between an apoptotic cell fate and one 
that results in necrosis, which occurs when the apoptotic program cannot be completed as 
designed. This case is termed secondary necrosis. For instance, if a cell receives an  
apoptotic stimulus that causes the MIM to be compromised, the apoptotic program can be 
completed so long as a sufficient number of mitochondria can generate the ATP needed 
(Krysko et al., 2001). However, if the MIM becomes permeabilized at some point in this 
process, upstream or downstream of MOM permeabilization, and ATP synthesis is lost, 
the cell will switch to a passive means of cell death and progress to a necrotic 
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morphology (Searle et al., 1982; Leist et al., 1997). Another instance where secondary 
necrosis may result is if the phagocytes do not reach the apoptotic bodies in sufficient 
time to clear them, leading to an inflammatory response. Evidently, apoptotic bodies 
cannot remain intact indefinitely as clearance must occur within a given time frame 
(Silva et al., 2008). Nevertheless, M.T. Silva has suggested that secondary necrosis 
should be understood as a possible outcome of a completed apoptotic regimen, rather 
than the result of a failed immune response or a “fall-back” plan (Silva, 2010).  
1.1.2 Extrinsic vs. Intrinsic Apoptosis 
 A cell can undergo apoptosis by two primary mechanisms: extrinsic or intrinsic 
apoptosis. These pathways are defined by the origin of the signals leading to apoptotic 
initiation.  In extrinsic apoptosis, the signal originates outside of the cell and leads to the 
ligation of death receptors of the Tumor Necrosis Factor (TNF) family, like TNF-α and 
CD95, on the PM (Lavrik & Krammer, 2009).  The ligation of these death receptors leads 
to the recruitment of intracellular components to form the Death-Inducing Signaling 
Complex (DISC), which results in the activation of caspase-8. Cells are classified as type 
1 if caspase-8 then directly initiates the effector caspases- 3, -6, and -7 leading to the 
execution phase of apoptosis. If caspase-8 leads to apoptosis through the engagement of 
mitochondria, the cells are classified as type II. In this instance, caspase-8 cleaves a pro-
apoptotic activator protein Bid to its active form, which will lead to the accumulation of 
pro-apoptotic lipids and proteins on the MOM to cause MOMP and intermembrane space 
(IMS) protein release and subsequent effector caspase activation (Krammer et al., 2007; 
Kroemer et al., 2007). In the intrinsic pathway of apoptosis, the signal to initiate the 
apoptotic process comes from within the cell. Typically, when cellular or DNA damage is 
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detected, the levels of p53, a tumor suppressor protein and a transcription factor, become 
elevated within the cell (Kroemer et al., 2007). p53 induces cell cycle arrest until DNA 
can be repaired. If the DNA damage is too severe to be repaired, activated p53 will lead 
to the upregulation of a number of pro-apoptotic proteins, namely of the Bcl-2 family of 
proteins (Hemann & Lowe, 2006) and can in some cases cause an increase in the bio-
active sphingolipid ceramide (Heffernan-Stroud & Obeid, 2011).   The activation of the 
pro-apoptotic members of the Bcl-2 family and neutralization of anti-apoptotic Bcl-2 
family of proteins will prime the MOM for the release of key intermembrane proteins like 
cytochrome c (Liu et al., 1996). Once in the cytosol, cytochrome c along with apoptotic 
protease activating factor 1 (APAF-1) and procaspase-9 form what is collectively called 
the apoptosome, resulting in cleavage and activation of caspase 9 which activates the 
downstream effector caspases-3, -6, and -7 (Li et al., 1997b). Effector caspase activation 
will lead to the execution of apoptosis and the hallmark morphological changes 
associated with it. In apoptosis, MIM permeability transition typically occurs downstream 
of caspase activation, and leads to mitochondrial inner membrane swelling and the 
eventual rupture of the MOM.    
 
1.2 MITOCHONDRIA-MEDIATED APOPTOSIS 
 Mitochondria, while most famous for being the powerhouse of the cell, are also a 
key mediator of apoptosis, and several modes of apoptotic regulation converge at the 
mitochondrial interface. This is because mitochondrial outer membrane permeabilization 
to IMS proteins, especially cytochrome c, can commit a cell to undergo apoptosis and is 
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essentially the point of no return (Liu et al., 1996).  For example, if cells are deprived of 
growth factor, cytochrome c and other proteins will be released from the IMS of 
mitochondria to the cytosol and the cell will be irreversibly committed to the execution 
phase of apoptosis. However, if growth factor is restored before MOMP occurs, 
cytochrome c will not be released and the cell will survive (Vander Heiden et al., 1999). 
Although a number of apoptosis-relevant proteins are released from mitochondria, only 
release of cytochrome c is required to initiate downstream caspase activation and 
microinjection of even small amounts of cytochrome c into normal cells can induce 
apoptosis (Zhivotovsky et al., 1998). The other apoptosis-relevant IMS proteins released 
includes: apoptosis inducing factor (AIF), endonuclease-G (Endo-G), second 
mitochondria-derived activator of caspase/direct inhibitor of apoptosis binding protein 
with a low pI (Smac/DIABLO), and Omi/high temperature requirement protein A2 
(Omi/HtrA2) (Kroemer et al., 2007). AIF and Endo-G can directly promote DNA 
fragmentation and chromatin condensation. Smac/DIABLO and Omi/HtrA2 promote cell 
death indirectly by countering the survival efforts of the family of inhibitor of apoptosis 
proteins (IAP), which prevent effector caspase activation (Kroemer et al., 2007).   
1.2.1 Characteristics of Mitochondrial Outer Membrane Permeability 
From the time a cell is exposed to a cytotoxic agent or stress, the cell begins 
preparations to decide its own fate. When the cell is not salvageable, the decision to 
proceed with the organized breakdown of the cell is characterized by the increase in 
permeability of the mitochondrial outer membrane to IMS proteins. The increase in 
permeability of the MOM has been demonstrated to be a highly coordinated and fast 
event with most of the mitochondria in a cell releasing their cytochrome c within 5-10 
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minutes (Martinou et al., 2000). However, there is evidence that suggests that there is 
some heterogeneity of mitochondria within cells (D'Herde et al., 2000); while most 
mitochondria do become permeabilized, a small population of normal mitochondria can 
retain their cytochrome c. Taken together, this suggests that for apoptosis to progress to 
the execution phase, sufficient cytochrome c release must occur in order to have enough 
effector caspase activation. Some factors that might affect this threshold are cell type, the 
nature of the mutations the cell has incurred, and how primed the mitochondria are in 
these cells to allow for IMS protein release. The MOMP inducing entity must be non-
selective because a variety of proteins are released concomitantly with cytochrome c 
(Munoz-Pinedo et al., 2006). In fact, cytochrome c represents the lowest molecular 
weight cutoff for a pro-apoptotic mitochondria pore as other IMS proteins known to exit 
mitochondria are much larger i.e. Adenylate Kinase 2 (AK2, 140kDa) (Kohler et al., 
1999) and other complexes, like EndoG (66 kDa dimer) (Cote & Ruizcarrillo, 1993).  
Moreover, evidence suggests that the pore must be stable enough to remain open for long 
periods of time post cytochrome c release as proteins like AIF, a mitochondrial inner 
membrane protein, require processing before it can be released (Munoz-Pinedo et al., 
2006).  
 
1.3 REGULATION OF MITOCHONDRIAL OUTER MEMBRANE 
PERMEABILIZATION: THE BCL-2 FAMILY OF PROTEINS 
 A highly studied family of proteins called the Bcl-2 family proteins regulates 
MOMP. Bcl-2 family proteins are all nuclear encoded and can be categorized into two 
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functional categories: pro-apoptotic and anti-apoptotic. Based on sequence homology, 
anti-apoptotic members contain up to four Bcl-2 homology domains (BH1234) and pro-
apoptotic members contain up to three Bcl-2 homology domains (BH123). A sub class of 
pro-apoptotic members contains only the BH3 domain (BH3) and typically function to 
activate the pro-apoptotic Bcl-2 family members or neutralize anti-apoptotic Bcl-2 
members. Some prototypical members of the anti-apoptotic side of the family tree 
include of Bcl-2, Bcl-xL, BFL/A1, Bcl-w, and Mcl-1. Pro-apoptotic multi-domain 
proteins include Bax, Bak and Bok and some of the BH3 only members include Bid, 
Bim, Bad, Puma, Noxa and Bik.  A major way by which Bcl-2 family proteins are 
thought to regulate apoptosis is by antagonizing the actions of members with opposing 
functions at the mitochondrial interface (Leber et al., 2010). The BH3 domain, which is 
shared by all Bcl-2 family proteins, facilitates the direct antagonism between the pro- and 
anti-apoptotic proteins.  
In normal cells both pro- and anti-apoptotic Bcl-2 family proteins have been 
found to occupy a variety of sub-cellular locations. Mitochondria of normal cells contain 
Bak, which is held in its inactive conformation by interactions with the Voltage Gated 
Anion Channel isoform 2 (VDAC2) (Cheng et al., 2003; Lazarou et al., 2010), along with 
anti-apoptotic proteins Bcl-2, Bcl-xL and Mcl-1 (Boise et al., 1993; Mikhailov et al., 
2001; Andersen & Kornbluth, 2012). While Bak and Bcl-2 are constitutively localized to 
mitochondria, Bcl-xL and Mcl-1 reserves reside in the cytosol, and are held inactive with 
neutralizing BH3 only proteins (Yao et al., 2009). Bax and Bid are cytosolic proteins and 




Upon applying an apoptotic stimulus, a number of changes in sub-cellular 
location, conformation, and expression of Bcl-2 proteins take place. Bid is cleaved by 
caspase 8 to yield the active 15kDa fragment, tBid, which disassociates from its inactive 
fragment upon binding to the mitochondrial membrane (Billen et al., 2008; Lovell et al., 
2008). tBid and Bim can activate Bax in the cytosol, causing a conformational change 
that exposes the hydrophobic interior of Bax, which allows its translocation to the MOM 
(Zhou et al., 2006; Renault & Manon, 2011).  At the MOM, tBid facilitates the insertion 
of Bax into the MOM and promotes the oligomerization of activated Bax with other Bax 
and/or Bak molecules (Annis et al., 2005; Zhang et al., 2010). Activated Bax itself can 
also activate and oligomerize with other Bax molecules without tBid (Tan et al., 2006).  
tBid also activates Bak to dissociate from VDAC2. The increase of active pro-apoptotic 
Bcl-2 family proteins in the MOM are prevented from causing MOMP by a concomitant 
translocation of their anti-apoptotic counterparts, Bcl-xL and Mcl-1. The pro- and anti- 
apoptotic proteins heterodimerize in the MOM, antagonizing and effectively neutralizing 
each other until the cell has decided whether the damage inflicted can be reversed. If the 
damage can be fixed, an increase in expression of the anti-apoptotic proteins will 
overcome the increased concentration of pro-apoptotic proteins in the MOM and MOMP 
is prevented. If the extent of damage is too severe, the cell will signal the increase in 
expression and activation of pro-apoptotic Bcl-2 members. The BH3 only protein Bad 
will neutralize Bcl-xL, Bcl-2 and Mcl-1 by binding to hydrophobic groove of these 
proteins.  Once the anti-apoptotic proteins are neutralized and outnumbered by the pro-
apoptotic proteins, the mitochondrial outer membrane will become permeabilized to IMS 
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proteins, and the execution phase of apoptosis will commence.  Thus, it is the sensitive 
balance of anti-and pro-apoptotic proteins that hold the key to life and death of the cell.  
1.3.1 Bax Channels  
The true nature of the entity responsible for MOMP remains unknown and is the 
topic of much debate. However, the major paradigm implicates channels composed of 
Bax homooligomers or heterooligomers of Bax and Bak as responsible for IMS protein 
release during apoptosis. The finding that Bax can form channels grew from studies that 
described structural similarities of Bcl-xL to the pore forming domains of diphtheria 
toxin and bacterial toxins called colicins A1 and E1 (Muchmore et al., 1996) and the 
discovery that Bcl-xL could form ion channels in synthetic membranes (Minn et al., 
1997). The membrane active structure of Bax is currently unknown and a number of 
conformational changes are known to precede membrane association, oligomerization 
and channel formation. The N-terminus of the protein, containing α-helix 1, contains the 
mitochondrial targeting sequence termed the Apoptotic Regulation of Targeting domain 
(Goping et al., 1998). The C-terminal α-helix 9 has also been shown to play a role in 
mitochondrial targeting (Nechushtan et al., 1999). α-helixes 5 and 6 form the 
hydrophobic groove of the protein and are flanked by the other 7 helices (Suzuki et al., 
2000). The C-terminal α- helix 9 sits within the hydrophobic groove, stabilizing the 
protein in its inactive form. The N-terminal face of Bax contains a binding site for 
activating BH3 only proteins and this site is opposite to the BH3-groove. When an 
activating BH3- only protein binds Bax, the Apototic Regulation of Targeting Domain 
undergoes a shift and this is sufficient to target the protein to the MOM (Goping et al., 
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1998) as well as expose the Bax BH3 domain found on α-helix 2 (Gavathiotis et al., 
2010). Binding of tBid also causes a conformational change at α-helix 9 which now 
moves to expose the hydrophobic groove of Bax. Exposure of this hydrophobic groove 
activates Bax and leads to membrane insertion. Active membrane bound Bax can activate 
other Bax molecules as well (Tan et al., 2006). Further conformational changes in the 
membrane occur leading to oligomerization and/or channel formation. It is known that α-
helices 5, 6 and 9 are transmembrane domains and α-helix 5 and 6 form the lumen of the 
channel (Heimlich et al., 2004).    
Bax mediated membrane permeabilization has been shown to display a number of 
different properties and it is quite possible that Bax channels are not entirely 
proteinaceous in nature. For example, Bax can form small ion channels that are 
impermeable to cytochrome c when activated by tBid (Schlesinger et al., 1997; Roucou et 
al., 2002); oligomeric Bax can also form large supra-molecular openings in liposomes 
(Kuwana et al., 2002) capable of releasing dextrans of up to 2 MDa in size; Bax and/or 
Bak oligomers can form Mitochondrial Apoptosis Inducing (MAC) channels which are 
voltage independent and just large enough to release cytochrome c (Martinez-Caballero 
et al., 2009); and Bax peptides corresponding to α-helices 5 and 6 can induce proteo-
lipidic toriodal pores with similar properties to full-length Bax (Garcia-Saez et al., 2005; 
Garcia-Saez et al., 2006). Recent findings have indicated that Bax can form two types of 
channels: one that is small and one that is large. The small channels are of a uniform size, 
cytochrome c impermeable, and voltage dependent; while the large channels are protein 
permeable and voltage independent with a variable size (Lin et al., 2011).  
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With such a wide range of properties described for Bax channels, the lack of 
uniformity of these studies suggest that Bax channel properties are affected by cell-type, 
apoptotic stimuli, intrinsic membrane curvature, and the method by which Bax is 
activated. Although there is even some controversy of whether activated Bax is even an 
oligomer (Ivashyna et al., 2009), the current opinion in the field of apoptosis suggests 
that oligomeric Bax channels are responsible for cytochrome c release and the induction 
of apoptosis. The study by Lin and associates would suggest that both small and large 
Bax channels could exist, with an as yet unknown molecular component being 
responsible for switching between the two when IMS protein release is signaled (Lin et 
al., 2011).  
 
1.4 THE ROLE OF CERAMIDE IN APOPTOSIS 
 Ceramide is a bioactive sphingolipid that has been implicated in many different 
biological processes such as cell signaling, cell senescence, and cell differentiation. 
Importantly, many studies have implicated ceramide as a pro-apoptotic and anti-
proliferative lipid, earning it the nickname “the tumor suppressor lipid” (Fig 1.1).  
 
Figure 1.1 The Structure of Ceramide.  
Natural long-chain ceramide is shown here with a fatty acyl chain length of 16 carbons. Other 
naturally occurring ceramide species vary in fatty acyl chain length from 12 to 24 carbons 
whereas synthetic ceramides can range between two ten carbons. 
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A variety of apoptotic stimuli can lead to an increase in intracellular ceramide 
levels, including TNF-α, etoposide, endotoxin, staurosporine, ionizing irradiation, and 
UV irradiation. Ceramide generation can occur either upstream or downstream p53 
activation or independently of p53 activation (Heffernan-Stroud & Obeid, 2011). 
Stimulating ceramide generation can promote cell death whereas inhibiting ceramide 
generation or metabolizing ceramide to other non-threatening species can delay or 
prevent cell death (Mullen & Obeid, 2012). Thus, it has been demonstrated that cell death 
can be mediated by controlling ceramide levels (Lucci et al., 1999a; Itoh et al., 2003; Liu 
et al., 2004; Reynolds et al., 2004). It has been found in a number of different cells lines 
that a cellular sensitivity to number of chemotherapeutic agents is mediated by the ability 
to elevate ceramide, including gemcitabine, circumin and doxorubicin (Lavie et al., 1997; 
Lucci et al., 1999b; Reynolds et al., 2004; Dumitru et al., 2009). Thus, importance of 
ceramide in apoptosis is widely acknowledged and understanding its role in apoptosis is 
vital to understanding and preventing disease (Siskind, 2005; Carpinteiro et al., 2008; 
Mullen & Obeid, 2012).  
1.4.1 Ceramide Metabolism 
 Sphingolipid metabolism involves a multitude of enzymes with unique functions 
and several metabolites found in a number of sub cellular compartments. New enzymes 
continue to be discovered as more studies are undertaken to better understand this 
intricate metabolic scheme (Mullen & Obeid, 2012).  With such a complex system, there 
is much overlap between ceramide generating pathways, which allows both functional 
redundancy as well as many opportunities for the system to go awry, making the precise 
control of ceramide levels in in vivo quite difficult to study. The effectiveness of specific 
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pharmacological inhibitors of ceramide synthesis, or other sphingolipids, is often 
curtailed as the product of interest can often be generated by other means. Despite this 
level of complexity, upon an apoptotic stimulus, the cell manages to elevate ceramide 
levels, specifically in mitochondria, with the exact stereochemistry, extent of unsaturation 
and hydrocarbon chain length required for apoptotic control. Clearly this is a highly 
controlled and deliberate mechanism of apoptotic control in cells. 
Two main pathways could generate the ceramide accumulated in mitochondria 
under apoptotic stress: the de novo pathway and the salvage pathway (Fig 1.2). De novo 
synthesis occurs in the endoplasmic reticulum (ER) (Hanada et al., 2003; Lahiri & 
Futerman, 2005). The salvage pathway leads to the generation of ceramide from other 
lipid species including the conversion of sphingomyelin, by sphingomyelinases, 
sphingosine, by ceramide synthase, and glycosphingolipids, like glucosylceramide, by 
glycosidases, like glucocerebrosidase (Mullen & Obeid, 2012). 
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Figure 1.2 Major Pathways Involved in the Metabolism of the Sphingolipid Ceramide 
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1.4.2 Modulation of Ceramide Metabolism: Balancing Cell Death and Immortality 
Modulating ceramide generation reveals the importance of ceramide in cell death 
and how lack of ceramide can contribute to the immortality of cancer cells. The majority 
of sphingolipid metabolism occurs outside of the mitochondria, in the ER, Golgi 
apparatus, and lysosomal, nuclear and plasma membranes. However, Birbes and 
associates found that only targeting sphingomyelinase to mitochondria resulted in 
apoptosis (Birbes et al., 2001; Birbes et al., 2005). Thus, while the mechanism of 
ceramide formation in mitochondria during apoptosis is incomplete, mitochondrial 
ceramide must play a key role in mitochondria-mediated apoptosis. There is now 
evidence that mitochondria possess the enzymes necessary to generate ceramide 
(Shimeno et al., 1998; Wu et al., 2010) and ceramide can be rapidly transferred to 
mitochondria from mitochondrial associated membranes (MAMs) (Stiban et al., 2008) 
and from the plasma membrane (Babiychuk et al., 2011). Exogenously added ceramide 
can also induce cell death in cells (Obeid et al., 1993; Cifone et al., 1994; Jarvis et al., 
1994; Quintans et al., 1994; Flowers et al., 2012). A study by Yang and associates 
demonstrated that if sphingomyelin synthase 1, which generates sphingomyelin and 
diacylglycerol from ceramide and phosphatidylcholine, were expressed in yeast, these 
cells showed an increased resistance to cell death induced by ceramide treatment (Yang 
et al., 2006). Multiple studies by M.C. Cabot and others have demonstrated that 
glucosylceramide synthase overexpression, and subsequent increase in the level of 
glucosylceramide is a main contributor to the development of multidrug resistance in 
cancer cells and inhibition of the glycosylation can re-sensitize cells to chemotherapeutic 
drugs (Komori et al., 1999; Liu et al., 1999; Lucci et al., 1999a; Liu et al., 2001; 
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Kohyama-Koganeya et al., 2004; Patwardhan et al., 2009). Another study found that 
inhibition of ceramide glycosylation can also re-instate p53 dependant apoptosis in p53 
mutant cells (Liu et al., 2011). Thus, if the ceramide generating enzymes are increased in 
a cell, then cell death can be promoted; if ceramide consuming enzymes are increased, 
then cell death is prevented (Fig 1.3).  
 
Figure 1.3 Control of Cell Death and Survival Through Modulation of Ceramide 
Metabolism.  
Upon an apoptotic stimulus, ceramides become elevated in the outer membrane of mitochondria. 
If this elevation can be prevented or if the ceramide generated is converted to less lethal species, 
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1.5 CERAMIDE CHANNELS 
The exact mechanism by which ceramide mediates cell death is still a matter of 
debate. Is ceramide elevation simply priming the mitochondrial outer membrane for 
permeabilization by other pro-apoptotic factors or could ceramide play a more direct 
role? It was found by multiple laboratories that natural ceramide could increase the 
permeability of the MOM to IMS proteins (Ghafourifar et al., 1999; Siskind & 
Colombini, 2000; Di Paola et al., 2004). Dr. Siskind and Dr. Colombini discovered that 
ceramide can form stable transmembrane channels in membranes that are large enough 
for the release of IMS proteins, which is the irreversible step committing the cell to 
apoptosis (Siskind & Colombini, 2000). Two key pieces of evidence further implicated 
the role of ceramide channels as an important piece of the MOMP generating and 
regulating machinery: first, that, unlike the parental strain, Bax/Bak double knockout 
cells, which are highly resistant to apoptosis, are also unable to elevate mitochondrial 
ceramide levels (Siskind et al., 2010) and second, anti-apoptotic Bcl-2 family proteins 
can disassemble ceramide channels directly and prevent MOMP (Siskind et al., 2008). 
This section will focus on novel studies that have been conducted to characterize this 





1.5.1 Structure of Ceramide Channels 
 Like protein assemblies or complexes, ceramide channels take a form dictated by 
its monomers. There are five important features of the ceramide molecule that allow for 
the formation of ceramide channels.   These features are highlighted in (Fig 1.4, top).   
 
 
Figure 1.4 Model of a Ceramide Channel 
Top: Five important areas of the ceramide molecule contribute to channel formation. Bottom: 
Ceramide molecules arrange themselves into columns with a free amide nitrogen on one end and 
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a free carbonyl group at the other. Adjacent ceramide columns have an antiparallel orientation to 
satisfying the dipole moment of each column.  Ceramide columns are held together by hydrogen 
bonding between C1 and C3 hydroxy groups to form a cylindrical channel. An expanded view of 
two ceramide columns in antiparallel orientation is shown on the bottom right. Each column 
consists of a stack of 6 ceramide molecules. The figure shows the hydroxyl groups that would 
face the channel lumen and the hydrocarbon chains extending into the background, toward the 
lipid bilayer. The yellow bars indicate the hydrogen-bonding between the amide group of one 
ceramide and the carbonyl group of the adjacent ceramide. Bottom image is reproduced from 
(Perera et al., 2012) 
 
The C4:C5 trans double bond is thought to confer the pro-apoptotic function of ceramide 
as the precursor dihydroceramide, which lacks the double bond at this position, is widely 
considered the inactive form (Bielawska et al., 1993; Obeid et al., 1993; Ahn & 
Schroeder, 2010; Grösch et al., 2011). In fact, the presence of dihydroceramide can 
inhibit ceramide channel formation, suggesting the molecular incompatibility of these 
molecules when it comes to channel formation (Stiban et al., 2006). The amide linkage is 
responsible for stabilizing the secondary structure of proteins, like in an α−helix, and 
allows for the arrangement of ceramide monomers into ceramide columns (Fig 1.4, 
bottom left).  These ceramide columns have one free amide nitrogen at one end and a 
carbonyl oxygen at the other and this results in a dipole moment. Ceramide columns 
arrange themselves in an anti-parallel fashion in order to offset their respective dipoles. 
The C1 and C3 hydroxy groups hold these columns together to form a channel in the 
membrane (Fig 1.4, bottom right).  The length of the fatty acyl chain and the sphingoid 
chain have little influence on the ability of ceramide to form channels as even a fatty acyl 
chain of only 2 carbons can easily form channels. It is important to note however that 
only long chain natural ceramides, C16, C18 and C20 ceramides are commonly elevated 
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upon an apoptotic stimulus and this must be of some physiological relevance (Mizutani et 
al., 2005; Pewzner-Jung et al., 2006; Grösch et al., 2011). Molecular dynamics studies 
(Anishkin et al., 2006) highlighted another important structural characteristic of ceramide 
important for channel formation: ceramide probably has a dual curvature (Fig 1.5). The 
intrinsic curvature of a lipid is the ratio of the relative bulk of the head group compared to 
the hydrophobic region. If the head group and the hydrophobic region of a given lipid 
have approximately the same size, then it will form a membrane with zero curvature. If 
the head group is smaller, than the lipid will favor a negative curvature; if the opposite 





Figure 1.5 Ceramide Channels Have a Dual Curvature 
Top: Molecular dynamics simulations revealed that ceramide probably has a dual curvature 
(Anishkin et al., 2006). This allows ceramide to form cylindrical channels with a negative 
curvature in the plane of the membrane (bottom right). Cytochrome c is pictured in the lumen of 
the channel. Bottom left: ceramide channels have a positive curvature perpendicular to the plane 
of the membrane. The positive curvature as shown here allows for a low energy compromise by 
both the ceramide channel and phospholipid membrane to mutually curve to stabilize the channel-
membrane border, and thus the stability of the channel, and prevent high energy exposure of the 
a-polar regions to the aqueous phase. The phospholipids (shown with the light blue head group) 
curve in to form a continuous polar surface with the ceramide channel. The bottom images are 




molecule allows ceramide channels to form a negative curvature in the plane of the 
membrane and a positive curvature perpendicular to the plane of the membrane (Fig 1.5). 
This allows for the stabilization of the channel-membrane interface, and essentially 
allowing for the lowest energy interaction.  
 Evidence from studies conducted by Siskind and associates demonstrated that 
ceramide does not simply induce membrane defects or have detergent like effects but 
indeed forms channels. For example, ceramide channels formed in the MOM are easily 
disassembled when fatty acid free bovine serum albumin (BSA) is added, in a mechanism 
consistent with shifting the dynamic equilibrium of ceramide molecules away from 
channel formation and to ceramide monomers and ceramide bound to BSA (Siskind et 
al., 2002).  In planar phospholipid bilayers containing a ceramide channel, lanthanum 
ions induce channel disassembly after a variable delay and the channel disassembles 
preferentially in multiples of 4 nS, or multiples of two ceramide columns (Siskind et al., 
2003). The variable delay indicates that channel disassembly is a stochastic event, 
inconsistent with that of a membrane defect.  Moreover, while detergents can easily lyse 
erythrocyte membranes and disrupt solvent free planar phospholipid membranes, 
ceramide does not do either (Siskind et al., 2006). In fact, mitochondria can be 
permeabilized a level greater than 75% of maximum by treatment with ceramide and this 
is still reversible by the addition of BSA while mitochondria treated with detergent or 





1.5.2 Properties of Ceramide Channels. 
 For ceramide to be a good candidate pathway for the release of IMS proteins from 
mitochondria, the properties of ceramide channels should be in line with the known 
properties of the enigmatic pathway responsible for the permeabilization of mitochondria, 
and most importantly ceramide channels must be tightly regulated.  
1.5.2.1 Size of ceramide channels 
 Ceramide channels can form in a variety of sizes as observed in planar bilayer 
membranes, liposomes and mammalian mitochondria. Ceramide channels were recently 
visualized using transmission electron microscopy of negatively stained liposomes 
(Samanta et al., 2011). This method allows one to visualize a topographical view of the 
liposome. Ceramide channels are detected as a stain filled cylindrical pores (Fig 1.6, 
arrow). The average size of the pore detected through this method was about 10 nm in 
diameter, which could allow the passage of proteins <500kDa. As discussed in section 
1.2, a variety of proteins exit the mitochondria upon apoptosis and the apoptotic pore is 
both unselective and large enough to accommodate up to 150kDa MW proteins (Munoz-
Pinedo et al., 2006). A ceramide channel would easily accommodate cytochrome c (12 
kDa, 3.4 nm in diameter) and also the largest proteins known to exit the mitochondria 




Figure 1.6 Electron Micrograph of a Ceramide Channel in a Liposome 
Left: Negative stained liposome that was not treated with ceramide. Right: C16-Ceramide 
treatment of a liposome resulted in the formation of a ceramide channel, which is seen here filled 
with negative stain. These images are reproduced from (Samanta et al., 2011). 
 
1.5.2.2 Ceramide channel lifetime.  
  Ceramide channels are highly stable long lasting structures as detected in 
mammalian mitochondria and in electrophysiological recordings of channels formed in 
planar membranes. During apoptosis, it was found that the release of cytochrome c 
occurred in a synchronized fashion from all or most of the mitochondria in a cell 
(Heiskanen et al., 1999; Goldstein et al., 2005). However, while the release of 
cytochrome c alone is sufficient to induce apoptosis, another protein known to exit the 
mitochondria upon MOMP, AIF is a MIM protein and requires processing before it can 
exit the MOM (Otera et al., 2005).  Published evidence by Munoz-Pineda et al. suggests 
that, due to the sustained release of AIF over a long period of time following MOMP, the 
pro-apoptotic pore must be long lived and stable (Munoz-Pinedo et al., 2006). Ceramide 
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channels as observed in mammalian and yeast mitochondria, using the cytochrome c 
accessibility assay that detects real-time permeabilization, can persist for at least 40 min 
(this is a minimum as tests of longer times have not been conducted, unpublished data). 
In planar bilayer membranes, ceramide channels can remain stable for hours.  
1.5.2.3 Membrane specificity of ceramide channels 
 Another interesting property of ceramide channels is that they are specific to the 
mitochondrial outer membrane. Birbes and associates demonstrated that while ceramide 
levels could be elevated in cellular and sub-cellular membranes, only a mitochondrial 
ceramide increase resulted in the release of cytochrome c and cell death (Birbes et al., 
2001; Birbes et al., 2005). To test whether ceramide channel formation could occur in 
plasma membranes, erythrocytes were employed as a model plasma membrane. The 
results indicated that a 60-fold increase in the ceramide needed to permeabilize MOMs 
did not elicit detectible permeabilization in erythrocytes (Siskind et al., 2006).  
 In addition, ceramide channels do not form in the MIM. Whole mitochondria 
were treated with ceramide and assayed for the release of fumarase, a mitochondrial 
matrix protein; and while the mitochondrial outer membrane was permeabilized to 
cytochrome c, no fumerase release could be detected (Siskind et al., 2002). Moreover, 
natural long-chain ceramides are a potent inhibitor of MIM permeabilization and the 
permeability transition pore (PTP) formation in response to calcium overload 
(Novgorodov et al., 2008b). As PTP and mitochondrial depolarization is typical of late 
apoptosis downstream of effector caspase activation and more often seen in necrosis, it is 
possible that the elevation of mitochondrial ceramides, concurrently promotes MOMP, 
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and inhibits MIM permeabilization in order to allow for the completion of the apoptotic 
program (Novgorodov et al., 2008a).  
The difference must lie in the composition of these membranes and warrants 
further study. However, what is clear is that through the process of evolution, traits that 
confer an advantage to survival persevere and thus, the sensitivity of MOM’s to 
permeabilization by ceramide and the resistance to permeabilization of the plasma 
membrane and the MIM, must be beneficial to survival. 
1.5.2.4 Regulation of Ceramide Channels 
 Any factor that promotes or prevents apoptosis must be tightly regulated as the 
fate of the cell, and in some cases the whole organism, hangs in the balance. There are a 
number of ways that ceramide is regulated by the cell (Mullen & Obeid, 2012). First, the 
cell controls the levels of ceramide in mitochondria. Mitochondrial ceramide levels are 
kept low, and increase in the MOM, only when a pro-apoptotic signal is delivered. 
Second, while total cellular levels of ceramide are elevated in multiple compartments of 
the cell, ceramide channel formation is restricted to the MOM (Siskind et al., 2002; 
Siskind et al., 2006; Mullen & Obeid, 2012). The specific composition of the MOM is 
such that it is conducive to channel formation while the compositions of other 
membranes are not. Third, the anti- apoptotic Bcl-2 proteins, CED-9 (the Bcl-2 homolog 
of C. elegans) and Bcl-xL, can regulate ceramide channels (Siskind et al., 2008). These 
anti-apoptotic proteins can directly disassemble ceramide channels formed in isolated 
mammalian mitochondria, isolated yeast mitochondria (which lack other Bcl-2 proteins), 
and solvent free planar bilayer membranes (which are devoid of proteins and other 
29	  
	  
mitochondrial factors). This suggests that while other proteins and mitochondrial factors 
may be involved, the regulation of ceramide channels by anti-apoptotic Bcl-2 family 
proteins is direct and does not require other such factors for this interaction.   
 
1.6 THE SCOPE OF THE PRESENT STUDIES  
 The work presented in this dissertation was designed with the aim of identifying 
the key features of ceramide that allow ceramide channel formation and regulation in the 
context of mitochondrial outer membrane permeabilization. To elucidate the specific 
structural features of the ceramide molecule that contribute to ceramide channel 
formation and stability, a collection of ceramide analogues, or mutants if you will, were 
studied in Chapter 3. These results lead to the publication “Ceramide Channels: Influence 
of Molecular Structure on Channel Formation in Membranes,” in the journal Biochimica 
et Biophysica Acta in 2012. In Chapter 4, “Ceramide and Activated Bax Act 
Synergistically to Permeabilize the Mitochondrial Outer Membrane,” the interaction of 
ceramide channels and the pro-apoptotic Bcl-2 family protein, Bax, is explored. This 
work was published in the journal Apoptosis in 2010. The work described in chapter 3 
and 4 is the result of a fruitful collaboration with a fellow grad student, Vidyaramanan 
Ganesan, who made an equal contribution to those publications. The fifth chapter of this 
thesis explores the location of a molecular site of interaction of both anti- and pro- 
apoptotic Bcl-2 family proteins on ceramide channels by use of ceramide analogues that 
retained channel formation. This work culminated in the publication of “Bax and Bcl-xL 
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Exert Their Regulation on Different Sites of the Ceramide Channel” in the Biochemical 


























CHAPTER 2:  
GENERAL METHODS 
















2.1 PURIFICATION OF FULL LENGTH RECOMBINANT HUMAN BAX 
2.1.1 Overview of Bax purification 
The purification of Bax is facilitated by the use of a pTYB1 vector (IMPACT-CN 
system, New England Biolabs) which adds a C-terminal Intein tag to the protein. The 
protein, once expressed in E. coli, can be purified by affinity chromatography using chitin 
beads which bind the Intein tag. The advantage of this system is Bax can be eluted from 
the chitin column in one step by the addition of a thiol such as DTT, which induces a 
specific self-cleavage of the intein tag from the Bax protein; the Intein remains bound to 
the column and Bax is eluted without the addition of any extra residues to the protein or 
the use of proteases as with other purification techniques. No detergents should be used 
during the isolation process as the goal of the purification is to isolate pure, monomeric 
and inactive protein. Detergents can not only activate the protein leading to changes in 
conformation but may cause the protein to oligomerize with a wide range of high MW 
structures being formed. SDS-PAGE analysis with reducing conditions would disrupt 
many of these oligomers, and unfortunately many studies site such analysis as proof of 
the homogeneity of their monomeric Bax preparations. Moreover, purified monomeric 
Bax can oligomerize over time when stored at 4 °C (the protein can be stored with a low 
concentration of DTT to prevent oligomerization, although long term storage in these 
conditions is not recommended). In our hands, without the use of detergent, we are able 
to purify inactive monomeric protein (confirmed by SDS-PAGE with and without 
reducing conditions, planar membrane experiments, and mitochondrial experiments) and 
we employ a technique of rapidly freezing our protein that preserves the function and 
native monomeric state of Bax which ensures the homogeneity of our protein sample 
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over time and across experiments.  I would like to thank Dr. Richard Youle for the gift of 
the Bax plasmid and Dr. Antonella Antigani for assistance with the purification 
procedure. 
2.1.2 Detailed Bax purification procedure 
Recombinant human Bax was purified as described previously by (Suzuki et al., 
2000) and the modifications to the original procedure are described as follows. DH5α E. 
coli cells were transformed with the plasmid pTYB1-Bax according to the manual (Z-
Competent Cells, Zymo Research). These transformed cells were used to generate stock 
plasmid preps according to standard mini-prep kit instructions (Qiagen) and plasmid 
DNA was stored -80 °C (samples for sequencing are stored in double distilled H2O 
(ddH2O), all others are stored in TE buffer (10mM Tris-HCl, 1mM EDTA pH 8.0)). 
Before every protein purification, BL21(DE3) E. coli competent cells are freshly 
transformed and plated on LB plates containing ampicillin (AMP), as the plasmid confers 
resistance to this antibiotic, and incubated in a 37 °C oven overnight. In the morning, the 
day before the purification, all the colonies are inoculated into 40 mL of Terrific Broth 
Medium (TBM) containing AMP (100 mg/L) and incubated with shaking for two hours 
at 37 °C. Aliquots of pure TBM are saved in sterile microfuge tubes for later use when 
monitoring the O.D. of the bacterial cultures. Equal parts of the 40 mL culture are added 
to two large flasks containing 980 mL TBM containing AMP and incubated at 37 °C with 
shaking for approximately 1.5-2 h until the O.D.600nm =0.6-0.8 at which point the culture 
is induced with a 1 M stock of IPTG (final concentration 0.1 mM) for an additional three 
hours. The cells are harvested by pouring the cultures into two 1 L centrifuge bottles, and 
centrifuging at 3000 g for 15 min (Beckman J-6B centrifuge). The supernatants are 
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discarded and the bottles are placed upside down to drain any excess fluid for 5 min.  The 
bottles containing the pellets can stored at -80 °C until the following morning but it was 
found that resuspending cells stored in this manner is quite difficult. Thus, it was 
preferable to resuspend each pellet of cells in about 30 mL of TEN* buffer (20 mM Tris-
HCl, 5 mM EDTA, 500 mM NaCl, pH 8.0) and transferring the suspension to 50 mL 
conical tubes before freezing overnight at -80 °C.  The French press cell and all tubes and 
vessels to be used for the purification the following day should be washed with double 
distilled water and air dried. The French press cell and all of its parts should be placed in 
the refrigerator at 4 °C to cool overnight.  
The day of the purification, the frozen cell suspensions are removed from the 
freezer and placed in a beaker with several changes of room temperature water until they 
are just thawed and then placed immediately on ice. This way of thawing the cells is not 
only faster, but the cells are kept cool during the process. All other tubes should be placed 
on ice, tubes used to hold the lysate should be rinsed with TEN buffer (20 mM Tris-HCL, 
1 mM EDTA, 500 mM NaCl, pH 8.0). Once the cells are thawed and cooled on ice, the 
French press cell should be removed from the refrigerator and a generous coating of 
silicone grease should be applied to the o-rings. The cells are then French pressed at 1000 
psi for two passes (or just until the lysate appears translucent and is no longer opaque; no 
more than three passes as this process is not innocuous). Samples are kept on ice between 
passes through the French press as this process can generate heat. The lysate is then 
transferred to 10 mL ultracentrifuge tubes, carefully balanced, and spun at 40k rpm 
(Beckman L8-70M ultracetrifuge, 50Ti rotor) for 30 min at 4 °C to spin down cell 
fragments. After the centrifugation is complete, the supernatants are carefully removed so 
35	  
	  
as not to disturb the pellets and filtered through a 0.2 µm filter to ensure the lysate is free 
of bacteria and any debris that could potentially clog or contaminate the chitin column. 
The lysate is then loaded on to the chitin column (~10 mL of chitin beads are packed into 
the column, beads are regenerated and reused up to 5x according to manufacturer 
protocol, New England Biolabs), prewashed with 50 mL TEN, in a cold room at 4 °C. 
The flow rate should be slow at a rate of about 0.5-1 mL/min. The column is then washed 
with about 50 mL of TEN, taking care that all the walls of the column have also been 
washed of lysate. About 7-10 mL of TEN + 30 mM DTT is quickly flushed through the 
column and more of the same solution is added to induce on-column specific self 
cleavage of the Intein tag from the Bax protein. The column is stopped with about a 6- 8 
mL reservoir above the beads and a clean conical tube is placed underneath the column in 
case of any leakage.   After three days, about 15-17 mL of protein is eluted (the Intein tag 
remains bound to the column) with TEN buffer and transferred into two separate dialysis 
bags (12,000 M.W.C.O.) and dialyzed against 3 L of 10 mM Tris-HCl, 1 mM EDTA, pH 
8.0 overnight to remove the DTT. The bags are then dialyzed against 5 L of 10 mM Tris-
HCl pH 8.0 for another 24 hours with constant stirring. I recommend refrigerating the 
dialysis solutions before adjusting the pH as the pH is more basic at colder temperatures. 
The protein is then filter sterilized and the protein concentration is determined by the 
micro BCA assay (PIERCE). The typical yield of protein is between 15-30µg/mL. The 
protein is 95% pure as assayed by SDS-Page and silver stain.  
It is typical for others who purify Bax to store the protein at 4 °C for a month or 
more with or without a low concentration of DTT. In our experience as well as others in 
field (Brustovetsky et al., 2010), the monomeric Bax that is isolated has a tendency to 
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oligomerize over time and this has also been noted by others in the field as well 
(Brustovetsky et al., 2010). To avoid this complication and to ensure the uniformity of 
the protein we use for our assays, we add sterile glycerol to our protein to 10% (v/v) as a 
cryoprotective agent and rapidly shell-freeze our protein using ethanol/dry ice in small 
one-time use aliquots (50-300µL in sterile thin-walled glass tubes) and stored these at -80 
°C.  A fresh protein sample is thawed on ice before use and a sample is never refrozen.  
2.1.3 Activation of monomeric Bax 
The monomeric Bax purified by this method is activated by incubating the sample 
with 10% β-octyl glucoside to a final concentration of 1% on ice for at least 30 min. At 
these conditions, it was published that over 95% of the protein is activated (Hsu & Youle, 
1997; Antonsson et al., 2000) and we confirmed the activation on our protein by taking 
advantage of previously published methods showing that activated Bax is partially 
resistant to trypsin digestion (Lucken-Ardjomande et al., 2008) (Fig 2.1). 
Figure 2.1 SDS-PAGE analysis of activated Bax treated with trypsin.  
Activated Bax is partially resistant to Trypsin digestion yielding a15 kDa digestion 
fragment as seen on the left. Untreated, detergent activated Bax is shown on the right.  
37	  
	  
2.2 PURIFICATION OF FULL LENGTH HUMAN BCL-XL 
2.2.1 Overview of Bcl-xL purification 
 A pGEX2T vector (Amersham Pharmacia Biotech) was used to clone glutathione 
S-transferase (GST) tagged full length human Bcl-xL with a thrombin cleavage site 
between the tag and the protein. Using a bacterial expression system to produce the 
protein, the protein can be purified from the lysate using glutathione-agarose beads which 
bind GST. Adding biotinylated thrombin to the column results in cleavage of the protein 
from the GST tag while the GST remains bound to the column. Once the protein is 
eluted, biotinylated thrombin can be removed by incubating the elute with streptavidin 
beads which can be sedimented and discarded. Finally, the buffer can be changed to the 
by dialyzing against the desired solution.  Unlike Bax, which is a cytosolic protein in the 
inactive form, Bcl-xL is a membrane protein thus Triton X-100 is used increase the 
recovery of the protein and to help disrupt inclusion bodies. To determine the effect of 
using detergent during the isolation on protein function, I isolated Bcl-xL with and 
without Triton X-100 and found that the function of the protein remained unchanged with 
either method while the yield was obviously much greater with Triton X-100. I would 
like to thank Dr. Marie Hardwick for providing us with the Bcl-xL plasmid and Heather 
Lamb for providing the purification procedure. 
2.2.2 Detailed Bcl-xL purification procedure 
           The purification of GST-Bcl-xL was originally described by (Basañez et al., 2001) 
and the modifications are described in detail as follows. The plasmid stock is generated 
using DH5α E. coli cells. Prior to each protein purification, BL21 competent E. coli cells 
are freshly transformed with the Bcl-xL plasmid. The transformed bacteria are plated on 
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LB plates with AMP, the selection marker encoded by the plasmid, and incubated in a 37 
°C oven overnight. The following evening, 10 mL of LB + AMP is inoculated with four 
of the resulting colonies and grown at 37 °C with shaking overnight. The French press 
cell and other vessels to be used during the isolation should be rinsed with ddH2O and air 
dried and French press cell should be placed in the refrigerator overnight. The next 
morning, the dense culture is transferred to 1 L of LB + AMP and grown with the same 
conditions until the O.D.600nm=0.600 (approximately 2.5-3 hours). The culture is then 
induced with a 1M IPTG stock to 0.1 mM final concentration for 2 h. Cells are harvested 
by centrifugation at 4000 g in a 1 L bottle for 15 minutes (Beckman J-6B centrifuge).  
The supernatant is discarded and the pellet is resuspended in 40 mL of phosphate 
buffered saline (PBS) and the following is added and mixed well after each addition: 1% 
Triton X-100, 140 U lysozyme, and 36 µM phenylmethylsulfonyl fluoride (PMSF) 
(PMSF is dissolved in isopropanol, to avoid a high concentration of solvent locally one 
should vortex while adding). Incubate this mixture with the cells on ice for 15- 20 min. 
Only after this step should the French press cell be removed from the refrigerator and 
silicone grease should be applied to the o-rings. The cells are lysed by two passes through 
the French press (but no more than thrice) at 1000 psi. Between passes, the cells are kept 
on ice to prevent them from warming up. The lysate is transferred to 10 mL 
ultracentrifuge tubes, balanced and spun at 40k rpm (Beckman L8-70M Ultracentrifuge, 
50Ti rotor) for 30 min at 4 °C to remove cell fragments.  The supernatant is carefully 
removed as to not disturb the pellets and is filtered through a 0.2 µm syringe filter to 
remove any additional debris or cells that could potentially clog the column. The lysate is 
then incubated with 5 mL (packed volume) of pre-washed glutathione agarose beads for 2 
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hours at 4 °C with gentle rotation. The beads are then packed into a column and the flow 
through is discarded.  The beads are washed with at least 10 column volumes of cold PBS 
+ 36 mM PMSF followed by 10 column volumes of 20mM Tris-HCl, pH 8.0 without any 
protease inhibitors. 10 mL of 20 mM Tris-HCl pH 8.0 with 5 U of biotinylated thrombin 
is then added to the beads and incubated overnight at 4 °C with gentle rotation (this 
incubation could also be conducted at room temperature with or without rotation as no 
detriment to the activity of the protein was detected in our assays).  The next day, the 
protein is eluted from the column and an additional 2-3 mL of 20mM Tris-HCl pH 8 
buffer is added to recover any additional protein.  The GST tag remains bound to the 
column however the biotinylated thrombin must be removed by incubating the elute with 
a sufficient volume of streptavidin beads to bind the added biotinylated thrombin 
(streptavdin beads should be pre-washed with the 20mM Tris-HCL pH 8.0 buffer). This 
incubation should be done for at least 30 min with rotation at room temperature. The 
streptavidin beads are pelleted and discarded. The pure protein is filter sterilized through 
a 0.2 micron filter and frozen as described earlier for the Bax protein (section 2.1.2). The 
concentration is determined by the micro BCA assay and is typically measured to be 
around 160 µg/mL for batches isolated without detergent and around 1.3 mg/mL for 






2.3 PURIFICATION OF RECOMBINANT N/C BID (CLEAVED HUMAN BID, 
tBID) 
2.3.1 Overview of N/C Bid Purification  
Full length human Bid with 6-histidine tag attached to the COOH-end was cloned 
into a pGEX4T1 vector which, like the pGEX2T vector used to purify Bcl-xL described 
above, adds a GST tag and allows for the purification of the protein using GST affinity 
chromatography. In addition, a thrombin cleavage site was inserted in place of residues 
57-62. In a cell, Bid is cleaved at this position by caspase 8 to yield the COOH-terminal 
active fragment called truncated Bid (tBid). Thus, when the full length GST-Bid is bound 
to the GST column, incubation with thrombin will yield the COOH-active fragment tBid-
His6. The major advantage of this method allows one to purify and separate both inactive 
and active fragments of Bid (N/C Bid: N-terminal inactive fragment, C-terminal active 
fragment) resulting from caspase 8 cleavage by making modifications to the final steps of 
the same purification and avoiding the need to make multiple constructs and multiple 
purifications. We thank Dr. Donald D. Newmeyer for the gift of the N/C Bid plasmid and 
Ryan Hastie for assistance with the purification procedure. 
2.3.2 Detailed N/C Bid Purification Procedure 
 Recombinant full length Bid was purified as previously described (von Ahsen et 
al., 2000) (Kuwana et al., 2002) and the modifications are described in detail as follows. 
DH5α E. coli cells are used to produce plasmid stocks and BL21 E. coli cells are freshly 
transformed with the N/C Bid plasmid and plated on LB plates with AMP (the selection 
marker) overnight at 37 °C. The next morning, all plated colonies are inoculated into 40 
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mL of pre-warmed LB+ AMP (100 mg AMP/L LB) medium and are incubated with 
shaking for 3 hours at 37 °C. This culture is transferred to a flask containing 400 mL pre-
warmed LB medium with AMP and grown with the same conditions for about another 
1.5 h until the O.D.600nm= 0.6. At this point the culture is induced with IPTG to a final 
concentration of 0.4 mM. The culture is incubated for another 3.5 hours with shaking at a 
reduced temperature of 30 °C.  The cells are then harvested by centrifugation at 4000 rpm 
in 1L centrifuge bottles for 15 min. The cells are then resuspended in about 30 mL of 
“PBS-EN buffer” (PBS with 1mM EDTA, 500mM NaCl pH 7.4) and frozen in a 50 mL 
tube at -80 °C overnight. The French press cell and all vessels to be used the next day 
should be rinsed with ddH2O and air dried. The French press cell should be placed in the 
refrigerator overnight. 
In the morning, the cell resuspension is thawed in a beaker of room temperature 
water until just thawed and then placed on ice. The French press cell is removed from the 
refrigerator and the o-rings are lubricated with silicone grease. Tubes to hold the lysate 
are pre-rinsed with PBS-EN buffer. The cells are lysed using 2 passes through the French 
press at 1000 psi and placed on ice. Triton-X100 is added while vortexing to a final 
concentration of 0.1%. The lysate is transferred into cooled ultracentrifuge tubes, 
carefully balanced and centrifuged at 40,000 rpm using the 50-Ti rotor for 30 min at 4 °C 
in the Beckman J-6B ultracentrifuge. The lysate is carefully removed so as not to disturb 
the pellets and the pellets are discarded. The lysate is filter sterilized through a 0.2 µm 
filter to remove any particulates or cells that could potentially clog the column. In a 50 
mL conical tube, incubate the lysate with 1 mL glutathione-sepharose beads (prewashed 
with at least 20 mL PBS-EN buffer) and gently rotate at 4 °C overnight. The next 
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morning, the beads are spun down at 3000 RPM for 2 min (Fisher Scientific Marathon 
21K/BR centrifuge). The supernatant should be carefully removed and discarded. The 
protein-bound beads are washed with 20 mL PBS (without the additional EDTA and 
NaCl) and spun down.  The supernatant is discarded and the beads are suspended in a 
small volume of PBS and transferred into a column. The column is washed with an 
additional 10 column volumes of PBS. To isolate tBid, 10U of biotinylated thrombin is 
added to the column in a volume of 500 µL PBS and incubated overnight at room 
temperature. In the morning, 4 mL of tBid was eluted from the column with PBS. 
Streptavidin beads are added to the elute to remove thrombin and incubated at room 
temperature for 30 min. The streptavidin beads are spun down and the supernatant is 
transferred into 8 kDa M.W.C.O. dialysis bags and dialyzed with constant stirring against 
5 L of 50 mM Tris-HCl pH 8.0 (the dialysis solution was cooled before the pH was 
adjusted to 8.0) at 4 °C overnight. The protein is then filter sterilized through a 0.2 µm 
filter, the concentration is determined, and frozen in 100 µL aliquots (see section 2.1.2 
for details on the freezing method. The typical yield of tBid is about 4 mg/mL and this 
can be diluted to an appropriate or useful concentration with 50 mM Tris-HCl pH 8.0 
before freezing (typically we dilute the protein to 0.4mg/mL before freezing).  
 
2.4 ISOLATION OF MITOCHONDRIA 
2.4.1 Isolation of Rat Liver Mitochondria 
Rat liver mitochondria were isolated from male Sprague Dawley rats by 
differential centrifugation of tissue homogenates as described previously (Parsons et al., 
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1966) and modified (Siskind et al., 2002). The evening before the isolation, one rat is 
transferred into a new cage with new bedding and water (rats are only fed distilled or 
filtered water) and fasted overnight. In the morning, all solutions to be used are removed 
from the freezer and thawed in warm water until just thawed and promptly placed on ice 
to cool down. It is important that all steps of this isolation, and all vessels and solutions 
used are kept at ice cold temperatures to ensure the quality and integrity of the organelles 
we purify.  300 mL of H-buffer (70 mM sucrose, 210 mM mannitol, 5 mM HEPES, 0.1 
mM EGTA, pH 7.4) is poured into a beaker (pre-rinsed with the same solution) and 0.5% 
(w/v) of fatty-acid depleted bovine serum albumin (BSA) is added to the beaker and 
allowed to float until dissolved (do not stir) to make HB-buffer. Once the BSA has 
dissolved, the beaker is gently swirled to mix. A glass petri dish, a 100 mL beaker, and 
homogenizing tube with pestle are pre-rinsed with HB and placed on ice. Several 50 mL 
tubes are also placed on ice but are pre-rinsed with the appropriate buffer (HB-, H- or 
FH- buffer) and placed on ice.  
The rat is anesthetized with carbon dioxide and sacrificed by decapitation using a 
guillotine. Quickly, while the heart is still beating, the abdomen is dissected with scissors 
and the liver is excised, with care to avoid hair and other organs, and placed in a cold 100 
mL beaker with two changes of HB to wash the liver of blood. The liver is then placed in 
the petri dish with some more HB and chopped with scissors into small pieces. One 
fourth of liver is homogenized at a time, with HB added to ¾ of the capacity of the 
homogenizing tube. Two passes using a motorized Potter-Thomas Teflon-glass 
homogenizer was sufficient to break the cells and care was taken not to infuse air into the 
homogenate during the process. The mitochondria are then purified using differential 
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centrifugation and all the following steps are conducted at 4 °C. The homogenate is 
transferred into 50 mL tubes and spun using the pre-cooled Sorvall RC-5B centrifuge 
with the SS-34 rotor at a low speed (about 620 RCF (average)) for 10 min. The 
supernatant is transferred into new tubes and the pellet is discarded. The supernatant is 
spun at high speed (8700 RCF (average)) for 10 min. Following this spin, the supernatant 
is now discarded and the walls of the tubes are wiped free of fat and other contaminants 
using a Kimwipe. The pellets are gently rinsed with HB buffer twice and then 
resuspended with a small amount of HB using a blunted glass pipet and bulb to gently 
blow solution at the pellet. Care is taken to avoid resuspending any blood cells that may 
be left over at the center of the pellet or blowing air at the pellet. The organelle 
suspensions in four tubes are combined into two new tubes and filled with HB. These 
tubes are spun at low speed for 10 min and the supernatants are poured into new tubes, 
taking care to avoid the pellet.  These are then spun at high speed for an additional 10 
min and the supernatants are discarded. The pellets are rinsed twice and resuspended with 
H-buffer (without BSA), taking care to avoid resuspending any lysosomes or 
peroxisomes that may be left over at the very bottom and center of the pellet, and spun 
again at high speed for 10 min. The previous step is repeated to ensure the BSA has been 
removed. The supernatant is discarded and the pure mitochondria are resuspended with 
about 5 mL of FH buffer (280 mM mannitol, 0.1 mM EGTA, 2 mM HEPES, pH 7.4) and 
stored on ice. The animal use protocols were approved by the Institutional Animal Care 
and Use Committee. The animals were euthanized by a procedure consistent with the 
Panel on Euthanasia of the AVMA. The animal facility used to house the animals is 
accredited by AAALAC. 
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2.4.2 Isolation of Yeast Mitochondria 
 The procedure used for isolating S. cerevisiae mitochondria was published by 
(Daum et al., 1982) and modified by (Lee et al., 1998). The following procedure 
elaborates on further modifications to the procedure but it remains largely the same as 
published by (Lee et al., 1998). Yeast stocks (9 mL) were recultured every 3 months. 
Stock yeast cells were made by inoculating a colony of yeast cells into 100 mL of yeast 
medium (0.3 g yeast extract, 0.1 g potassium phosphate, 0.1 g of NH4Cl, 0.05 g CaCl2, 
0.05g NaCl, 0.06 g MgSO4, 30 µL of 1% FeCl3, 2.4 mL of 85% lactic acid, pH 5 was 
reached by slowly adding about 2 g solid KOH and this medium is autoclaved under a 
fluid cycle for 15 min at 230°C) and grown with shaking at 30 °C until the O.D.600nm is 
between 0.6 and 0.8 (blanked with lactic acid). At this point, 9 mL aliquots were 
dispensed into autoclaved glass culture tubes, capped and stored at 4°C.  
 The day before the yeast mitochondria isolation, two liters of yeast medium are 
inoculated with one 9 mL stock each and are grown for a minimum of 24 hours (can be 
up to 27 hours depending on the O.D. measurement) at 30°C with shaking until the O.D. 
at 600 nm is 0.6. Cells were harvested in 1 L bottles by spinning at 4000 RPM for 15 
min. The supernatant is discarded and the pellet is rinsed and resuspended with ddH2O 
(about 40 mL per bottle) and transferred into two pre-weighed 50 mL tubes.  The cells 
are then centrifuged in the Sorvall RC-5B centrifuge using the SS-34 rotor for 5 min at 
10k RPM. Then, the supernatant is discarded and the tubes are weighed again to calculate 
the wet weight of the pellet (typically 4-5 grams of cells are collected). 1 mL of Tris-
buffer is required per 0.5 g of cells, so once the volume of Tris-buffer (100mM Tris-SO4, 
pH 9.4) needed is determined, then the required amount of DTT is measured and added to 
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this volume so that the final concentration of DTT is 10 mM. This volume of Tris-buffer 
with DTT is added to the cells which are resuspended using a blunted glass pipette and 
combined into one tube and incubated with shaking for 10 min at 30 °C.  After this 
incubation, the cells are once again centrifuged at 10k RPM for 5 min.  The supernatant is 
discarded and the cells are resuspended in1.2M sorbitol and spun again with the same 
conditions. The supernatant is discarded and the cells are resuspended in 20 mL of 
sorbitol-phosphate buffer (1.2 M sorbitol, 20 mM K2HPO4, pH 7.2) and 10 mg of 
Zymolyase (20 kU/g) was added per gram of cells and incubated at 30 °C with very 
gentle shaking for 25 min to digest the cell wall. To monitor spheroplast formation, a 
glass slide was prepared with a sample of the cells subject to enzymatic digestion of the 
cell wall, and extent of lysis after adding a drop of 10% N-lauroylsarcosine to the corner 
of the coverslip was visualized with a phase contrast microscope. 
The rest of the isolation should be conducted with all vessels, centrifuges, rotors 
and solutions being pre-cooled to 4 °C. The cells are transferred into a 250 mL centrifuge 
bottle and using the adaptors, the cells and the balance bottle should be spun at 6 k RPM 
for 5 min using the SLA-1500 rotor. The pellet will form in the bottle adjacent to the 
outer wall of the rotor. The supernatant is discarded and the pellet is gently rinsed twice 
with sorbitol-phosphate buffer by pouring a small amount into the bottle, swirling and 
discarding the waste. More sorbitol-phosphate buffer is added (enough so that when the 
bottle is held at a tilt and the pellet is adjacent to the outer wall of the rotor, the entire 
pellet is covered with solution). To thoroughly but gently wash,, the bottle is rotated 180 
degrees (about the long axis of the bottle, so that the pellet is now near the center of the 
rotor and not the outer wall), and spun at 6 k RPM for 5 min.  The supernatant is 
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discarded, and the pellet is again rinsed, turned 180 degrees and spun as before with more 
Sorbitol-Phosphate-Buffer. The supernatant is discarded and 40 mL of HY-buffer (0.6 M 
mannitol, 0.1 mM EGTA, 10 mM Tris, and 6 g polyvinylpyrrolidone, pH 7.2) is added to 
the washed spheroplasts. A blunted glass pipette is used to gently suspend the 
spheroplasts in this hypotonic solution and lyse the spheroplasts effectively without 
employing harsh methods such as homogenizing or blending the cells and minimizing 
damage to the mitohcondria. The resuspension is transferred to a 50 mL tube and 
centrifuged for 5 min at 3 k RPM. The supernatant is saved and placed on ice while the 
pellet is resuspended as before with HY-buffer and the centrifugation is repeated. The 
supernatant is transferred into a new tube and both supernatants are centrifuged at 8500 
RPM for 10 min. The resulting pellets are resuspended with 20 mL HY-Buffer each, 
combined into one tube and spun at 3000 rpm for 5 min. The supernatant is transferred 
into a new tube and the purified mitochondria are sedimented at 8500 RPM for 10 min. 
The mitochondria are resuspended in about 3 mL of HY-Buffer and placed on ice.     
2.4.3 Measurement of Mitochondrial Protein Concentration and Determination of 
the Number of Mitochondria  
The concentration of mitochondria is measured following the method described 
by (Clarke, 1976) by taking 1/20 dilution of the mitochondria in H-Buffer (25 µL 
mitochondria, 475 µL H-buffer) and mixing with an equal part of P-buffer (100 mM Tris-
H2SO4, 0.4 % SDS pH 8.0) and reading the absorbance at 280 nm and 310 nm (blanked 
with equal parts H-buffer and P-buffer). The concentration of mitochondrial protein 
(mg/mL) is given by  40 ∗ 𝐀𝟐𝟖𝟎!𝐀𝟑𝟏𝟎
𝟏.𝟎𝟓
.   
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It has been published that there are 7.2x109 mitochondria per mg of mitochondrial 
protein (Estabrook & Holowins.A, 1961), thus the number of mitochondria in a given 
sample can be calculated for known concentration of mitochondrial protein. 
2.4.4 Measurement of the Intactness of Mitochondria 
 The method of subjecting mitochondria to mild hypotonic shock was described by 
(Douce et al., 1987) and modifications were made to the original procedure. Rat liver 
mitochondria are osmotically shocked by adding twice the amount of mitochondria used 
for the mitochondrial dilution one is using for a respective experiment (ex. if the dilution 
being used is 0.5 mg/mL H-buffer, then make 1 mg/mL ddH2O) and adding ddH2O to 1 
mL. This dilution is incubated on ice for 10 min and the osmotic pressure is restored by 
adding an equal volume of shocked mitochondria to 2H-buffer (H-buffer with twice the 
contents). The percent intactness of the mitochondria is determined by comparing the rate 
of oxidation of exogenously added cytochrome c (described in section 2.5.1) by an equal 
amount control mitochondria vs. mitochondria subject to mind hypotonic shock: 
𝐑𝐚𝐭𝐞𝐥𝐲𝐬𝐞𝐝!𝐑𝐚𝐭𝐞𝐢𝐧𝐭𝐚𝐜𝐭
𝐑𝐚𝐭𝐞𝐥𝐲𝐬𝐞𝐝
∗ 100 . For rat liver mitochondria, the intactness is typically 
about 85%. For yeast mitochondria, the procedure is the same except the appropriate 







2.5 DETECTION OF CHANNEL FORMATION IN MEMBRANES 
 2.5.1 Cytochrome C Oxidase Accessibility Assay 
 This assay detects real-time permeabilization of the mitochondrial outer 
membrane (MOM) by monitoring the oxidation of exogenously added cytochrome c by 
cytochrome c oxidase (complex IV of the electron transport chain), found on the 
mitochondrial inner membrane (MIM). The MOM is impermeable to exogenously added 
reduced cytochrome c (~12 kDa), and thus cannot access cytochrome c oxidase which is 
found on the inner mitochondrial membrane, unless the integrity of the MOM is 
compromised by the formation of a channel, a pore or damage like osmotic shock.  Thus, 
channel formation can be detected by monitoring the oxidation of exogenously added 
reduced cytochrome c either by monitoring oxygen consumption or directly by 
monitoring the absorbance of reduced cytochrome c (ε550(red-ox) = 18.5 mM-1 cm-1 
(Margoliash & Frohwirt, 1959)) which will decrease as the protein becomes oxidized.  
This assay is useful to detect the real-time permeability of the MOM as well as detect 
changes in permeability over time whereas release assays can only tell you that the 
mitochondria were permeabilized at some point, perhaps transiently.  
 This assay is conducted as described by (Wojtczak et al., 1972) and modified by 
(Siskind et al., 2002). Further modifications have been introduced to optimize 
reproducibility of results and the integrity of the mitochondria over time. Freshly isolated 
mitochondria are suspended as a concentrated stock in FH-buffer (or HY-buffer for yeast) 
as mitochondria have been found to be more stable at high concentrations.  Once the 
concentration of mitochondrial protein has been determined (section 2.4.3) a working 
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dilution is made in the same buffer, typically between 0.2-0.5 mg/mL and stored on ice, 
and a new working dilution is made for every set of samples tested in parallel. 50 µL of 
this dilution is added to microfuge tube containing 650 µL of room temperature reaction 
buffer H* (for rat liver mitochondria, this is the same as FH buffer supplemented with 5 
mM DNP and 1.4 µM antimycin A pH 7.25, if a reaction buffer with a higher salt content 
is desired, then the amount of mannitol is reduced to 160 mM and supplemented with 60 
mM KCl; for yeast mitochondria the reaction buffer H*Y is composed of HY buffer 
supplemented with 5 mM DNP and 1.4 µM antimycin A, pH 7.2) and inverted several 
times to mix. The mitochondria are allowed to acclimate to room temperature for at least 
5 min prior to ceramide dispersal and the volume added is less than 5% of the total 
volume of the reaction mixture to minimize any effect of the vehicle, typically 2-propanol 
for ceramides or ceramide analogs. All vehicle controls are conducted in parallel with the 
sample of interest. Ceramides and their analogs are dispersed very carefully while 
vortexing for about 15 s and the vortexing is continued, for a total of 30 s, after which the 
sample is incubated for 10 min at room temperature. About 27 µM reduced cytochrome c 
is added to the sample, immediately inverted 7 times to mix and read in a 
spectrophotometer for 2 min. The initial linear portion of the rate cytochrome c oxidation 




Figure 2.2 Cytochrome c accessibility assay.  
A typical experiment is described here along with illustrations of how the rate of 
cytochrome c oxidation represents the level of permeabilization of the mitochondrial 
outer membrane.  
 
2.5.1.1 Preparation of Reduced Cytochrome C 
 5mM horse-heart cytochrome c (Sigma) was made in 700 µL of 0.2 M J-buffer 
(0.2 M Tris-HCl, pH 7.5) and reduced by adding an excess of ascorbate (97 mM final). 
This mixture was inverted to dissolve and the ascorbate was removed from the 
cytochrome c using a Sephadex G-10 gel-filtration column. About 2.4 mL of elute is 
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collected in a single vial and the concentration of cytochrome c is determined 
spectrophotometrically (ε550(red-ox) = 18.5 mM-1 cm-1 (Margoliash & Frohwirt, 1959)). The 
concentration is adjusted to about 1.5 mM reduced cytochrome c with J-buffer; so that 10 
µL of reduced cytochrome c added to 700 µL of J-buffer gives an absorbance reading at 
A550nm of 0.4. This is done so that the concentrations of cytochrome c stocks are uniform 
across different preparations.  Prior to freezing at -20 °C, the reduced cytochrome c 
divided into 600 µL aliquots and the microfuge tubes are flushed with argon and wrapped 
with Parafilm to prevent oxidation.  These stocks are used within 3 months. The column 
is stored in J-buffer with 0.05 % sodium azide and washed with 10 column volumes of J-
buffer before use. 
2.5.2 Release of Adenylate Kinase 
 Adenylate kinase is a 24 kDa protein and, like cytochrome c, is located in the 
intermembrane space of mitochondria unless the MOM is permeabilized. This, like other 
release assays, allows one to determine that the mitochondria have been permeabilized at 
some point during the assay, as well as determine the percent of mitochondria that have 
been permeabilized.  This assay is conducted as described earlier by (Sottocasa et al., 
1967) and modified by (Siskind et al., 2002). After mitochondria have been isolated, a 
working stock of mitochondria is made (1.6 mg mitochondrial protein/mL FH buffer).  
100 µL of this is added to 900 µL of incubation buffer (60 mM potassium lactobionate, 
180 mM mannitol, 0.1 mM EGTA, and 2 mM HEPES pH 7.4) so that the final 
mitochondrial concentration is 160 µg/mL. This concentration of mitochondrial protein is 
about 3 times that used for the cytochrome c accessibility assay in order to obtain higher 
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rates and increase signal to noise. Ceramide and proteins are added as done for the 
cytochrome c oxidation assay and incubated in a 30 °C water bath for 30 min. The 
mitochondria are sedimented at 14k RCF for 5 min at 4 °C and placed on ice. 300 µL of 
supernatant is added to 700 µL of room temperature Adenylate Kinase Reaction Buffer 
(50 mM Tris, 5 mM MgSO4, 10 mM glucose, 5 mM ADP, 0.2 mM NADP, pH 7.5) that 
has been pre-incubated for 2 min with 5 µL of the enzyme mixture (2.5 U of hexokinase 
and 8.7 U of glucose-6-phosphate dehydrogenase; 50-100 µL aliquots of this mixture are 
stored at -20 °C and are only thawed on ice shortly before use; the enzyme should remain 
ice cold until it is added to the sample and any left over enzyme should be discarded). 
The sample is inverted to mix and the absorbance is recorded immediately at 340 nm for 
5 min. The initial rate is used as a measure of the adenylate kinase activity as an increase 
in absorbance at 340 nm. Maximal release was observed when mitochondria are exposed 
to hypotonic shock: 160 µg mitochondria protein, directly from the concentrated stock, 
not the working dilution, is added to 1 mL of ddH2O and incubated on ice for 10 min.   
2.5.3 Permeabilization of Planar Phospholipid Membranes 
 This technique allows one to observe ceramide channel behavior and the direct 
effects of proteins on ceramide channels in a defined system. Planar phospholipid 
membranes were generated by the monolayer method described by (Montal & Mueller, 
1972) and modified by (Colombini, 1987a). A Saran partition (polyvinylidene chloride 
(PVDC)), containing a 100 µm diameter hole, separates two halves of a Teflon chamber 
(Fig 2.3). The hole is coated on both sides of the partition with a moderate application of 
petrolatum (2 % petrolatum (w/v) in petroleum ether) and allowed to dry for 15 min. To 
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generate a solvent free membrane, both sides of the chamber are filled with an aqueous 
solution (typically 1 M KCl, 1 mM MgCl2, 5 mM PIPES pH 6.95) to a level below the 
partition. 30 to 60 µL of a lipid solution (0.5 % (w/v) 1,2-diphytanoyl-sn-glycero-3-
phosphocholine, 0.5% (w/v) asolectin, and 0.05% (w/v) cholesterol dissolved in hexane) 
is layered on the aqueous solution on either side of the chamber and the solvent is 
allowed to evaporate for 5 min. Then, the solution on the trans side is raised to a level 
above the hole in the partition, forming a monolayer across the hole, followed by raising 
the solution on the cis side to match the level solution on the trans side, to complete the 
formation of a bilayer. Calomel electrodes are used to interface the aqueous solutions on 
either side of the membrane with the electronics. The voltage is clamped at 10 mV and 
the current is recorded. Only membranes that displayed less than 0.05 nS in conductance, 
were stable at increased voltage and stirring were used for experiments. All experiments 






Figure 2.3 Schematic diagram of the experimental setup used for planar membrane 
studies.  
 A Teflon chamber is separated into the cis and trans sides by a Saran partition. A 
monolayer is formed on the surface of the aqueous solutions on either side of the 
membrane and a bilayer is formed across a 100 µm hole in the partition. The amplifier 
(►) is wired in the inverted mode and the feedback resistance (Rf) is usually 108Ω. 
 
 To generate a ceramide channel, or that of a structural analog of ceramide, 5-15 
µL of a ceramide solution (typically 0.05 mg/mL in isopropanol) is added to the cis side 
of the chamber while stirring both cis and trans solution for 15 seconds. These additions 
are repeated in 15 min intervals between additions until a ceramide conductance is 
observed. The time to generate a channel is typically variable but once a channel is 
nucleated, the channel will often grow rapidly until a stable level is reached.  Proteins are 
typically added to the cis side while stirring both compartments. When LaCl3 is used to 
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disassemble ceramide channels, about 5-10 µL of 10 mM LaCl3 if a high dose is desired 










































The sphingolipid, ceramide, has been demonstrated to self-assemble in the 
mitochondrial outer membrane (MOM), forming large channels capable of translocating 
proteins.  These channels are believed to be involved in protein release from 
mitochondria, a key decision-making step in apoptosis.  Synthetic analogs of ceramide, 
bearing modifications in each of the major structural features of ceramide were used to 
probe the molecular basis for the stability of ceramide channels.  Channel stability and 
mitochondrial permeabilization were disrupted by methylation of the C1-hydroxyl group 
whereas modifications of the C3 allylic hydroxyl group were well tolerated.  A change in 
chirality at C2 that would influence the orientation of the C1-hydroxyl group resulted in a 
strong reduction of channel-forming ability.  Similarly, methylation of the amide nitrogen 
is also detrimental to channel formation. Many changes in the degree, location and nature 
of the unsaturation of ceramide had little effect on mitochondrial permeabilization. 
Competition experiments between ceramide and analogs resulted in synergy with 
structures compatible with the ceramide channel model and antagonism with 
incompatible structures.  The results are consistent with ceramide channels being highly 
organized structures, stabilized by specific inter-molecular interactions, similar to the 








The sphingolipid, ceramide, has been shown to be able to form channels in planar 
membranes (Siskind & Colombini, 2000), liposomes (Stiban et al., 2006) and the 
mitochondrial outer membrane (Siskind et al., 2002; Siskind et al., 2006).  In mammalian 
mitochondria, channel formation occurs at physiologically relevant ceramide levels 
(Siskind et al., 2006); levels measured in mitochondria from cells early in the apoptotic 
process (García-Ruiz et al., 1997; Rodriguez-Lafrasse et al., 2002; Birbes et al., 2005).  
In addition, the propensity to form channels and their size is influenced by Bcl-2 family 
proteins (Siskind et al., 2008; Ganesan et al., 2010).  These channels are large, stable and 
capable of allowing proteins to cross membranes (Siskind et al., 2002; Siskind et al., 
2006).   The size was determined from the molecular weight of proteins released from 
mitochondria (Siskind et al., 2002), from the conductance of single channels formed in 
planar membranes (Siskind et al., 2003), and from visualization of the pores by electron 
microscopy (Samanta et al., 2011).  A range of sizes was reported with a typical channel 
having an estimated pore diameter of 10 nm (Siskind et al., 2003; Samanta et al., 2011). 
Thus hundreds of ceramide molecules must spontaneously self-assemble in the 2-
dimensional liquid phase of the membrane.  Unlike the fluid and transient toroidal pores 
or lipidic pores formed when lamellar lipids are disturbed by amphipathic molecules such 
as peptides or synthetic structures (Bechinger, 1997; Sansom, 1998; Qian et al., 2008), 
whole proteins (Basanez et al., 2002; Schafer et al., 2009), or at the phase transition 
(Blicher et al., 2009), the channels formed by ceramide seem to be highly structured and 
rigid.  The disassembly of channels formed by short-chain ceramide shows a quantization 
of conductance with a strong preference for large conductance drops to be multiples of 4 
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nS (Siskind et al., 2003).   This finding not only supports the notion that ceramide 
channels are highly-organized cylindrical structures, but is also consistent with a 
modification of the originally-proposed barrel-stave structure (Siskind & Colombini, 
2000).  Each stave of the barrel is proposed to consist of a stack of ceramide molecules 
held together by intermolecular hydrogen-bonding through the amide and carbonyl 
groups of the amide linkage.  These span the membrane forming a cylinder when 
arranged in an anti-parallel fashion (Fig. 1.4) (Siskind et al., 2003).  Molecular dynamic 
simulations indicate that this structure is stable (Anishkin et al., 2006). 
The working structure of the ceramide channel is fundamentally a barrel-stave 
structure similar to the structure, both proposed and solved, for many channels.  The main 
difference is that for all other channels described to date, there is a strong preference for a 
fixed number of monomers forming a channel.  Forming channels with one stave more or 
less is highly unfavored.  If the ceramide channel has such a preference, it is not a strong 
preference.  Perhaps this unexpected feature is due to the large size of pore needed to 
allow the translocation of proteins resulting in a large radius of curvature.  Thus relatively 
small changes in this radius of curvature, as more staves are added to the barrel, may be 
accommodated by relatively small changes in the conformation of the polar headgroup.  
Alternatively, the structure of the polar region may allow enough flexibility to adapt to 
changes in the radius of curvature.  The difficulty observed in initially forming a 
ceramide channel and the rapid growth following initial formation [11] may indicate that 
a small radius of curvature is energetically unfavorable. 
The ability of ceramide to form channels must, at least in part, be attributed to the 
structural features of the ceramide molecule.   The polar head group of ceramide (Fig. 
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3.1), with its amide linkage and two hydroxyl groups located in close proximity, 
constitutes a tridentate hydrogen-bonding donor/acceptor center and is capable of 
generating an effective network of directed hydrogen bonding interactions.  These 
structural features may partly explain its ability to form large, stable channels in 




Figure 3.1 Structure of N-palmitoyl-D-erythro-sphingosine (D-e-C16-ceramide or C16-Cer) 
showing the major features of the molecule and the codes used for the synthetic analogs: H 
for changes to the hydroxyl groups, S for changes in stereochemistry, A for changes to the amide 
group, T for changes to the trans double bond and L for changes to the chain length. 
 
 
groups are critical to achieve a stable structure.  In addition, other structural features 
(such as the length of the hydrocarbon chains and the number and configuration of the 
double bonds) may be important. Therefore, we have undertaken a study of synthetic 
ceramide analogs (Table 3.1, Fig. 3.2) to determine (a) if naturally occurring ceramides 
are uniquely suited to form large aqueous pores and (b) the structural and stereochemical 





Table 3.1 Ceramide analogs. 
 
Code Structural Change Type/Location of 
Change 
S1 enantiomer: 2S,3R to 2R,3S Stereochemical 
S2 diastereomer: 3R to 3S 




A3 N-methylation of amide chain 
A4 urea-ceramide 
A5 α-methoxy group in amide chain of C8-ceramide 
H1 O-methylation of C1-hydroxyl group hydroxyl group 
H2 O-methylation of C3-hydroxyl group 
H3 oxidation of C3-OH to keto group; no double bond 
T1 translocation of double bond on sphingoid base 
T2 phytoceramide: double bond replaced by OH at C4 
T3 double bond converted to triple bond 
T4 allene: adjacent double bonds 
T5 4,6-diene: conjugated trans double bonds in C8-ceramide 
T6 trans double bond converted to cis in C8-ceramide 
T7 translocation of double bond and C3-OH in C8-ceramide 
L1 C10-ceramide hydrocarbon chains 
































3.3 MATERIALS AND METHODS 
3.3.1 Reagents: 
N-Palmitoyl-D-erythro-sphingosine (D-e-C16-ceramide or C16-Cer) and N-oleoyl-
D-erythro-sphingosine (D-e-C18:1-ceramide or C18:1-Cer) were obtained from Avanti Polar 
Lipids (Alabaster, AL).  The analogs of C16-Cer and D-e-C8-ceramide (C8-Cer) and (T1, 
T4) (Fig. 3.2) were synthesized as described previously (Karasavvas et al., 1996; He et 
al., 2000a; He et al., 2000b; Usta et al., 2001; Chun et al., 2002; Chun et al., 2003; 
Brockman et al., 2004; Chalfant et al., 2004).  Antimycin A, 2,4-dinitrophenol (DNP), 
horse heart cytochrome c, and fatty acid depleted bovine serum albumin (BSA) were 
purchased from Sigma (St. Louis, MO). DPX (p-xylene-bis-pyridinium bromide) was 
purchased from Molecular Probes (Invitrogen).  5(6)-carboxyfluorescein was purchased 
from Acros Organics. 
3.3.2 Preparation of rat liver mitochondria: 
Rat liver mitochondria were isolated by differential centrifugation of tissue 
homogenates as described previously (Parsons et al., 1966) as modified (Siskind et al., 
2002).  Briefly, male Sprague Dawley rats were fasted overnight and sacrificed by 
decapitation.  The liver was excised and minced in cold isolation medium, H buffer (70 
mM sucrose, 210 mM mannitol, 0.1 mM EGTA, 5.0 mM HEPES, pH 7.5), supplemented 
with 0.5% (w/v) fatty-acid depleted BSA followed by homogenization in a motorized 
Potter-Thomas Teflon-glass homogenizer (two passes).  The homogenate was subjected 
to 10-min cycles of low speed (600 g) and high speed (8600g) centrifugations in the same 
medium (twice each) at 4oC in a Sorvall SS-34 rotor.  After the low speed spin, the 
supernatant was collected and spun at high speed.  The pellet obtained after the high 
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speed centrifugation was resuspended in the medium of the same composition and 
centrifuged.  BSA was removed by centrifugation at 8600g in BSA-free medium.  The 
final mitochondrial pellet was resuspended in an ice cold sucrose free isotonic buffer FH 
(280 mM mannitol, 0.1 mM EGTA, 2 mM HEPES, pH 7.4). The mitochondrial 
intactness was determined from the rate of cytochrome c oxidation (vide infra) compared 
with the rate measured after mild hypotonic shock (Douce et al., 1987). 
3.3.3 Preparation of cytochrome c: 
Horse heart cytochrome c (2 mM) was reduced by an excess of reducing agent, 
ascorbate (40 mM), 0.2 M Tris-Cl (pH 7.5).  The reduced cytochrome c was separated 
from ascorbate by using Sephadex G-10 gel filtration (Siskind et al., 2002).  The 
concentration of reduced cytochrome c was determined spectrophotometrically from the 
absorbance at 550 nm. 
3.3.4 Cytochrome c oxidation assay as a measure of mitochondrial outer membrane 
permeability: 
The rate of oxidation of exogenously-added reduced cytochrome c by cytochrome 
oxidase in isolated mitochondria is a measure of the permeability of the outer membrane 
to cytochrome c because translocation of cytochrome c through the outer membrane is a 
rate limiting step (see Fig. 3.2).  The procedure previously described (Wojtczak et al., 
1972) was modified to improve reproducibility.  As the mitochondria were found to be 
more stable at higher concentrations, mitochondria were diluted in H buffer at 4 oC to a 
concentration of 0.2 mg/mL, in small batches just before the assay.  Then, 50 µL aliquots 
were dispersed in 650 µL of room temperature H buffer supplemented with 5 mM DNP 
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and 5 µM antimycin A.  The final protein concentration was 14.3 µg/mL.  The 
mitochondria were allowed to acclimate at room temperature (10 min) in a microfuge 
tube.  Then ceramide or one of the analogs (dissolved in 2-propanol at 1 mg/mL) was 
delivered to the mitochondria while the suspension was vortexed for 30 s to achieve 
effective dispersal of the sphingolipid.  After dispersal, the mixture was incubated for 10 
min at room temperature followed by addition of cytochrome c (20 µL; final 
concentration, approx. 25 µM) and immediate measurement of the absorbance at 550 nm 
for a period of 2 min. The initial rate of decline of absorbance of reduced cytochrome c 
was used as a measure of the permeability of the outer membrane to cytochrome c; ε550 
(red-ox) = 18.5 mM-1 cm-1.  Vehicle controls were treated in an identical way.  The 
percent of mitochondria with intact MOMs in these experiments was greater than 85%.   
Rates were corrected for the rate of oxidation observed with vehicle alone and this was 
very close to the untreated rate arising from a small number of damaged mitochondria. 
The sensitivity of isolated mitochondria to permeabilization by added ceramide or 
analogs varied from one preparation to another.  Therefore experiments with analogs 
were always performed in parallel with experiments with C16-Cer.  In this way the 
permeabilization produced by the analog (measures as the rate of cytochrome c 
oxidation) could be compared to that of C16-Cer, either directly by reporting both rates or 








Table 3.2 Relative potency of analogs to permeabilize the mitochondrial outer membrane. 
MOM was permeabilized by the addition of the indicated amount of analog (nmoles of analog per 
µg of mitochondrial protein) and the degree of permeabilization, as measured by the rate of 
cytochrome c oxidation is expressed as a percent (± S.E. of at least 3 trials) of the 
permeabilization measured in parallel experiments with C16-Cer. The P values indicate the 
statistical significance of the permeabilization compared to that observed with C16-Cer using the 
Student’s T test. N/D means not done. N/S means not significantly different at the 95% 
confidence level. 



















S1 No effect (P = 
0.32 relative to 
vehicle control) 











A3 No effect (P = 
0.41 relative to 
vehicle control) 











H2 125 ± 3 N/S 107 ± 15 N/S 60 
(2S)-3-keto-C16-dh-
ceramide 










T2 429 ± 27 <0.03 230 ± 50 <0.05 460 
(2S,3R) C16-4,5-tb-
ceramide 











L1 46 ± 17 
  





L2 1310 ± 104 <0.005 606 ± 27  
 
<0.005 -- 
N-palmitoyl-serinol L5 N/D  306 ± 92 <0.01 -- 
(2S,3R,4E) 
C18:1-ceramide 






The degree of cooperativity between an analog and C16-Cer was determined by 
averaging the rate of cytochrome c oxidation achieved with a specific amount of each 
agent alone (called the “expected average”) and comparing this with the rate observed 
with half the amount of each agent added combined (called the “combined effect”).   The 
degree of cooperativity is expressed as the ratio of the combined effect to the expected 
average.  A result not significantly different from “1” means no cooperativity; greater 
than “1” is synergy; less than “1” is antagonism. 
3.3.5 Measurement of adenylate kinase release: 
The assay was performed as described earlier (Wieckowski et al., 2001).  
Mitochondrial suspensions containing 160 µg of mitochondrial protein were resuspended 
in isotonic buffer to a final volume of 1 mL.  After the mitochondria were acclimated at 
room temperature for 10 min, ceramide or the analog was added, while vortexing.  The 
mitochondria were incubated for 10 min at room temperature followed by centrifugation 
(14000 g) for 5 min at 4 oC (Beckman Coulter Microfuge 22R Centrifuge). A portion of 
the supernatant (300 µL) was combined with adenylate kinase reaction mixture (700 µL; 
50 mM Tris, 5 mM MgSO4, 10 mM glucose, 5 mM ADP, 0.2 mM NADP, pH 7.5) that 
had been preincubated for 2 min with enzyme mixture (5 µL; 2.5 units of hexokinase and 
8.7 units of glucose 6-phosphate dehydrogenase) to consume ATP present in the reaction 
mixture prior to addition of the supernatant.  The absorbance increase at 340 nm, from 
the generation of NADPH, was measured over 2 min.  The maximal release was 
determined by measuring the activity of the supernatant obtained from an equal amount 
of osmotically shocked mitochondria.  Measurement of adenylate kinase release does not 
measure the mitochondrial outer membrane (MOM) permeability but rather detects that, 
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at some point after treatment, the MOM was made permeable (perhaps transiently) to this 
26 kDa protein. 
3.3.6 Measurement of lipid insertion into mitochondria: 
C16-Cer, one of the analogs, or a combination of both was added to a 0.7 mL 
mitochondrial suspension containing 160 µg of mitochondrial protein in H buffer.  In 
each experiment 30 µL of a 1 mg/mL 2-propanol solution of the lipid(s) was added while 
vortexing as described above.  The suspension was then layered on 0.7 mL of ice-cold 
solution of 15% (w/v) sucrose, 5mM HEPES pH 7.5 and centrifuged at 18,000 g for 5 
min at 4 oC. (Beckman Coulter Microfuge 22R Centrifuge).  The mitochondria 
sedimented and the uninserted lipid remained out of the sucrose layer(prior experiments 
showed that dispersed ceramide floats at this density (Samanta et al., 2011)).  Most of the 
supernatant was aspirated gradually and the tube inverted and any liquid wiped off with 
paper wipe.  The pellets were used for lipid extraction and measurement of the 
mitochondria incorporated ceramide and analogs by LC-MS/MS as previously described 
(Bielawski et al., 2006; Bielawski et al., 2009). 
3.3.7 Liposome permeabilization: 
Single-walled liposomes (93% asolectin and 7% cholesterol, by weight) were 
prepared by the extrusion method as previously described (Stiban et al., 2006).  In 
summary, lipids (total mass, 5 mg) were hydrated in a buffer containing 1.5 mM 
carboxyfluorescein (CF), 6 mM DPX, 38.8 mM NaCl, 10 mM HEPES, and 1 mM EDTA, 
pH 7.0.  The mixture was vortexed and subjected to 4 cycles of freeze-thaw-sonication 
followed by freeze-thawing and extrusion through a polycarbonate membrane (13 times) 
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to form uniform single walled vesicles (100 nm diameter).  A Sephacryl S200 gel 
filtration column (1.5 cm×30 cm) was used to separate the liposomes from untrapped 
fluorophore using an isoosmotic elution buffer lacking carboxyfluorescein and DPX (50 
mM NaCl, 10 mM HEPES, 1 mM EDTA, pH 7.0).  Aliquots (100 µL; containing 
approximately 0.1 mg of lipid) of the liposome suspension were diluted into 2 mL of the 
eluting buffer.  CF was excited at 495 nm and the emitted light was detected at 520 nm in 
a Deltascan spectrofluorometer (Photon Technology Instruments).  The fluorescence 
intensity was measured as a function of time under constant stirring and the test 
compound was added.  The increase in fluorescence intensity was the result of the release 
of CF from the liposomes and its dilution from the quenching agent, DPX.  The maximal 
increase in fluorescence intensity was measured after the addition of 150 µL of 5% 
Triton-X 100. The liposome permeabilization was plotted as % release of CF relative to 
maximal release. 
3.3.8 Channel formation in planar membranes: 
Electrophysiological studies were conducted on some of the analogs to determine 
whether they were able to permeabilize planar phospholipid membranes devoid of 
proteins or other mitochondrial factors. Planar phospholipid membranes were generated 
using the monolayer method as previously described (Montal & Mueller, 1972) and 
modified (Colombini, 1987b).  The lipids comprising the monolayers were 1,2-
diphytanoyl-sn-glycero-3-phosphocholine, asolectin, and  cholesterol at a 1:1:0.1 ratio by 
weight.  The aqueous solutions were 1.0 M KCl, 1mM MgCl2, 5mM PIPES pH 6.9 on 
both sides of the chamber.  The bilayer was formed across a 100µm diameter hole in a 
Saran (polyvinylidene chloride) partition Calomel electrodes were used to interface with 
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the aqueous solution, the voltage was clamped at 10 mV and the current recorded using a 
Digidata 1322A digitizer by Axon Instruments and Clampex 9.0 software by Axon 
Laboratories.  To form a channel, successive additions of 5-20 µL of 0.05 mg/mL of the 
analog in 2-propyl alcohol were stirred into the aqueous solution (5 mL) on one side of 




The analogs were tested for their ability to permeabilize the outer membrane of 
isolated rat liver mitochondria to proteins, using the cytochrome c oxidation assay (Fig. 
3.2).  Permeation through the MOM limits the rate of oxidation of exogenously-added 
cytochrome c by cytochrome oxidase in the inner membrane and thus the initial rate of 
oxidation of cytochrome c was utilized as a measure of the permeabilization of the MOM 
to proteins.  Sample dose-response curves are shown in Fig. 3.3.  Note that the shapes of 
these curves vary from rectangular hyperbola to sigmoid, making rigorous comparisons 
difficult.   Generally a dose of 30 nmoles per 10 µg of mitochondrial protein was chosen 
as the common dose for comparison because it was low enough to avoid pronounced 
saturation by some analogs but high enough to detect permeabilization by the less-
effective analogs.  Results with lower doses are also reported.  The sensitivity of 
mitochondria to MOM permeabilization varied from one isolation to the next so the 
permeabilization results summarized in Table 3.2 are expressed as a percentage of the 
permeabilization achieved by ceramide in the same mitochondrial preparation, either C16-





Figure 3.3 Examples of dose-response curves of the analogs used.  The cytochrome c 
oxidation rate was used to assess the permeability of the MOM to proteins.  The indicated amount 




An indication of MOM permeabilization was also obtained by measuring the 
extent of release of adenylate kinase.  This is not a measure of MOM permeabilization 
but rather an indication of the fraction of mitochondria that have been permeabilized.  
With one notable outlier (vide infra) the MOM permeabilization assay and the adenylate 
kinase release assay yielded similar results for the analogs when compared to the effect of 
ceramide (Fig. 3.4).  The permeabilizing ability of the analog is expressed as a fraction of 
the ability of the corresponding ceramide, either C16-Cer or C8-Cer.  The line drawn is not 
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Figure 3.4 Correlation between changes in MOM permeability and adenylate kinase release 
by analogs.  The “permeabilization relative to ceramide” is the rate of cytochrome c oxidation 
induced by the analog divided by that induced by ceramide (C16-Cer for triangles and C8-Cer for 
inverted triangles) under the same conditions.  “adenylate kinase release relative to ceramide”  is 
the activity of adenylate kinase released from mitochondria by analog addition divided by that 
released by ceramide.  The error bars are standard error of at least three experiments. 
 
 
The MOM permeabilization is dependent on the extent of insertion of the analog 
into the mitochondria, the propensity for channel formation, and the stability of the 
channels.   Typically, only 0.3 to 1% of the added analog actually inserted into the 
mitochondrial membranes (Table 3.3).  Phytoceramide was the exception with nearly 5% 
insertion.  The extent of insertion helped to interpret the observed ability of an analog to 
permeabilize the MOM. 
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Table 3.3 Extent of delivery of ceramide and its analogs to mitochondrial membranes. 
The indicated amount of lipid was added to a mitochondrial suspension (160 µg protein).  The 
percent of the added lipid that incorporated into mitochondria is shown as mean ± S.E. of 4 trials 
or the values of individual trials.   Column 4 shows the extent of analog insertion when added 
with equal amounts of C16-Cer.  The insertion of C16-Cer was not affected by the presence of the 





% incorporation % incorporation 
in the presence 
of C16-Cer 
P value 
D-C16-Cer 56 1.04 ± 0.23   
L-C16-Cer (S1) 56 0.41 ± 0.06   
C10-Cer (L1) 66 0.95 ± 0.07 2.45 ± 0.34 0.01 
Phytoceramide (T2) 54 4.78 ± 0.80 1.64 ± 0.36 0.004 
N-Me-C16-Cer (A3) 54 0.74, 0.85   
1-O-Me-C16-Cer (H1) 54 1.00, 1.25   
3-O-Me-C16-Cer (H2) 54 0.35, 0.95   




3.4.1 Ability of analogs to permeabilize the MOM to proteins 
Changes in the non-polar portions of ceramide did not interfere with channel 
formation.  The analogs of ceramide having a shorter N-acyl chain (L1) or a shorter 
sphingosine backbone (L2, L5) were more potent in permeabilizing the MOM than C16-
Cer (Table 3.2).   For C2-ceramide (Siskind et al., 2006) the additional potency was 
attributed to an enhanced ability to incorporate into the mitochondrial membrane.  That is 
not the case for C10-ceramide (L1) (Table 3.2, column 5) as the permeabilization was 
increased 6 fold despite no difference in the degree of incorporation into the MOM.  
Increasing the effective bulk of the hydrocarbon chain by using fluorescently labeled C6-
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NBD-ceramide (L4), or C18:1-Cer (L6) with a cis double bond in the middle of the acyl 
chain, inhibited cytochrome oxidase activity.  After correction for the inhibition, channel 
formation by C18:1-Cer (L6) was indistinguishable from that of C16-Cer (Table 3.2). 
Major alterations in ceramide’s trans double bond were also well tolerated (Table 
3.2 and 3.5).  Some of these were analogs of C8-ceramide.  Under identical treatments, 
C8-Cer (L3) permeabilized the MOM to cytochrome c 36% of the maximal 
permeabilization, whereas the cis isomer (T6) resulted in a 61% of maximal 
permeabilization (Table 3.5).  An analog with an extra double bond (6E) in conjugation 
with the first (T5) permeabilized the outer membrane to the same extent as the cis isomer 
(T6).  Moving the 4E double bond to a position between the two hydroxyl groups by 
putting it at the C3 position and moving the C3-hydroxyl group to the C5 position (T7) 
did not prevent MOM permeabilization.  Similar results were obtained with analogs of 
C16-Cer.  C16-phytoceramide (T2), where the 4E-double bond is replaced by a C4-
hydroxyl group, had a 2-fold higher ability to permeabilize the MOM as compared to 
C16-Cer but this can be more than accounted for by an enhanced ability to insert into the 
MOM (Table 3.3).  Replacing the 4E-double bond by a C4, C5-triple bond (T3) also did 
not significantly affect the ability of the molecule to permeabilize the MOM.  Moving the 
double bond farther down the chain (T1) to a position that does not form an allylic 
system results in an enhanced MOM permeabilization, despite a substantial reduction in 
its ability to insert into mitochondria.   Hence the location, conformation, and degree of 
unsaturation do not have significant effects on channel-forming ability. 
The amide linkage in ceramide is proposed to have similar organizing effects as 
the amide linkages in proteins (Bittman, 2009).  The hydrogen-bonding ability of this 
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linkage was proposed to organize ceramide monomers into columns.  We found that 
increasing the hydrogen-bonding ability of this region by introducing a “urea” linkage 
(A4) resulted in an enhanced ability to permeabilize the MOM (Table 3.2).  Moreover, 
reducing the hydrogen-bonding capacity by using C8- and C16-ceramines (A1, A2), which 
differ from ceramide by having an amino instead of an amide group, eliminated the 
molecule’s ability to permeabilize MOM to proteins.  Since both of these ceramines 
strongly inhibit cytochrome oxidase activity, release of adenylate kinase from the 
mitochondrial intermembrane space was measured.  The ceramines caused no significant 
release of adenylate kinase.  For C16-ceramine, kinase release was -0.6 ± 7% for the 
highest dose tested (8 nmol/µg mitochondrial protein).  C8-ceramine was much more 
effective at releasing carboxyfluorescein from liposomes than C8-Cer (Table 3.4) 
showing that it readily forms channels but these are very small.  Methylation of the amide 
nitrogen, affording N-methyl-C16-Cer (A3), drastically reduced but did not completely 
eliminate the ability of the molecule to permeabilize the MOM to cytochrome c (Table 
3.2).   The partitioning of (A3) into mitochondria was slightly reduced, however the 
reduced insertion into the membrane of this analog could not account for the extent of its 















Table 3.4 Comparison of channel-forming activity in mitochondria and liposomes. 
Liposomes and mitochondria were treated with ceramide analogs to assess the latter’s 
ability to permeabilize membranes.  For the liposomes (column 3) the % release of 
contents was performed at 2 different doses: 87 and 147 nmoles per 2.5 mL of liposome 
suspension. For the MOM permeabilization (column 4) results are expressed as a % 
permeabilization achieved by hypotonic shock.  The dose used was 0.19 nmoles/µg 
protein.  Measurements of adenylate kinase release (column 5) are expressed as percent 
of the kinase activity released following treatment with 0.25 nmoles/µg protein. 
 
Compound Code Liposome 







L3 17 ± 2 
22 ± 3 
36 ± 4 24 ± 2 
(2S,3R,4E) C8-ceraminea A2 100 N/D none 
(2S,3R,4E) C2-OCH3-C8-
ceramide 
A5 18 ± 2 
24 ± 3 
18 ± 3 18 ± 2 
(2S,3R,4E,6E)C8-ceramide 
(diene) 
T5 32 ± 3 
40 ± 3 
62 ± 5 42 ± 4 
(2S,3R,4Z) C8-ceramide  
(cis analog) 
T6 37 ± 3 
47 ± 4 
61 ± 6 39 ± 7 
(2S,5R,3E) C8-ceramide 
 
T7 36 ± 3 
46 ± 4 
76 ± 6 43 ± 6 
 
 
a Release from liposomes was complete with as little as 15 nmoles per 2.5 mL of liposome 
suspension.  MOM permeabilization could not be done (N/D) because of strong inhibition of 





The ability of (A3) to form channels, even at a much reduced potency raises a 
severe problem with the working model of the ceramide channel where the hydrogen 
bonding from the amide nitrogen is essential to the overall structure. In the model, the 
amide nitrogen of one ceramide molecule forms a hydrogen bond with the carbonyl 
group of another to form ceramide columns. Methylation of the amide nitrogen as in (A3) 
would effectively prevent such interactions.  However, in molecular dynamic simulations 
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performed by Andriy Anishkin (Anishkin et al., 2006), whereas the working model of the 
ceramide channel is the predominant form arising from such simulations, other, minor 
forms were also detected.  In some of these the carbonyl oxygen is not hydrogen bonding 
with the amide hydrogen of the adjacent ceramide but hydrogen bonding with a C1-
hydroxyl through a water bridge (e.g. Fig. 3.5).  Thus it may be possible for (A3) to form 
a similar structure. 
 
 
Figure 3.5 The top view of a ceramide channel structure. This figure, which was obtained by 
Andriy Anishkin as part of the structures formed by simulated annealing, is one of a few 
structures in which the carbonyl oxygen forms a hydrogen bond with one of the hydroxyl groups 
rather than forming a hydrogen bond with the amide group of an adjacent ceramide molecule.  In 




The C1 and C3 hydroxyl groups have been proposed to stabilize channel structure 
via hydrogen bonds with the corresponding functional groups on adjacent ceramide 
molecules.  Analogs of these functional groups were utilized to determine the 
contribution of these groups to the channel structure. O-Methylation of the C1-hydroxyl 
group (H1) was chosen because the methyl group should prevent this hydroxyl group 
from participating in a hydrogen bond. The methylation of the C1 hydroxyl resulted in an 
almost complete loss of any stable MOM permeabilization despite no change in ability to 
insert into mitochondria (Table 3.4).  When the ability of (H1) to release adenylate kinase 
was tested, it was almost double that observed with C16-Cer indicating that twice as many 
mitochondria were permeabilized, if only transiently, by (H1).  When reconstituted into 
planar membranes, (H1) produced conductances that were transient (vide infra) as 
opposed to the growing conductances observed with C16-Cer.  These were similar to 
those published for sphingosine (Elrick et al., 2006) except that these are large enough to 
allow the release of adenylate kinase (Fig. 3.4). 
Unlike (H1), methylation at the C3-hydroxyl (H2) produced functional properties 
very similar to those of C16-Cer (Table 3.2).  Both the cytochrome c oxidation assay and 
the adenylate kinase release assay produced results indistinguishable from those of C16-
Cer.  The importance of the location of the C3-hydroxyl group and the stereochemistry of 
the adjacent chiral center were tested by relocating the hydroxyl to the C5 position (T7) 
and by changing configuration from (2S,3R)-C16-Cer to (2S,3S)-C16-Cer (S2), 
respectively. Neither of these alterations had a large effect on the ability of these 
molecules to permeabilize MOMs of isolated mitochondria (Table 3.2).  Thus the 
location and orientation of the C3-hydroxyl can be changed with minimal consequences.  
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By sharp contrast, converting the (2S,3R)-C16-Cer to (2R,3S)-C16-Cer (S1) (i.e. an 
additional change in the chirality at C2) greatly reduced its ability to permeabilize 
MOMs, consistent with the importance of the C1-hydroxyl group (Table 3.2).  Unlike the 
results with (H1), (S1) was unable to permeabilize the MOM or release adenylate kinase 
at 1 nmole/µg protein and produced only 16% of the permeabilization of  C16-Cer at 3 
nmoles/µg protein.  The amount of insertion was reduced by a little over half but not 
enough to account for the large reduction in ability to permeabilize the MOM.  Thus, the 
stereochemistry of ceramide that limits the possible and preferred positions of its polar 
groups (Bittman, 2009), can also influence the propensity for channel formation in the 
MOM. 
3.4.2 Interactions between D-e-C16-ceramide and its analogs 
Isolated mitochondria were treated with either C16-Cer alone or the analog alone, 
or an equimolar mixture of C16-Cer and the analog at half the dose.  Thus, the total 
amount of sphingolipid added was kept constant.  The ability of each of the three 
treatments to permeabilize the MOM to cytochrome c was measured. Examples of the 






Figure 3.6 Cooperativity between analogs and C16-Cer. For an individual addition, a total of 
40 nmol was used.  For combined additions (both), 20 nmol of each was used.  The average bar 
(avg) shows the average of the results obtained with each lipid alone.  The statistics are shown in 
Table 3.5.  The individual and combined additions for each analog were performed with the same 
batch of mitochondria under the same conditions to avoid the variability in sensitivity to ceramide 
found among mitochondrial preparations. 
 
 
(designated as both) yielded a higher rate of cytochrome c oxidation (and therefore a 
higher permeability) than the average of the individual treatments (avg), thus indicating 
synergy.  The converse was true for (T4), indicating antagonism.   For (S2) there was no 
82	  
	  
significant difference, indicating neutrality or no cooperativity. Depending on the 
experimental set, 40 nmol or 60 nmol of lipids were utilized (as indicated in Table 3.5).  
The permeability resulting from the combined treatment (“combined effect” in Table 3.5) 
was compared to the “expected average” which is the average of the permeabilities 
observed with the individual sphingolipid treatments. The ratio is reported in Table 3.5 
along with the P values of statistical significance and the interpretation of the results.  
Ratios significantly greater than 1 indicate synergy and ratios significantly less show 
antagonism. 
A subtle change, such as the replacement of the 4E double bond of ceramide with 
a C4,C5-triple bond (T3), resulted in a neutral effect when combined with C16-Cer (Table 
3.5).  Experiments with the diastereomer (S2) (2S,3S as opposed to 2S,3R for C16-Cer) 
were also consistent with simple neutrality (Fig. 3.6 and Table 3.5). 
Treating mitochondria with a mixture of C16-Cer and the shorter chain analog, 
13C/C16:0 (L2) resulted in a permeabilization that was greater than the average of 
treatments with individual compounds (Fig. 3.6).  Similar results were obtained with 
other short-chain analogs (L1, L5) (Table 3.5) and with urea-ceramide (A4). 
Mitochondria treated with an equimolar mixture of ceramide and phytoceramide 
(T2) achieved a much reduced level of permeabilization than expected from averaging 
the individual treatments (Fig. 3.6, Table 3.5).  This inhibition was also found between 
phytoceramide (T2) and L-e-C16-Cer (S1) (data not shown).  A similar antagonistic 
interaction was found between C16-Cer and either N-methyl-C16–Cer (A3) or the 




Table 3.5 Cooperativity between C16-ceramide and its analogs. The analog was mixed in 
equimolar quantities with C16-Cer and the permeabilization of the MOM was compared to the 
average permeabilization observed with equal total amounts of either C16-Cer or the analog alone.  
At least 3 experiments were performed for each condition and P values for the t-tests are listed.  
Using 95% confidence, ratios significantly greater than 1 are labeled synergistic; significantly 
less than 1, antagonistic; not significantly different, neutral. 




P value Nature of 
interaction 



























(2S)-3-keto-C16-dh-ceramide H3 1.0 0.41 Neutral 


































N-palmitoyl-serinol L5 1.4 0.002 Synergistic 
 a The increase in MOMP resulting from the addition of a total of 3.6 nmoles/µg protein of an 
equimolar mixture of C16-Cer and the specified analog was compared to 3.6 nmoles/µg protein of 
either C16-Cer or the analog alone. In the other experiments, 5.6 nmoles/µg protein were used. 
 
 
The type and degree of cooperativity correlates with the channel-forming ability 
of the analog. A plot of the channel-forming potency relative to that of C16-Cer versus the 
cooperativity ratio from Table 3.5 shows the strong correlation (Fig. 3.7).  The upper 
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right quadrant contains data from the analogs showing synergy and higher propensity for 
channel formation whereas the lower left quadrant contains data from those displaying 
antagonism and lower channel-forming propensity.  Analogs showing no cooperativity 
and essentially similar channel-forming propensity to C16-Cer tend to cluster at the 
“origin”.  The other two quadrants are essentially vacant. 
 
Figure 3.7 Correlation between degree of cooperativity and ability of an analog to 
permeabilize the MOM.  Relative cooperativity is from column 3 of Table 3.5.  The 





The permeabilization of the MOM following the dispersal of ceramide or an 
analog must involve at least two processes: insertion and self-assembly.  The 
cooperativity could take place at one or both of these.  The influence of combined 
delivery on the insertion of the sphingolipids was assessed for one analog showing 
synergy (L1) and one showing antagonism (T2) (Table 3.3).   The presence of C16-Cer 
influenced the ability of the analogs to insert into the MOM in harmony with the 
observed cooperativity.  The amount of (T2) that inserted when combined with C16-Cer 
was one third of that measured following its individual addition whereas the insertion of 
(L1) doubled.  The insertion of C16-Cer was not significantly affected by the presence of 
the analog. 
The antagonism observed in mitochondrial experiments was also evident in 
experiments with liposomes, showing a direct interaction between these lipids. Premixing 
C16-Cer and C16-phytoceramide (T2) resulted in a much smaller permeabilization of 








3.4.3 Channel formation in phospholipid membranes 
To directly observe channel formation by ceramide analogs and to gain insight 
into their stability and dynamics, experiments were performed in defined systems 
consisting of phospholipid membranes:  planar membranes and liposomes.  In planar 
membranes, channel formation was monitored as changes in conductance to K+ and Cl- 
ions.  In liposomes, the release of carboxyfluorescein and the quenching agent, DPX, was 
used to assess the permeabilization of single-walled liposomes by the analogs.  In both of 
these experimental systems, the analogs that were able to permeabilize the MOM were 
also able to permeabilize phospholipid membranes that were free of proteins, 
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demonstrating that the analogs form channels rather than inducing MOM proteins to form 
channels. 
Most of the analogs that could permeabilize the MOM produced conductances in 
planar membranes with similar characteristics to those of C16-Cer.  Examples for 
phytoceramide (T2) and urea-ceramide (A4) are shown in Fig. 3.6.  Channel formation 
occurred after a lag phase and usually required a few separate additions.  Fig. 3.9A shows 
how a sustained conductance developed after a final addition of 1 nmole of (A4).  The 
conductance increased in steps of varying size until it reached a plateau.  Sometimes the 
increase was rapid, reaching a high conductance (Fig. 3.9B).  At the reduced gain 
required to observe the total conductance the increase appears to be very smooth.  
Addition of La+3 resulted in channel disassembly after a variable delay (Fig. 3.9B), which 
is similar to the effect of La+3 on a C16-ceramide channels as previously reported (Siskind 
et al., 2003).   The variable delay is characteristic of a stochastic process (Siskind et al., 
2003) and is also consistent with the formation of a single channel that enlarges in size.  
Most of the analogs appear to form a single large channel in the planar membrane (data 











Figure 3.9 Electrophysiological recording of conductances formed by ceramide analogs in 
planar phospholipid membranes.  A. The formation of a channel by urea ceramide (A4).  Equal 
amounts of the analog were added at intervals (for a total of 4.6 nanomoles) with the last shown 
in the figure.  B. The formation of a C16-phytoceramide (T2) channel and its partial disassembly 
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by the addition of LaCl3.  Channel formation followed the addition of 0.46 nmoles of C16-
phytoceramide (T2).   C. Segments of conductance transients observed after addition of 1 nmole 
of ceramide methylated at the C1-hydroxyl (H1).  The bursts shown were observed over a 40 min 
time period.   D. Transient channels formed by (L6) C18:1-ceramide. A total of 25nmol of C18:1 
was added at intervals and similar patterns of channel growth and disassembly were seen after 
each addition.  In all cases the transmembrane voltage was clamped at 10 mV. 
 
 
Marked exceptions were the behaviors of the conductances produced by 1-O-
methyl-C16-ceramide (H1), N-methyl-C16-ceramide (A3) and C18:1-Cer (L6).  With these 
compounds, the conductance rose rapidly but was transient, declining and returning to the 
baseline shortly thereafter.  This behavior was often observed multiple times in the same 
membrane.  Only occasionally would a prolonged conductance form. The analog with the 
shortest conductance bursts was (H1) (Fig. 3.9C).  The figure shows samples of 
conductance burst recorded within a 40 min period of activity.  (L6) was at the other end 
of the spectrum, producing greater conductances but these also tended to decay (Fig. 
3.9D).  The addition of more sample produced a second transient conductance.  (A3) was 
intermediate between these (data not shown).  The behavior of these analogs is consistent 
with a less stable structure and in agreement with the observations made with isolated 
mitochondria.  (H1) produced virtually no permeability; (A3) had a much diminished 
permeabilizing ability (21% of that induced by C16-cer, Table 3.2); (L6) produced an 
effective permeabilization similar to C16-Cer.  Clearly the channel dynamics are not 
detectable in mitochondrial experiments and only the average permeability to cytochrome 
c is assessed. 
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In general, liposome permeabilization experiments and adenylate kinase release 
experiments produced results in agreement with mitochondrial permeability 
measurements (Table 3.4 and Fig. 3.4). (H1) and the ceramines (A1) and (A2) were the 
exception.  (A2) induced the maximal release of liposomal contents, but did not facilitate 
the release of adenylate kinase from the mitochondrial intermembrane space (Table 3.4).  
The fact that ceramine can permeabilize liposomes to carboxyfluorescein, but did not 
permeabilize the MOM to adenylate kinase is consistent with its formation of small 
channels capable of allowing small molecules to cross membranes, but not large enough 
to allow the passage of proteins. These conductances resemble those published for 
sphingosine (Elrick et al., 2006).  Like (H1), these conductances did not grow in size but 
returned to the baseline and were likely the result of the formation of small pathways 
such as the toroidal structures induced by amphipathic structures (Bechinger, 1997; 
Sansom, 1998; Qian et al., 2008).  Unlike (H1) the transient conductances did not 




The data presented show that the structure of ceramide can be altered in a number 
of ways without losing the ability of the molecule to permeabilize membranes in a 
manner that is consistent with self-assembly into large channels capable of translocating 
proteins through membranes.  The mitochondrial and planar membrane experiments 
suggest that many of the analogs form large, stable channels.   The results indicate the 
relative importance of specific structural features of ceramide for channel formation, 
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namely the differential importance of the hydroxyl groups, the role of the trans double 
bond, and the importance of the stereochemistry. 
3.5.1 Ceramide channel formation is minimally affected by apolar chain length 
Physiologically, the length of the N-acyl chain of ceramide is clearly very 
important (Megha et al., 2007; Pruett et al., 2008). For example, the ceramide synthases 
show strong specificity for different acyl-CoA substrates (Venkataraman et al., 2002; 
Mizutani et al., 2005; Laviad et al., 2008; Menuz et al., 2009).  Some preferentially 
produce long-chain ceramides such as C16-Cer, whilst others preferentially produce very 
long-chain ceramides such as C24-Cer (Venkataraman et al., 2002; Mizutani et al., 2005).  
Many enzymes that metabolize ceramide do not recognize C2-Cer (El Bawab et al., 2002; 
Wijesinghe et al., 2005).  Yet, with regard to the ability to form channels, the length of 
the N-acyl chain was found to be relatively unimportant (Siskind & Colombini, 2000; 
Siskind et al., 2002).  After compensating for the difference in delivery to the 
mitochondrial membranes, the potency of C16-Cer and C2-Cer were found to be 
indistinguishable (Siskind et al., 2006).   Here we tested analogs having shorter N-acyl 
chains (L1, L3) and shorter sphingoid base backbones (L2, L5).  The results indicate that 
these can also form permeability pathways in membranes in a manner consistent with 
channels and interact synergistically with ceramide.  For (L1), the synergy arises from 
the ability of C16-Cer to aid in the insertion of (L1) into mitochondria. 
It is important to note that the minimal ceramide analog, N-palmitoyl-serinol 
(L5), functions very well with only one aliphatic chain.  Thus, one might ask why natural 
ceramides have such a large amount of apolar mass.  The simplest answer would be that 
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the extra bulk anchors the lipid in the membrane, limiting spontaneous, uncatalyzed 
motion between membranes of different organelles. 
3.5.2 C1- hydroxyl group is critical to stable ceramide channel formation; 
modifications to the trans double bond are well tolerated 
An important feature in the ceramide structure is the C4,C5-trans double bond in 
the sphingoid base backbone (Bittman, 2009; Phillips et al., 2009).  For permeabilization 
of the MOM, many changes were well tolerated, namely conversion of trans to cis, 
displacement of the double bond relative to the adjacent hydroxyl, and replacement of the 
double bond by a third hydroxyl.  Thus, a variety of structures are capable of 
permeabilizing membranes in a manner consistent with the channels formed by C16-
ceramide. 
The ability to form stable channels was lost by O-methylation of the C1-hydroxyl 
group (H1). It forms transient pores capable of allowing adenylate kinase release but too 
short-lived to significantly increase the overall MOM permeability to proteins.  The 
transient conductances were evident in planar membrane experiments.  By contrast, O-
methylation of the C3-hydroxyl group (H2) was well tolerated.  Similar results with the 
C3-keto (H3) analog provide additional evidence that C3-hydroxyl modifications are well 
tolerated.  Further evidence for a difference in the importance of these two hydroxyl 
groups comes from results obtained with stereochemical isomers.  The diastereomer 
studied in which “3R” was changed to “3S” (S2) showed no change in MOM 
permeabilizing properties despite a change in orientation of the C3-hydroxyl.  However, 
the enantiomer, with the same change at the C3 position and an additional change from 
“S” to “R” at the C2 position (S1), was much weaker in its capacity to permeabilize 
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mitochondria.   Thus the presence and orientation of the free hydroxyl at C1 is critical to 
the stability of the channels, indicating that this hydroxyl forms part of a highly organized 
structure. 
3.5.3 Amide linkage provides stabilizing structural support for the ceramide channel 
The importance of the amide linkage as an organizing unit is supported by the 
finding that the conversion of an amide chain to an amine-linked chain in ceramine (A1, 
A2) prevents the permeabilization of the MOM to proteins.  If the ceramides are arranged 
in the channel as proposed by the structural model (Siskind et al., 2003; Anishkin et al., 
2006), then the conversion of the amide linkage to an amine would indeed destabilize the 
structure by eliminating the hydrogen bonding that has been proposed to be the basis for 
the columns that make up the channel.  By contrast, the greater hydrogen-bonding and 
ordering ability of a urea linkage according to the structural model would be expected to 
stabilize the channel, and indeed this analog (A4) forms channels (Fig. 3.9A).  The 
introduction of a methoxy group in the amide region (A5) still allowed channel 
formation, indicating that the modification is tolerated. 
N-methyl C16-Cer (A3) can still form channels, which is in apparent contradiction to the 
structural model because the methyl group that replaces the C3 hydroxyl cannot 
participate in hydrogen bonding.  Whilst its ability to permeabilize the MOM is much 
reduced as compared to C16-Cer and in planar membranes it forms unstable channels, the 
ability to form channels at all seems to invalidate the structural model of the ceramide 
channel.  However, channel formation by (A3) is antagonistic with that of C16-Cer, 
indicating that structural incompatibilities were introduced by N-methylation.  Molecular 
modeling studies show that a channel can be formed with the carbonyl group hydrogen-
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bonding with the C1-hydroxyl group through a water bridge as shown by the  example 
structure in Fig. 3.5.   This structure is quite different from the working model of the 
ceramide channel (Anishkin et al., 2006). 
3.5.4 Cooperativity between ceramide and analogs 
Combined addition of C16-Cer and an analog showed cooperativity in membrane 
permeabilization in certain cases: either synergy or antagonism.  The cooperativity 
correlates well with the ability of individual lipids to permeabilize the MOM.  
Surprisingly, the cooperativity seems to involve the insertion into the MOM.  Insertion 
may be catalyzed by structures formed by sphingolipids in the membrane.  Perhaps 
ceramide forms phases or domains in the membrane that could engage or exclude other 
analogs depending on the compatibility or incompatibility of the molecular structures (i.e. 
their ability to bind to each other).  Organized structures composed of many sphingolipids 
would require that each component fit well sterically and in bonding interactions.  Thus 
very similar structures would be interchangeable, complementary structures would show 
synergy and poorly compatible structures would show antagonism.  Without structural 
information it will be difficult to understand the molecular basis for the cooperativity. 
3.5.5 Influence of structural changes on channel function 
The ability of ceramide to self-assemble and form membrane channels is 
remarkably resistant to changes in molecular structure.  However, structural changes in 
specific regions such as the C1-hydroxyl and the amide linkage do decrease channel 
stability or form channels too small to release proteins.  These changes would reduce or 
eliminate the ability of the channel to release proteins from mitochondria.  A reduction in 
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the rate of release and amount of protein release does result in a failure to initiate 
apoptosis.  The use of lasers to damage mitochondria in live cells (Khodjakov et al., 
2004) failed to induce apoptosis presumably because of insufficient protein release and 
thus failure to achieve a critical cytosolic concentration of pro-apoptotic proteins such as 
cytochrome c.  Thus natural selection pressure maintains the structure of ceramide and 
the ability to form large and stable channels. 
 
3.6 CONCLUSIONS 
The results of previously published work on ceramide channels strongly suggests 
that these channels have a highly organized structure, one in which an altered 
configuration of the polar lipid head region would disrupt the structure.  The results 
presented here identify key functional groups important for ceramide channel formation 
and structural aspects where changes are tolerated. The C1-hydroxyl is indispensable for 
channel stability whereas C3-hydroxyl is not critical for channel formation.   It is 
interesting that further elaborations of ceramide in cells involve additions to the C1-
hydroxyl rather than the C3-hydroxyl, thus interfering with the propensity to form 
channels.  The amide linkage is also highly important for channel stability.  Reducing the 
length of the hydrocarbon chains favors channel formation and indeed a single chain is 
sufficient.   The allylic system is not necessary and the trans double bond does not seem 
important to the ability to form channels.  The sensitivity of channel stability to the 
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CERAMIDE AND ACTIVATED BAX ACT SYNERGISTICALLY TO 






A critical step in apoptosis is mitochondrial outer membrane permeabilization 
(MOMP), releasing proteins critical to downstream events.  While the regulation of this 
process by Bcl-2 family proteins is known, the role of ceramide, which is known to be 
involved at the mitochondrial level, is not well-understood.  Here, we demonstrate that 
Bax and ceramide induce MOMP synergistically.  Experiments were performed on 
mitochondria isolated from both rat liver and yeast (lack mammalian apoptotic 
machinery) using both a protein release assay and real-time measurements of MOMP. 
The interaction between activated Bax and ceramide was also studied in a defined 
isolated system: planar phospholipid membranes.  At concentrations where ceramide and 
activated Bax have little effects on their own, the combination induces substantial 
MOMP.  Direct interaction between ceramide and activated Bax was demonstrated both 
by using yeast mitochondria and phospholipid membranes.  The apparent affinity of 
activated Bax for ceramide increases with ceramide content indicating that activated Bax 
shows enhanced propensity to permeabilize in the presence of ceramide. An agent that 
inhibits ceramide-induced but not activated Bax induced permeabilization blocked the 
enhanced MOMP, suggesting that ceramide is the key permeabilizing entity, at least 
when ceramide is present.  These and previous findings that anti-apoptotic proteins 
disassemble ceramide channels suggest that ceramide channels, regulated by Bcl-2-







 Apoptosis, a type of programmed cell death, is a regulated process where 
unwanted or damaged cells are eliminated.  The permeabilization of the mitochondrial 
outer membrane (MOM) to key intermembrane space (IMS) proteins such as cytochrome 
c, Smac/Diablo, and apoptosis-inducing factor, is an irreversible and decision-making 
step in apoptosis, which leads to the execution phase involving effector caspase 
activation.  Ceramide, a pro-apoptotic sphingolipid, has been reported (Pettus et al., 2002; 
Hannun & Obeid, 2008) to act as a second messenger in several cellular processes, 
including apoptosis. It can also form channels (Siskind et al., 2002) and thus can directly 
permeabilize the MOM without the aid of ancillary proteins (Siskind et al., 2008).  
Physiological studies show that ceramide is both an extracellular stimulus and 
intracellular mediator (Pettus et al., 2002; Hannun & Obeid, 2008) of mitochondrial 
apoptosis.  Several lines of evidence indicate that cellular levels of ceramide become 
elevated (Thomas et al., 1999; Charles et al., 2001; Kroesen et al., 2001; Rodriguez-
Lafrasse et al., 2001; Ardail et al., 2009), most importantly in mitochondria (Vance, 
1990; Matsko et al., 2001; Dai et al., 2004; Birbes et al., 2005; Siskind et al., 2006; 
Ardail et al., 2009).  We have shown that Bcl-xL and Bcl-2 can inhibit permeabilization 
induced by ceramide in isolated rat liver mitochondria (Siskind et al., 2008).  This is 
achieved by the anti-apoptotic proteins inhibiting ceramide channel formation and 
disassembling pre-formed ceramide channels.   
 The mechanism by which Bax increases MOMP is cause for much debate 
(Roucou et al., 2002; Antonsson, 2004; Guihard et al., 2004; Zhou & Chang, 2008).  Bax 
is located in the cytosol or loosely associated with the MOM in the monomeric form.  
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Upon an apoptotic signal, Bax inserts into the MOM and becomes activated and 
oligomerized.  Activated Bax and/or Bak are proposed to be directly responsible for the 
release of intermembrane space proteins by forming channels in cells and indeed, in 
phospholipid membranes, Bax treated with β-octyl glucoside (activated Bax) is capable 
of forming channels (Antonsson et al., 1997; Schlesinger et al., 1997). Yet whether these 
channels are large enough to allow for the release of all the IMS proteins is unclear 
(Roucou et al., 2002).  In yeast cells that lack the mammalian apoptotic machinery, 
expression of Bax still leads to leads to cytochrome c release and cell death indicating 
that Bax channels may suffice despite the presence of ceramide.  However the effect of 
Bax is inhibited by co-expression of sphingomyelin synthase, which consumes ceramide 
(Yang et al., 2006).  In mammalian cells, ceramide-induced cytochrome c release does 
not require Bax (Neise et al., 2008; Siskind et al., 2008) but Bax enhances apoptosis 
induced by ceramide (von Haefen et al., 2002).  Also, ceramide has been found to 
activate monomeric Bax in the presence of the MOM (Birbes et al., 2005; Kashkar et al., 
2005).  When combined, these publications can be interpreted to indicate that Bax and 
ceramide may interact cooperatively to generate the MOMP.  This is clearly not the view 
of most investigators in the field but it is a logical conclusion from published 
experiments.  The present work provides direct evidence of a synergistic interaction 
between activated Bax and ceramide resulting in enhanced MOMP to proteins. We also 






4.3 MATERIALS AND METHODS 
4.3.1 Reagents 
C16-ceramide was bought from Avanti Polar Lipids. Antimycin A, 2, 4-
dinitrophenol (DNP), horse heart cytochrome c, fatty acid-depleted bovine serum 
albumin (BSA), and sodium ascorbate were bought from Sigma Chemical Co. Other 
chemicals were reagent grade.  
4.3.2 Isolation of mitochondria 
Rat liver mitochondria were isolated essentially as previously described (Siskind 
et al., 2002). The isolation buffer was 210 mM mannitol, 70 mM sucrose, 0.1mM EGTA, 
0.05% fatty acid free BSA, 5mM HEPES, pH 7.4. To achieve a high level of intactness, 
mitochondria were sedimented at 5600 RCF (average).  Finally, the BSA was removed 
by sedimenting the mitochondria in isolation buffer without BSA.  These were suspended 
in sucrose-free medium (280 mM mannitol, 0.1 mM EGTA, 2 mM HEPES, pH 7.4), 
typically to a protein concentration of 9-10 mg/mL and stored on ice.  
 Yeast mitochondria were prepared and isolated as previous described (Lee et al., 
1998) until the washed spheroplast pellet was obtained.  Twice, the pellet was 
resuspended in H-medium (0.6 M mannitol, 0.1 mM EGTA, 10 mM HEPES, pH 7.2) and 
spun at 700 RCF for 5 min to yield the mitochondrion-containing supernatants.  The 
supernatants were spun at 5600 RCF for 10 min and the pellets were retained.  The 
pellets were resuspended in H-Medium, combined and spun at 700 RCF for 5 min. The 
supernatant was spun at 5600 RCF for 10 minutes yielding the final mitochondrial pellet 
which was resuspended in H-medium.  
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 The intactness of the mitochondria, as measured by comparing their rate of 
cytochrome c oxidation with that of osmotically shocked mitochondria (Siskind et al., 
2002), was more than 85% for rat mitochondria and over 93% for yeast mitochondria. 
4.3.3 Preparation of Bax 
Recombinant human Bax was produced as described previously (Suzuki et al., 
2000) except the Bax eluted from the chitin column (New England Biolabs Inc) was 
dialyzed in 12000 M.W. cut-off dialysis membranes at 4oC for 24 hours in 3L (1mM 
EDTA and 20mM Tris-HCl pH 8.0) and then changed into 5L (20mM Tris-HCl pH 8.0) 
for 48 hours.  The Bax was then filter sterilized through a 0.2 µm filter and 0.5 mL 
aliquots were made.  Glycerol (10%) was added to some of these and they were rapidly 
shell-frozen in ethanol and dry ice and stored at -80oC. The protein content was typically 
10-25µg/mL, assayed by the Micro BCA Protein Kit (Pierce Chemical Co), and 
SDS/PAGE analysis showed a 95% pure m-Bax band.   No detergents were used during 
the protein isolation. It must be noted that monomeric Bax, when stored in solution at 4oC 
shows a tendency to oligomerize over time, which is why most of the protein was 
immediately frozen after purification and only thawed on ice just before use. This method 
of freezing did not alter protein activity. The native Bax was oligomerized by adding 
10% β-octyl glucoside to a final concentration of 0.7% and incubated for 30 min on ice.  
The proper folding of the detergent treated Bax was confirmed by its partial resistance to 
trypsin (Fig. 2.1), as published elsewhere (Lucken-Ardjomande et al., 2008). Note that 
the concentrations of activated Bax reported in the paper were based on the molecular 




4.3.4 Purification of N/C Bid 
Recombinant N/C Bid (cleaved human Bid) was purified as previously described 
(Kuwana et al., 2002).  Once the Bid was bound to the glutathione-sepharose beads, 
50U/ml thrombin in PBS was loaded onto the column and allowed to incubate overnight 
at room temperature.  The addition of thrombin directly to the column allowed us to elute 
only N/C Bid without the contamination of the GST tag in one step.  The elution was then 
dialyzed overnight against 50mM Tris-HCl pH 8.0, filter sterilized, aliquotted and rapidly 
frozen as described above. The yield was typically 3 mg/mL as assayed by the Micro 
BCA Protein Kit (Pierce Chemical Co.) and SDS/PAGE analysis showed an over 95% 
pure N/C Bid band. Wherever N/C Bid was used, protease inhibitors were added to 
prevent any deterioration of protein activity.  The final concentration of the protease 
inhibitors was: 1.5µM pepstatin, 16.5µM chymostatin, 2.2µM leupeptin, .6µM aprotinin 
and 20µM PMSF. 
4.3.5 Cytochrome c accessibility assay 
Shortly before use, mitochondria were diluted in the isolation buffer to 0.5 mg 
protein/mL and stored on ice.  Once diluted, mitochondria lose function more rapidly and 
so the diluted suspension is used within an hour.  In a typical experiment, 50µL of this 
dilution was dispersed in 650µL of room temperature incubation buffer (the sucrose-free 
buffer supplemented with 5mM DNP and 5µM antimycin A and pH 7.25 (Siskind et al., 
2002) to final protein content of 25 µg in 700µL).  Unless otherwise stated, this was done 
for all experiments.  In most experiments, when Bax was added, it was added 
immediately.  Then the mitochondria were incubated for 10 min at room temperature to 
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allow them to acclimate and interact with Bax.  In experiments where N/C Bid and 
monomeric Bax were used, the mitochondria were incubated with the permeabilizing 
agents for 30 minutes at 30oC in a rotary shaker set for gentle mixing.  Ceramide was 
generally added at this point from a 1 mg/mL solution in isopropanol. It was added while 
simultaneously vortexing the microfuge tube vigorously so as to achieve rapid and 
effective dispersal of the sphingolipid (controls show that this does not damage the outer 
membrane).  After dispersal, the mixture was incubated for 10 min followed by 
measurement of the outer membrane permeability.  Reduced cytochrome c (Siskind et al., 
2002) was added to the mitochondrial suspension (10µL; final concentration approx 
25µM) and the absorbance at 550nm was measured immediately for 2 min.  The initial 
rate was used to assess the permeability of the MOM to cytochrome c.  The extinction 
coefficient of 18.5 mM-1 · cm-1 (Δ∈Red.-Ox.) was used to convert absorbance units to µM 
units.  
4.3.6 Assessment of apparent dissociation constant of ceramide channels for 
activated Bax 
The oxidation rate was used as the functional parameter to evaluate the apparent 
dissociation constant of ceramide channels for activated Bax.  The data was plotted using 
the Hill formalism for cooperative binding.  
 
where the rates are the initial activated Bax-stimulated rates of oxidation at a specific 
ceramide concentration, above the rate observed with ceramide alone. rateBax is the rate at 








formalism.  The inherent variability in the experiments forced us to combine these 
parameters into one.  Since K and n increased simultaneously with amount of ceramide 
used, we found it more informative to combine these two parameters into one term: 
K0.5 = [1/K]1/n 
K0.5 is the Bax concentration at which the extent of permeabilization (as measured by the 
rate of cytochrome c oxidation) is half-maximal. It is a measure of the apparent 
dissociation constant, the reciprocal of the apparent affinity.  
4.3.7 Electrophysiological Experiments 
The monolayer method was used as described previously (Colombini, 1987a) to 
make planar phospholipid membranes.  Calomel electrodes were used to interface with 
the aqueous solutions (1.0 M KCl, 1mM MgCl2, 5mM PIPES pH 6.95] on either side of 
the membrane.  The voltage was clamped and the current recorded.  The lipid solution 
contains 0.5% (w/v) 1,2-diphytanoyl-sn-glycero-3-phosphocholine, 0.5% (w/v) asolectin, 
and 0.05% (w/v) cholesterol dissolved in hexane.  To form a ceramide channel, a stock 
solution of 0.05 mg/ml C16- ceramide was made in isopropanol and 10-20µL amounts 
were added to the cis side of the membrane while stirring for 15 seconds to induce an 
initial conductance.  The channel was then allowed to enlarge and stabilize before the 
addition of proteins or other compounds.  To obtain an activated Bax conductance, 
activated Bax was added to the cis side of the membrane only. 
4.3.8 Adenylate Kinase Assay 
As described earlier (Siskind et al., 2002), mitochondria were resuspended in the 
incubation buffer (50mM potassium lactobionate, 180mM mannitol, 0.1mM EGTA and 
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2mM HEPES and pH 7.4) to a final mitochondrial protein concentration of 160µg/mL.  
After adding ceramide and Bax, as done for cytochrome c oxidation assay, to 1 mL 
aliquots, mitochondria were incubated at 30oC for 30 min. The mitochondria were 
sedimented at 14,000 RCF  for 5 min at 4oC and 300µL of the supernatant was combined 
with 700µL adenylate kinase reaction buffer (50mM Tris, 5mM MgSO4, 10mM glucose, 
5mM ADP, 0.2mM NADP pH 7.5) that had been preincubated for 2 min with 5µL of 
enzyme mixture (2.5 units of hexokinase and 8.7 units of glucose-6-phosphate 
dehydrogenase).  The absorbance of the mixture at 340nm was recorded immediately and 
the initial rate used as a measure of the adenylate kinase activity. Maximal release of 
adenylate kinase was achieved by exposing the mitochondria to an osmotic shock.  An 
aliquot of the mitochondrial suspension (usually 10-20 µL containing 160 µg 
mitochondrial protein) was added to in 1mL distilled H2O (50 to 100 fold shock) and 
incubated on ice for 10 min.  
4.3.9 Statistics 
The Student’s t test was used to determine the probability values. 
 
4.4 RESULTS 
4.4.1 Activated Bax enhances ceramide-induced MOMP 
To evaluate the influence of Bax on ceramide permeabilization of the MOM, we 
used a dynamic cytochrome c accessibility assay, as previously described (Siskind et al., 
2002).  This is a dynamic measurement of permeability and permeability changes in the 
MOM to cytochrome c in real-time.  While treatment of isolated mitochondria with low 
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levels of ceramide or N/C Bid-monomeric Bax induced a small amount of membrane 
permeabilization, when the same amounts were added together, there was a synergistic 
increase in MOMP (Fig. 4.1A). This synergistic induction of permeabilization was also 
observed using the adenylate kinase release assay that evaluates release of proteins from 
the intermembrane space. (Fig. 4.1B). N/C Bid alone did not have any effect on 
ceramide-induced MOMP at these levels.  It must be noted that processed Bid itself is 
capable of permeabilizing mitochondria (Kluck et al., 1999), possibly by acting on Bak. 
Also, the degree of Bax activation varies with the amount of N/C Bid.  In order to 
eliminate the effects of N/C Bid alone on ceramide and differences in degree of Bax 
activation at different concentrations of N/C Bid, we used chemically activated Bax for 
subsequent experiments.  Bax activated chemically with detergent has been found to 
permeabilize the MOM in similar manner to physiologically activated Bax (Kuwana et 
al., 2002; Ivashyna et al., 2009) and shows similar restricted accessibility to trypsin 
(Lucken-Ardjomande et al., 2008).  A similar synergistic enhancement of 
permeabilization was also observed with ceramide and chemically activated Bax (Fig. 
4.1C). Under these conditions, there was no swelling of the mitochondria and thus the 




Figure 4.1 Ceramide (cer) and activated Bax increase the MOMP in a cooperative fashion 
assessed by the cytochrome c accessibility assay (A, C, D) or adenylate kinase release (B).   
A Isolated rat liver mitochondria diluted to 250µg protein/mL were pre-treated with both 45nM 
N/C Bid and 40nM monomeric Bax.  Sub-aliquots containing 25µg of mitochondria were either 
treated with 5 µL isopropanol (as a vehicle control) or 5µL of 1 mg/mL ceramide (in isopropanol) 
and incubated at room temperature for 10 min before assaying for cytochrome c accessibility. 
Respective vehicle controls were subtracted from the data shown. The “add” bar is the sum of the 
rates measured with ceramide alone and Bid/Bax alone.  The results are the means ± S.D. of 3 
experiments. The respiration rate of the combined treatment differed from the sum of the 
individual rates with p < .01.  B Rat liver mitochondria were treated either with 10 µg ceramide or 
a combination of 40nM monomeric Bax and 245nM N/C Bid or both and the released adenylate 
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kinase activity was measured.  The “add” bar is the sum of the results of individual treatments 
minus their product divided by the maximal possible release (to correct for both agents acting on 
the same mitochondrion).  The combined treatment exceeded the sum of individual treatments, 
“add”, with p < .05.  C Isolated rat liver mitochondria were treated with either 1 µg ceramide, 
15nM detergent activated Bax (ac-Bax), or both.  The results are mean ± S. E. of 3 experiments.  
The combined treatment exceeded the sum of individual treatments, “add”, with p < .05.  D 
Mitochondria isolated from wild-type S. cerevisiae were used and treated with 2 µg of ceramide 
and activated Bax as shown. The results are means ± S.E. of 3-5 experiments.  Statistical tests 
yielding p < .05 compared the results of the combined treatment of ceramide and ac-Bax with the 
numerical addition of the results of treatments with ceramide alone and ac-Bax alone. 
 
 
One possible interpretation for the synergistic interaction between ceramide and 
activated Bax is that activated Bax could be binding to anti-apoptotic proteins thus 
removing any inhibitory effect on ceramide induced MOMP.  To test if the anti-apoptotic 
Bcl-2 proteins are involved in this interaction, ceramide induced MOMP enhancement by 
activated Bax was tested using yeast mitochondria, which are devoid of Bcl-2 family 
proteins.  We found that activated Bax and ceramide interact synergistically to induce 
MOMP in yeast mitochondria also, suggesting that their interaction could be direct and 
not indirectly mediated by elimination of inhibition by anti-apoptotic members (Fig. 
4.1D).  This also suggests that the interaction between activated Bax and ceramide does 
not require processed Bid or Bak. 
4.4.2 Bax-mediated enhancement of ceramide-induced permeabilization can be 
inhibited by trehalose, a disaccharide that disassembles ceramide channels 
Since both Bax and ceramide are channel formers and each of them is capable of 
permeabilizing the MOM in the absence of the other, we wanted to test whether, in this 
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synergistic interaction, Bax is enhancing ceramide channels or vice versa.  Some insight 
was gained by using trehalose, a disaccharide that inhibits ceramide channels causing 
partial disassembly.  The same dose of trehalose inhibited both the ceramide induced 
MOM permeabilization and the enhancement of this permeabilization induced by 
activated Bax (Fig. 4.2A). In this experiment, activated Bax alone had essentially no 
effect.  Using a higher concentration of activated Bax (inset) a significant MOMP was 
achieved and trehalose had no effect on this MOMP induced by activated Bax alone.  The 
simplest interpretation is that the enhanced MOMP has the properties of ceramide 
channels.  Activated Bax could be acting by enhancing the permeabilization induced by 
ceramide, perhaps by favoring the growth of ceramide channels.  This observation can 
also be explained by a complex structural assembly of ceramide and activated Bax that is 
sensitive to trehalose. However, this observation is inconsistent with the possibility that 
ceramide is simply enhancing Bax activation.  In addition, if the enhanced MOMP were 
the result of ceramide monomers enhancing channels formed by activated Bax then it is 
hard to see how trehalose could interfere with this process because trehalose cannot 




Figure 4.2 Trehalose (23 mM final) inhibits MOMP induced by ceramide alone and that 
induced by the combination of ac-Bax and ceramide.   
In the main figure, samples were treated with 30 µg of ceramide and 10 nM ac-Bax as indicated.  
In the inset 43 nM ac-Bax was used to obtain a high enough MOMP.  The cytochrome c 




4.4.3 Bax expands ceramide-induced conductance in planar phospholipid 
membranes 
Planar phospholipid membranes are membranes consisting only of phospholipids 
and cholesterol.  Being a defined system, one can clearly demonstrate interactions 
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without the influence of other constituents found in natural membranes.  The ability of 
ceramide to form channels in planar membranes has been established (Siskind & 
Colombini, 2000).  To assess the effect of activated Bax on ceramide channels in an 
environment free of other membrane components, ceramide channels were formed in the 
planar membranes and then activated Bax was added.  Activated Bax caused a large 
increase in conductance while monomeric Bax (m-Bax) did not significantly affect the 
channel (Fig. 4.3A).  This is typical of many experiments.  These show that the 





Figure 4.3 Addition of activated Bax to a ceramide channel in a planar phospholipid 
membrane causes it to enlarge.  
A. The initial conductance was formed by the addition of 16 µg ceramide to a high-
resistance phospholipid membrane.  Once the conductance had stabilized first monomeric Bax 
then activated Bax were added to both sides of the membrane.  Once the conductance rise had 
restabilized at a higher level LaCl3 was added to the final concentrations indicated in the figure.  
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The LaCl3 additions were added to one side in the sequence: cis, cis, trans, trans. The experiment 
shown is representative of more than 8 experiments. Amounts of added ceramide and ac-Bax 
were different between experiments. Bax enhancement of a ceramide channel was seen in over 50 
experiments. B. A small ceramide channel was formed followed by the addition of ac-Bax at the 
indicated final concentration.  Trehalose was added as indicated.  C Activated Bax conductances 
were induced in a planar phospholipid membrane in the experiment illustrated in the figure.  The 
total amount of activated Bax added was equivalent to 42 nM.   Trehalose was added as indicated 




 Trehalose also inhibited the conductance of a ceramide channel formed in a 
phospholipid membrane (data not shown).  In Fig. 4.3B, a small ceramide conductance 
was greatly increased by the addition of activated Bax to a final calculated size of 50 nm.  
At the reduced scale used to show the experiment, the initial ceramide conductance is 
barely visible.  Once the conductance stabilized, trehalose was added resulting in an 
immediate decline in conductance.  Thus the activated Bax-enhanced conductance was 
reduced by trehalose (Fig. 4.3B).  Trehalose has no effect on the conductance produced 
by activated Bax alone (Fig. 4.3C).  Thus, trehalose is useful to effectively distinguish 
between a permeability formed by activated Bax and one formed by ceramide.  When the 
Bax/ceramide conductance was inhibited using lanthanum ions, there was stochastic 
delay in channel disassembly, suggesting that a singular structure is responsible for the 
conductance observed.  Ceramide and activated Bax may be forming a unified structure 
or activated Bax might enhance the size of the ceramide channel. These experiments also 
suggest that metabolism of ceramide to other sphingolipids like sphingosine is not 
necessary for interaction with activated Bax and the consequent changes in permeability.  
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4.4.4 The influence of activated Bax on MOMP depends on the amount of added 
ceramide 
At a low level of added ceramide 0.5 µg/mL, the amount of activated Bax needed 
to enhance the MOMP to half maximal was 20 nM.  At a higher dose of 1.0 µg ceramide, 
less activated Bax was needed to achieve a half-maximal effect (12nM) (Fig. 4.4A).  
Both of these results were obtained on the same mitochondrial preparation, eliminating 
variability between mitochondrial isolations.  This difference can be interpreted as a 
change in apparent affinity between activated Bax and a ceramide channel as the size of 
the ceramide channel increases.  In a separate set of experiments (Fig. 4.4B) low levels of 
ceramide still show a dose-dependence but at high levels (10 µg), the enhancement by 
activated Bax was not observed (Fig. 4.4B).  The lack of further stimulation was not due 
to the achievement of maximal cytochrome c accessibility to cytochrome oxidase because 
higher levels of ceramide did produce still higher rates of cytochrome c oxidation, closer 
to those observed with hypotonically-shocked mitochondria.  This indicates that the 
effect of activated Bax on ceramide induced-MOMP is a saturable function of the amount 
of ceramide. This saturation could be interpreted as activated Bax favoring an optimal 
size of the ceramide channel and if the channel is already at the optimal size there is no 




Figure 4.4 Dose-response curves of the enhancement of ceramide mediated MOMP by the 
addition of activated Bax to rat liver mitochondria. A, B Experiments were performed by 
preincubating the mitochondria with the indicated amount of activated Bax for 10 min followed 
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by addition of the indicated amount of ceramide.  A 0.5µg and 1µg of ceramide were used.  These 
results are mean ± S. E. of 4 experiments.  B 0.5µg and10µg of ceramide were used.  These 
results are mean ± S. E. of 3-4 experiments. Experiments within one panel were performed on the 
same batch of mitochondria.  C Summary of the results of 4 independent experiments.  Each set 
of data points defining each line was determined from a set of experiments performed on the 
same mitochondrial isolation.  The figure shows the increase in apparent affinity of activated Bax 
for ceramide channels with increase in ceramide content.  K0.5 is defined in the method section.  
These results were obtained from experiments such as those illustrated in A and B. 
 
 
cooperativity, n, and the constant, K.  The Hill parameters were combined (see methods) 
to evaluate the apparent dissociation constant, K0.5 (the Bax concentration at which half-
maximal enhanced permeabilization is achieved).  The resulting apparent dissociation 
constant of activated Bax for ceramide channels in the MOM decreases as the ceramide 
concentration increases (Fig. 4.4C). This is highly reproducible, despite the variation in 
intrinsic sensitivity of isolated mitochondria to added ceramide.  Each line represents the 
results of sets of experiments performed on one isolated batch of mitochondria.  These 
results indicate a relationship between the structure of activated Bax and the structure 
formed in the presence of ceramide. An increase in affinity indicates a better fit.  The 
increase in MOMP may result from an increase in diameter of the Bax-ceramide 
assembly resulting is a better match to the structure of activated Bax.  In this way 







The release of proteins from mitochondria is a critical, decision-making step in 
apoptosis and thus the identification of the structure responsible for this release has many 
important implications.  A favorite candidate for the release pathway is activated Bax 
since Bax is pro-apoptotic, can form channels and its activation on the MOM leads to 
protein release.  Interestingly, ceramide is also pro-apoptotic, can self-assemble to form 
channels (Siskind & Colombini, 2000; Pettus et al., 2002; Hannun & Obeid, 2008) and its 
delivery to the MOM leads to protein release (Birbes et al., 2001; Pettus et al., 2002; Di 
Paola et al., 2004; Birbes et al., 2005) Here we show that activated Bax and ceramide act 
synergistically to permeabilize the MOM.  
The nature of the channels formed in the presence of both ceramide and activated 
Bax is not known and could be a structure fundamentally different from that formed by 
either substance alone.  Some findings in this work, however, are easily interpreted in 
terms of activated Bax controlling the structure of ceramide channels.  The apparent 
affinity of activated Bax for ceramide-induced MOM permeability increases with the 
amount of ceramide added.  In other words, as the amount of added ceramide was 
increased, lesser amounts of Bax were required to achieve half-maximal 
permeabilization.  This could be due to more ceramide increasing the degree of Bax 
activation but at high levels of ceramide, where ceramide by itself produced a large 
permeability, there was no further stimulation by activated Bax (even though additional 
amounts of ceramide would have increased MOMP).  This observation is not easily 
compatible with ceramide activating Bax or the two channels mutually enhancing each 
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other.  It is more naturally explained by activated Bax favoring the growth of a ceramide 
channel up to a size designated by the structure of activated Bax.   
Activated Bax seems to enhance the size of ceramide channels up to some critical 
level, probably an optimum channel size.  The increased radius of curvature may offer a 
better fit for activated Bax.  Regardless of the site of interaction, if the interaction energy 
increases with channel size, then the binding of activated Bax to a smaller channel could 
generate stress on the channel that would be relieved by the channel growing in size (Fig. 
4.5).  The dynamic equilibrium between ceramides in the channel and non-conducting  
 
 
Figure 4.5  Illustration of how activated Bax might increase the size of the ceramide 
channel.   
On the left, a 32-column ceramide channel has a small radius of curvature than ac-Bax.  
When ac-Bax binds (center) it distorts the channel disturbing the equilibrium between ceramide 
aggregates on the monolayer and ceramides forming the channel.  The insertion of more ceramide 
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columns increases the channel size until its curvature matches that of activated Bax (right), 
forming a 48-column channel. 
 
ceramide in the membrane would be shifted toward ceramide insertion into the channel 
and thus growth of the channel size.  Once the optimal size is achieved, activated Bax 
would have no further effect and this was observed. It is possible that the physical shape 
of the activated Bax in the membrane might act as a molecular mold to drive the 
ceramide channel to an optimum size.  
The results obtained with phospholipid membranes argue that the interaction 
between activated Bax and ceramide channels must be direct. Furthermore, these 
demonstrate that activated Bax increases the size of the single existing ceramide channel 
because the disassembly of the resulting enhanced permeability shows stochastic 
properties consistent with a unified structure.  If the added Bax were to form a separate 
structure then the disassembly would show two separate processes rather than just one.  
This is in harmony with the natural interpretation of the mitochondrial experiments that 
measured the apparent affinity of activated Bax as described above.  
Experiments on isolated mitochondria raise the possibility of indirect effects.  
Ceramide could act on another mitochondrial component and thus indirectly influence the 
ability of activated Bax to permeabilize the outer membrane.  Indeed, a product of 
ceramide metabolism could be the active species.  Mitochondria have ceramidases that 
could convert ceramide to sphingosine (Bionda et al., 2004; Siskind, 2005).  Although the 
conversion rate was shown to be minimal under the conditions of our experiments 
(Siskind et al., 2005), even a small conversion might be important.  Sphingosine was 
shown to be capable of interacting with and influencing the formation of ceramide 
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channels (Siskind et al., 2005) and thus might influence the channel-forming ability of 
activated Bax.  Although this possibility cannot be excluded, the experiments performed 
in planar membranes demonstrate a direct functional synergism between ceramide and 
activated Bax in terms of channel formation.  The close parallelism between the results 
obtained with the two experimental approaches provides strong confidence that both are 
reporting the same synergistic permeabilization.   
It is not clear whether the release of IMS proteins in vivo is due to transient 
openings or sustained permeability.  Many publications (Jurgensmeier et al., 1998; Kluck 
et al., 1999) have reported a Bax-induced release of cytochrome c from isolated 
mitochondria over a period of hours without significant increases in the MOM 
permeability to cytochrome c.  Transient channel openings are a likely explanation.  Does 
this mean that the Bax/ceramide sustained permeabilization of the MOM and thus rapid 
release of protein is unnecessary or unphysiological?  It seems unlikely that the 
Bax/ceramide synergism is an interaction that is not specific and not maintained by 
natural selection, especially since anti-apoptotic proteins act precisely in the opposite 
manner (Siskind et al., 2008).  Further, Kluck et al. (Kluck et al., 1999), have shown that, 
in the presence of a putative apoptotic component of the cytosol (which would be 
expected to be available to apoptotic mitochondria in vivo), Bax induces sustained 
enhancement of permeability. Munoz-Piendo et al. (Munoz-Pinedo et al., 2006) report 
that a non-specific pore showing prolonged permeability is responsible for protein release 
during apoptosis.  Thus the sustained permeability observed in the presence of activated 
Bax and ceramide is not an aberration.   
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 It must be emphasized that the experiments were performed with physiologically 
relevant doses of ceramide and Bax.  The ceramide used in this study is C16-ceramide 
which is one of the common, naturally occurring, long-chain ceramides.  The amounts of 
ceramide used seem high but, only about 5% of the ceramide added to isolated 
mitochondria inserts into mitochondrial membranes (Siskind et al., 2006), requiring the 
addition of larger amounts of ceramide to the mitochondrial suspension to achieve 
MOMP. Nevertheless, as shown previously (Birbes et al., 2005; Siskind et al., 2006), we 
are working at mole fractions of ceramide typically found in mitochondria early in 
apoptosis. The amount of activated Bax used in these experiments is also at physiological 
levels. Enhancement of ceramide induced MOMP was achieved with levels of activated 
Bax in the low nM range. At these levels, activated Bax often has little or no effect on 
MOMP, indicating that its action on ceramide channels may be more important. 
Activation of Bax in cells is thought to be mediated by N/C Bid in cells. Apart 
from N/C Bid, non-ionic detergents, at their CMC, have also been found to activate Bax 
(Hsu & Youle, 1997; Lucken-Ardjomande et al., 2008).  This detergent-activated Bax 
shows similar reactivity to conformation specific antibody (Hsu & Youle, 1997) and 
restricted accessibility to trypsin digestion (Lucken-Ardjomande et al., 2008).  We have 
used detergent activated Bax for most of our experiments to focus on the Bax/ceramide 
interaction.  This is just part of a bigger, more complicated, picture.  For example, Bcl-2 
family proteins have been shown to regulate the formation of ceramide also, during 
apoptosis (Sawada et al., 2006).  
These and earlier studies with the anti-apoptotic Bcl-2 family proteins (Siskind et 
al., 2008) underscore that natural selection has favored mechanistic interactions between 
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some Bcl-2 family proteins and ceramide resulting in functional outcomes.  These 
functional interactions could be pivotal in regulating MOMP under circumstances where 
both ceramide and the Bcl-2 family proteins are present.   
 
 
4.6 CONCLUDING REMARKS 
Experiments with isolated mitochondria and phospholipid membranes show that 
low levels activated Bax and ceramide interact to enhance the membrane permeability to 
a level greater than each agent alone.  The results are best interpreted as activated Bax 
enhancing ceramide channels but other interpretations are not excluded.  These results are 
in harmony with published results showing that anti-apoptotic proteins disassemble 
ceramide channels.  These show that the Bcl-2 family of proteins that regulate protein 
release from mitochondria early in apoptosis also interact with ceramide and ceramide 
channels to influence MOMP.  This result is consistent with an emerging picture that 
ceramide channels may be a pathway by which proteins are released from mitochondria, 
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This study demonstrates the important structural features of ceramide required for 
proper regulation, binding and identification by both pro-apoptotic and anti-apoptotic 
Bcl-2 family proteins. The C4:C5 trans double bond has little influence on the ability of 
Bax and Bcl-xL to identify and bind to these channels. The stereochemistry of the head 
group and access to the amide N-H group of ceramide is indispensible for Bax binding 
indicating that Bax may be interacting with the polar portion of the ceramide channel 
facing the bulk phase. On the contrary, Bcl-xL binding to ceramide channels is tolerant of 
stereochemical changes in the head group. This study also revealed that Bcl-xL has an 
optimal interaction with long-chain ceramides that are elevated early in apoptosis while 
short-chain ceramides are not well regulated. Inhibitors specific for the hydrophobic 
groove of Bcl-xL including 2-methoxyantimycin A3, ABT-737, and ABT-263 provide 
insights into the region of Bcl-xL involved in binding to ceramide channels. Molecular 
docking simulations of the lowest energy binding poses of ceramides and Bcl-xL 
inhibitors to Bcl-xL were consistent with the results of our functional studies and propose 









The intrinsic pathway of apoptosis, a type of programmed cell death, is regulated 
at the mitochondrial level by the Bcl-2 family of proteins. Permeabilization of the 
mitochondrial outer membrane (MOM) leads to the release of key intermembrane space 
(IMS) proteins, such as cytochrome c, which irreversibly commit the cell to the execution 
phase of apoptosis.  The Bcl-2 proteins have pro-survival members, such as Bcl-xL, Bcl-
2, and Mcl-1, that maintain the integrity of the MOM in normal cells and pro-apoptotic 
members, like Bax, Bak and Bid that initiate the apoptotic process and facilitate IMS 
protein release when the cell is damaged or an apoptogenic signal is delivered. Whether 
the anti-apoptotic or pro-apoptotic Bcl-2 proteins prevail will determine whether IMS 
proteins are released by a pore through the MOM and thus the fate of the cell.  There are 
multiple pathways proposed for the release of IMS proteins from mitochondria (Dejean et 
al., 2005; Siskind et al., 2006; Chiara et al., 2008; Montessuit et al., 2010), and even Bax 
itself is able to form channels (Terrones et al., 2004; Lovell et al., 2008). Whatever the 
nature of the pathway, it must be tightly regulated to prevent unwanted cell death.  One 
such proposed pathway for IMS protein release is formed by the bio-active sphingolipid 
ceramide.  
The involvement of ceramide in apoptosis is widely recognized and in response to 
many different apoptotic stimuli intracellular ceramide levels increase; specifically, it is 
the elevation of ceramide in mitochondria that is pro-apoptotic (Birbes et al., 2001; 
Matsko et al., 2001; Dai et al., 2004; Birbes et al., 2005). Elevation of ceramide in 
mitochondria can  occur in a  number of ways (Siskind, 2005; Mullen & Obeid, 2011), 
including transfer of ceramides from mitochondrial associated membranes (Stiban et al., 
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2008).  In fact, while Bax/Bak knockout cells are known to be highly resistant to 
apoptosis (Wei et al., 2001; Zong et al., 2001), it was shown recently that this resistance 
is accompanied by a deficit in ceramide generation, as Bak regulates ceramide 
metabolism by activating a critical ceramide synthase to elevate mitochondrial ceramide 
levels (Siskind et al., 2010). Moreover, while metabolism of ceramide to other forms, 
such as glucosylceramide, can render cells less susceptible to cytotoxic agents (Komori et 
al., 1999; Liu et al., 2001; Itoh et al., 2003), blocking ceramide metabolism can sensitize 
multi-drug resistant cells to death (Lavie et al., 1997; Patwardhan et al., 2009; Liu et al., 
2011). Thus, the steady-state level of ceramide is an important step in the apoptotic 
program in a variety of cell types (Komori et al., 1999; Chapman et al., 2010), and 
cytotoxic stimuli (Lavie et al., 1997; Dai et al., 2004; Birbes et al., 2005) and ceramide 
channel formation can be demonstrated at these physiological levels of ceramide in 
mammalian mitochondria and yeast mitochondria (Siskind et al., 2002; Siskind et al., 
2006; Siskind et al., 2008). Ceramide channels have also been visualized in liposomes 
using transmission electron microscopy (Samanta et al., 2011). These structures are stable 
and have been shown to be large enough for the release of all known IMS proteins 
released from mitochondria during apoptosis (Siskind et al., 2002). 
The current model of the ceramide channel highlights the structural features that 
are important for channel formation ((Anishkin et al., 2006), see Table 5.1 for structure of 
ceramide and analogs). The amide nitrogen and carbonyl group allow for the formation of 
ceramide columns. Adjacent ceramide columns are held together by the C1 and C3 
hydroxy groups forming the lumen of the channel. The length of the hydrocarbon chains 
of ceramide, though physiologically important (Megha et al., 2007; Pruett et al., 2008), is 
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relatively unimportant for channel formation (Siskind et al., 2003). The sphingoid base is 
typically 18 carbons in length with a trans double bond at the C4:C5 position. The 
ceramide species in mammalian cells have fatty-acyl chains that range from 12 to 24 
carbons in length. It is important to note that ceramide channels are highly stable, rigid 
structures that are held together by a vast network of hydrogen bonds (Anishkin et al., 
2006; Ganesan et al., 2010) and not simply lipidic pores of a transient, non-specific 
nature.  
It was found that ceramide channels are regulated by the Bcl-2 family of proteins. 
The pro-survival Bcl-2 members, Bcl-xL and Ced-9 (the C. elegans homolog of Bcl-2) 
were shown to antagonize channel formation and disassemble ceramide channels (Siskind 
et al., 2008). Conversely, a pro-apoptotic Bcl-2 member, Bax, can directly enhance 
ceramide channels (Ganesan et al., 2010). The regulation of ceramide channels was 
demonstrated by the addition of purified Bcl-2 family proteins to isolated mammalian 
mitochondria (which have other Bcl-2 family proteins naturally present in those 
membranes), yeast mitochondria (which do not have potentially interfering Bcl-2 family 
proteins), and planar phospholipid bilayers (which are devoid of any proteins or 
specialized lipids). These results highlight the ability of Bcl-2 family proteins to identify 
and regulate ceramide channels. These interactions are highly specific and do not require 
other proteins or specialized lipids, demonstrating for the first time that a channel formed 
of lipids can be regulated by a protein. Remarkably, this regulation was in accordance 
with the known physiological function of these Bcl-2 proteins. 
In this study, we set out to further understand the interaction of ceramide channels 
and Bcl-2 family proteins. We provide insights into the specific sites on the ceramide 
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channel where Bax and Bcl-xL exert their regulatory effects. Moreover, to investigate the 
binding site on Bcl-xL for ceramide, we tested specific inhibitors of Bcl-xL that bind to a 
known location on the protein. Molecular docking studies were conducted with ceramides 
and Bcl-xL inhibitors to probe for the ceramide binding site and reveal the lowest energy 
binding modes of these molecules to Bcl-xL. We offer mechanistic insights as to how the 
specific interactions we discovered could lead to the regulation of ceramide channels and 
discuss the implications of these results.   
 
5.3 MATERIALS AND METHODS 
5.3.1 Reagents 
N-Acetyl-D-erythro-sphingosine (C2-Cer), N-butyryl-D-erythro-sphingosine (C4-
Cer), N-octanoyl-D-erythro-sphingosine (C8-Cer), N-palmitoyl-D-erythro-sphingosine 
(C16-Cer), N-oleoyl-D-erythro-sphingosine (C18:1-Cer), N-arachidoyl-D-erythro-
sphingosine (C20-Cer), and N-lignoceroyl-D-erythro-sphingosine (C24-Cer) were obtained 
from Avanti Polar Lipids (Alabaster, AL). Antimycin A, 2,4-dinitrophenol (DNP), and 
fatty acid depleted bovine serum albumin (BSA) were purchased from Sigma (St. Louis, 
MO). The analogs of D-e-C16-ceramide and the analog T4 and L5 (Table 5.1) were 
synthesized as previously described (He et al., 2000a; He et al., 2000b; Usta et al., 2001; 
Bieberich et al., 2002; Brockman et al., 2004). Horse heart cytochrome c was purchased 
from Acros, 2-methoxyantimycin A3 was purchased from Enzo Life Sciences (Plymouth 




5.3.2 Preparation of rat liver mitochondria 
Rat liver mitochondria were isolated from male Sprague Dawley rats by 
differential centrifugation of tissue homogenates as described previously (Parsons et al., 
1966) and modified (Siskind et al., 2002). BSA medium was used to wash the liver 
during the excision and initial centrifugation steps and was removed by centrifugation at 
8700 RCF (twice) in BSA-free medium.  The final mitochondrial pellet was resuspended 
in ~3-5mL of ice cold sucrose free isotonic buffer FH (280 mM mannitol, 0.1 mM 
EGTA, 2 mM HEPES, pH 7.4). The mitochondrial intactness was determined from the 
rate of cytochrome c oxidation (vide infra) compared with the rate measured after mild 
hypotonic shock (Douce et al., 1987) as described below. The animal use protocols were 
approved by the Institutional Animal Care and Use Committee. The animals were 
euthanized by a procedure consistent with the Panel on Euthanasia of the AVMA.   The 
animal facility used to house the animals is accredited by AAALAC. 
5.3.3 Purification of recombinant proteins 
 Recombinant human Bax was purified as described previously (Suzuki et al., 
2000) and modified (Ganesan et al., 2010). One change made was to reduce the Tris 
concentration from 20mM to 10mM in both dialysis steps; this change had no effect of 
the activity of the protein. The protein was shell-frozen in small aliquots in thin-walled 
glass tubes using ethanol/dry ice and stored at -84ºC. A fresh monomeric Bax sample was 
thawed before each experiment. Standardizing the concentration of Bax to 5-10µg/mL 
with FH buffer (10mM Tris-HCl pH 8.0 solution could also be used) before activation 
improved reproducibility between different Bax preparations. This monomeric Bax was 
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activated using 10% β-octyl glucoside to a final concentration of 1% and incubated for 30 
min on ice; this activated Bax was used in the experiments throughout this study. Full 
length recombinant Bcl-xL was isolated as previously described (Basañez et al., 2001) 
and the following changes are recommend. Only 5mL overnight culture was inoculated 
into 1 L of LB media and this was allowed to incubate with shaking until OD600=0.600. 
The culture was then induced with 0.01mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG) for 2h at 37oC. After the cells were harvested by centrifugation, the pellet was 
resuspended in 40 mL of PBS and incubated on ice for 20 min with 140 U of lysozyme 
and 35 µM PMSF (final concentration). The cells were then subjected to two passes 
through a French press and centrifuged to remove cell fragments. The lysate was then 
incubated with glutathione-agarose beads for 2 h at 4oC and packed into a column. The 
beads were washed with 10 column volumes of cold PBS containing 35 µM PMSF and 
another 10 column volumes of 20 mM Tris-HCl, pH 8.0. 10 mL of the same buffer 
supplemented with 5 U of biotinylated thrombin were added to the column and allowed 
to incubate overnight at 4oC. The protein was eluted, and 80 µL of streptavidin beads 
were added to remove the remaining thrombin. After a 30 min incubation with rotation, 
the beads were removed by centrifugation and the sample was filter sterilized. Glycerol 
(10%) was added to the protein and 100 µL aliquots were rapidly shell frozen in ethanol/ 
dry ice. The published method included the addition of Triton-X100 to the cells along 
with the PMSF and lysozyme prior to French pressing of the cells. This greatly increased 
the yield (1.4 mg/mL with Triton vs. 165 µg/mL without Triton). Both methods resulted 




5.3.4 Cytochrome c oxidation assay 
The ability of cytochrome c to translocate through the MOM and become 
oxidized by cytochrome c oxidase (found on the mitochondrial inner membrane) is the 
rate limiting step thus this assay is a measurement of the permeability of the MOM.  
While measurements from mitochondrial release assays indicate that mitochondria were 
permeabilized at some time point, perhaps transiently, one of the advantages of using this 
dynamic cytochrome c oxidation assay is that real-time permeability of the MOM can be 
measured. Thus, this assay allows us to garner more information about the nature and 
stability of the channels in question. This assay was performed as previously described 
(Wojtczak et al., 1972) with the following modifications to optimize reproducibility as 
mitochondria were found to be more stable at higher concentrations. In a typical 
experiment, unless otherwise noted in the figure legends, mitochondria were diluted in 
FH buffer at 4oC to a concentration of 0.5 mg/mL, in small batches just before the assay. 
Then, 50 µL aliquots were dispersed in 650 µL of room temperature reaction buffer 
(160mM mannitol and 60mM KCl, 5 mM DNP and 1.3 µM antimycin A (antimycin A 
was tested in our system with Bcl-xL and ceramide and no effect was seen at the highest 
concentration tested which was 2.7 µM), pH 7.25). The final mitochondrial protein 
concentration was 36 µg/mL. The mitochondria were allowed to acclimate at room 
temperature for 5 min in a microfuge tube. Then ceramide or a ceramide analog 
(dissolved in 2-propanol at 1 mg/mL) was delivered to the mitochondria while the 
suspension was vortexed for 30 s to achieve effective dispersal of the sphingolipid. After 
dispersal, the mixture was incubated for 10 min at room temperature followed by addition 
of cytochrome c (12 µL; final concentration 27 µM) and immediate measurement of the 
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absorbance at 550 nm for a period of 2 min. The initial rate of decline of absorbance of 
reduced cytochrome c was used as a measure of the permeability of the outer membrane 
to cytochrome c; ε550 (red-ox) = 18.5 mM-1 cm-1.  The amount of vehicle added was less 
than 4% of the sample volume and all vehicle controls were treated in an identical way.     
Rates were corrected for the rate of oxidation observed with vehicle alone and this was 
very close to the untreated rate arising from a small number of damaged mitochondria. 
The maximal rate of cytochrome c oxidation was assessed by subjecting the mitochondria 
to mild hypotonic shock as previously described (Douce et al., 1987) with the following 
modifications.  Briefly, mitochondria were diluted in double distilled water to 1mg/ml 
and incubated on ice for 10 minutes before adding 2xFH buffer (FH buffer with double 
the amount of additives) to restore the isotonic conditions. 50uL of this 0.5mg/mL 
mitochondrial stock is then added to the reaction buffer and tested for cytochrome c 
oxidation as described below. In these experiments, the intactness of the mitochondrial 
preparations was greater than 85%. The rate of cytochrome c oxidation was converted to 
% permeabilization of mitochondria by taking this rate as a percentage of the maximal 
rate of oxidation obtained by subjecting the mitochondria to mild hypotonic shock. The 
permeabilization induced by ceramide alone is given for each experiment in the figure 
legends.  It is important to note that even a relatively low % permeabilization of 
mitochondria, as seen with our Bax experiments, is physiologically relevant (Kluck et al., 
1999; von Ahsen et al., 2000; Siskind et al., 2006) and even low levels of cytochrome c 
release are sufficient to induce apoptosis in whole cells (Li et al., 1997a; Zhivotovsky et 
al., 1998).  
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It should be pointed out that unlike liposomes, mitochondria are complex 
organelles whose function decays with time.  Thus we are limited in what experiments 
can be performed within the functional time window.  Also, it is necessary to monitor the 
state of the mitochondria.  Before experiments are performed the mitochondria are tested 
for the ability of C16-Cer to permeabilize the MOM and for the ability of the Bcl-2 family 
proteins to alter this permeabilization.  These tests are repeated as time passes to ensure 
that any results obtained in the experimental trials are meaningful.  The disadvantages of 
using a “living” organelle are more than compensated for by performing experiments in 
the natural membrane environment.  Clearly, the greatest level of understanding is 
reached by performing experiments at various levels of complexity, from the intact cell to 
the pure components in a defined system.       
5.3.5 Testing Bcl-2 proteins on channels formed by ceramide and its analogs 
The sensitivity of isolated mitochondria to permeabilization by added ceramide or 
analogs varied from one preparation to another. Therefore experiments with analogs were 
always performed in parallel with experiments with C16-Cer.  Furthermore, the amounts 
of C16-Cer and analog added were adjusted (dilutions were made to keep the volume 
added to the sample constant at 10 µL) so as to induce approximately the same extent of 
mitochondrial outer membrane permeabilization (MOMP).  This was done because some 
analogs of ceramide may insert more or less readily into mitochondria or have a different 
propensity for channel formation.  By finding conditions that result in the same degree of 
MOMP, we achieve the same level of channel formation. The permeabilization was 
measured as the rate of cytochrome c oxidation. Bax, Bcl-xL, 2-MeAA3, ABT-737, and 
ABT-263 were added along with the mitochondria for a 5 min incubation at room 
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temperature prior to sphingolipid dispersal. Stock solutions of 2-MeAA3 (1.9 mM in 2-
propanol), ABT-737 (0.7 mM in DMSO) and ABT-263 (0.7 mM in DMSO) were diluted 
to the appropriate concentration with the same solvent so that the volume added to reach 
the concentration indicated in the figure remained constant (10 µL, 5 µL, and 5 µL 
respectively). Results are shown as a % change comparing the effect of adding a Bcl-2 
protein in combination with ceramide (or an analog) vs. the addition of ceramide (or the 
analog) alone. 
5.3.6 Molecular docking simulations of potential Bcl-xL inhibitors 
Modeling, simulations and visualizations were performed using Molecular 
Operating Environment (MOE) Version 2011.10 (Chemical Computing Group Inc., 
Montreal, Canada).  Simulations were performed on a Dell E8500 with an Intel Core 2 
Duo @ 3.16 GHz using Windows XP OS. All other computational procedures were 
performed using a Dell XPS M1530 with an Intel Core2 Duo processor T8300@2.40 
GHz w 2GB RAM using Windows Vista OS. The structural file used as input for analysis 
and docking simulations was pdb: 1PQ1 (PubMed: 14499110).  Before analysis and 
simulations the main chain protein was protonated at pH 7.5 with a salt concentration of 
0.2 M and the structures energy minimized using the Amber99 forcefield and Born 
solvation model. Simulations focused on the entire protein surface and Bcl-xL was held 
rigid while the ligand was flexed. Initial placement calculated 500 poses per molecule 
using triangle matching placement with London dG scoring, the top 250 poses were then 
refined using forcefield placement and Affinity dG scoring.  The resulting interaction 
after refinement is called E score 2.  This is a measure of the strength of the interaction 
with stronger interactions yielding a more negative number.  Ligands were prepared in 
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MOE, protonated at pH 7.5, and chirality formalized within the ligand database. The top 
poses generated from each ligand were then minimized in place as a system with Bcl-xl 
to allow the protein to flex as well as the ligand.  System minimization also used the 
Amber99 forcefield and Born solvation model. 
5.3.7 Statistical analysis 
 All results shown are an average of 3-4 trials and each experiment was repeated 
on three separate mitochondrial preparations. Student’s t test was performed to obtain P-
values and identify a statistically significant change from the additive value (for Bax 
experiments) or individual C16-Cer or analog addition (for Bcl-xL experiments).  As a 
standard, * indicates P<0.05, ** indicates P<0.01, and *** indicates P<0.001. Error bars 
represent ± SE of 3-4 experiments. 
 
5.4 RESULTS AND DISCUSSION 
 Previous results (Siskind et al., 2008; Ganesan et al., 2010) have indicated that the 
recognition between the ceramide channel and Bcl-2 proteins is highly specific. These 
findings prompted the present study in which we used a dynamic cytochrome c 
accessibility assay to assess the influence of Bax and Bcl-xL on the ability of ceramide 
and its analogs to permeabilize the MOM. To determine the specific site(s) of interaction 
of these Bcl-2 proteins on ceramide channels, we prepared ceramide analogs with 
changes in different functional groups thought to be important for channel formation.  
The analogs that retained channel-forming ability are illustrated in Table 5.1. 
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Experiments with ceramide and an analog were performed in parallel. Before each 
experiment, the amounts of ceramide or ceramide analog were adjusted so as to induce 
approximately the same extent of MOMP.  In this way we compensated for any 
differences in the propensity for channel formation and tested the Bcl-2 family proteins 
on the same degree of channel presence.  As a result the ability of the Bcl-2 family 







Table 5.1 Structures of Ceramides and Analogs Used. 
Coded boxes highlight the key areas of the ceramide molecule that are important for ceramide 
channel formation (top). The codes indicate the location on the ceramide molecule where changes 
were introduced (S for stereochemistry, H for hydroxy group, T for trans double bond, A for 
amide linkage, L for hydrophobic chain length) and the analogs are named throughout the 
manuscript using these short codes followed by a number as indicated in the table. 
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When different doses of ceramide or ceramide analogs were applied to achieve a 
comparable degree of permeabilization, the amount of Bcl-2 family protein added was 
kept the same.  This is because the amount of protein added greatly exceeded the number 
of channels present (for additional details, see Supplemental Information).  Thus the 
binding is not of very high affinity or stoichiometry.  Previous studies showed that the 
channels are responsive to the effective concentration of added protein in a manner 
consistent with a dynamic equilibrium.  Thus despite adding different amounts of the 
sphingolipid to achieve the same degree of permeabilization, it makes sense to use the 
same effective dose of Bcl-2 family protein to detect differences in effect on channel-
mediated permeability.      
 The results described were obtained at room temperature whereas apoptosis, in 
mammalian cells, typically takes place at 37ºC.  Thus differences in rates of reaction, 
fluidity, etc. resulting for a difference in temperature could easily affect the reported 
values but are unlikely to change the fundamental conclusions about the specificity of the 
sites of interaction with ceramide associated with Bax and Bcl-xL. Indeed, key 
experiments reproduced at 37°C yield similar results as seen at 23°C (Fig 5.3A, 5.4C, 
5.8A, B), indicating the physical properties of this interaction remain at physiological 
temperatures.    
5.4.1 The Importance of the trans-Double Bond 
The following changes were introduced to the C4:C5 trans double bond of the 
sphingoid backbone of ceramide: C16-phytoceramide (T4), which has a hydroxy group at 
the C4 position instead of the double bond; C16-4,5-tb-ceramide (T5), which has a triple 
140	  
	  
bond in place of the double bond; and C16-(4,5-allene)-ceramide (T6), which is a 4,5-
cumulated diene. Previous results showed that the addition of either detergent-activated 
Bax or tBid-activated Bax along with C16-Cer to isolated rat liver mitochondria resulted 
in a much greater permeabilization of the MOM than either entity alone, indicating that 
Bax enhances the formation of ceramide channels (Ganesan et al., 2010). Here we look 
for a similar result on ceramide analogs. An example of the result of a typical paired 
experiment with C16-Cer and an analog (T5) is shown in Figure 5.1A. Detergent-
activated Bax (“Bax”) induces a small permeabilization while C16-Cer (“C16”) produces 
a more significant permeabilization. However, when both are added together (“C16 + 
Bax”), the resulting permeabilization is much greater than the value obtained by adding 
the values of the “Bax” and “C16” bars, “Predicted C16 + Bax.” The permeabilization 
induced by T5 was enhanced by the addition of Bax to a similar extent indicating that the 
modification had not influenced the ability of Bax to act on T5 channels. Similar paired 
experiments were performed with the other analogs. Fig 5.1B shows that Bax enhanced 
the permeabilization induced by T4 to the same extent as T5 but was 40% less effective 




Figure 5.1 Testing the ability of Bax, Bcl-xL to regulate channels formed in isolated rat liver 
mitochondria by ceramide analogs with changes in the C4:C5 trans double bond or extent 
of unsaturation. 
The cytochrome c oxidation assay was used to determine the degree of MOM permeabilization 
induced by the addition of ceramide or an analog and the enhancement or inhibition of this 
permeability in the presence of Bax or Bcl-xL respectively. A. A typical Bax/C16-Cer/analog 
experiment: the amount of “C16”-ceramide (10 µg) and “T5” (5 µg) added was adjusted so that 
they induced approximately the same extent of MOM permeabilization when added alone. The 
addition of Bax (3.5 nM) along with C16-Cer (“C16+Bax” column) and T5 (“T5+Bax” column) 
resulted in enhancement of the MOM permeability induced by ceramide and the analog. These 
tested combinations are compared to the permeability predicted by adding the effect of the 
respective individual treatments (“Predicted” columns; i.e. “Bax” + “C16” = “Predicted C16 + 
Bax”). B. Bax (3.5nM) can enhance channels formed by T4 (5 µg), T5 (5 µg) and T6 (5 µg) and 
is shown as a % increase in MOMP. C. A typical Bcl-xL/C16-Cer/analog experiment is shown 
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here and is conducted similarly to panel A. Bcl-xL (0.4 µM) inhibits C16-Cer (10 µg) channels 
and T5 (6 µg) channels to a similar extent. As Bcl-xL does not induce a detectible MOMP (see 
Fig. 6A) the combination treatments of “C16 + Bcl-xL” and “T5 + Bcl-xL” were compared to the 
individual treatments of C16-Cer and T5 respectively and subject to the same statistical analysis as 
stated below. D. Bcl-xL (0.4 µM) inhibited C16-Cer (10 µg), T4 (7.5 µg), T5 (6 µg), and T6 (5 
µg) channels to the same extent and is shown as a % decrease in MOMP. For efficiency, all 
experiments henceforth will be shown as % change in MOMP as in panels B and D of this figure. 
 
In Bcl-xL experiments (Fig. 5.1C), as in the Bax experiments, the doses of 
ceramide and analog used were adjusted so that the extent of MOMP induced was 
approximately the same. When Bcl-xL is present (“C16 + Bcl-xL” and “T5 + Bcl-xL”), 
the permeabilization was greatly reduced in both cases and by the same amount. The % 
decrease of permeabilization is shown in Fig 5.1D. Bcl-xL (0.4µM) inhibited ceramide 
channel formation in isolated mitochondria by nearly 80% (Fig. 5.1C). The same dose of 
Bcl-xL was similarly effective on T4, T5, and T6.  
Analogs in which changes to the double bond were made by introducing a 
hydroxy group in its place (T4), changing it to a triple bond (T5), or adding another 
double bond next to it (T6) were well tolerated by both Bax and Bcl-xL. Thus, the 
location of the C4:C5 double bond and the degree of unsaturation at this position have 
little influence on the ability of Bax or Bcl-xL to regulate these lipid channels.  
5.4.2 Importance of the C1 and C3 Polar Groups 
The C1 and C3 hydroxy groups of the ceramide are thought to hold adjacent 
columns of ceramide together to form the lumen of the ceramide channel. 3-O-Methyl-
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C16-ceramide (H2) has the C3-hydroxy group blocked yet this analog can still form 
channels (Fig. 5.2A), suggesting that the C1-hydroxy group is sufficient to stabilize the 
channel. Both Bax and Bcl-xL can exert their respective effects on H2, indicating that the 
C3-hydroxy group is not a site at which either protein interacts (Fig. 5.2 A,B).  
The effect of changing the configuration at C2 or C3 of ceramide was explored by 
using two stereoisomers: the enantiomer (2R,3S,4E) C16-ceramide (S1) and the 
diastereomer (2S,3S,4E) C16-ceramide (S2). Bax was unable to enhance channels formed 
by S1 (Fig. 5.2C). S1 is the mirror image of the natural ceramide and Bax is unable to 
recognize channels formed by S1. However, Bax was able to enhance channels formed 
by S2 to a similar degree as C16-Cer (Fig. 5.2D), where only the orientation of the C3-
hydroxy group is altered. Bcl-xL was able to inhibit channels formed by S1 and S2 (Fig. 
5.2E), although to a lesser degree than those formed by C16-Cer. These results indicate 
that the ability of Bax to interact with ceramide channels does not require access to the 




Figure 5.2 Tests of the ability of Bax, Bcl-xL to regulate ceramide analogs with changes to 
polar head groups or stereochemistry.A, B. Blocking the C3 hydroxy group does not reduce 
the channel’s sensitivity to 3.5 nM Bax (5 µg C16-Cer, 2 µg H2, yielding ~10% MOMP) or 
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0.4µM Bcl-xL (7.5 µg C16-Cer, 5 µg H2, yielding ~12% MOMP). C. Bax (2 nM) is sensitive to 
changes in the stereochemistry found in analog S1. Mitochondria were treated with 10 µg each of 
S1 and C16-Cer (~20% MOMP). D. Channels formed by analog S2 (5 µg) interact with Bax (3.5 
nM) similarly to those formed by C16-Cer (5 µg) (~8% MOMP). E. Bcl-xL (0.4 µM) inhibits C16-
Cer (3.5 µg) channels more strongly than those formed by S1 and S2 (10 µg and 3.5 µg resp. 
yielding ~10% MOMP). 
 
5.4.3 The Importance of the Amide N-H group of Ceramide 
In the current model of the ceramide channel, the amide N-H group is thought to 
form a hydrogen bond with the carbonyl group of another ceramide molecule (Anishkin 
et al., 2006). These intermolecular interactions allow for the assembly of ceramide 
columns. Analog A3, N-methyl-C16-ceramide, features a methyl group instead of the N-H 
group. MOMP induced by A3 was not enhanced by the addition of 3.5nM of Bax, 
whereas parallel experiments with C16-Cer resulted in a 40% enhancement (Fig. 5.3A, 
S1A). Thus, Bax is unable to influence the structure of channels formed by A3, possibly 
due to a requirement for binding to the N-H group. Bcl-xL also has a much reduced 
interaction with A3 but the effect is not completely diminished as with Bax (Fig. 5.3B).  
(2S,3R,4E)-C16-urea-ceramide (A4) is a potent channel former as half as much is needed 
to permeabilize the MOM to the level achieved by a given amount of C16-Cer (Fig. 5.3C).  
This could be attributed to the enhanced hydrogen-bonding ability afforded by the urea 
group and thus the potential to further stabilize ceramide columns. This change is 
opposite to that of A3 in terms of hydrogen bonding ability of the molecule and Bax 
addition resulted in a greater enhancement of A4 channels than C16-Cer channels.  
Perhaps the increased hydrogen-bonding ability also serves to increase the strength of the 
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interaction with Bax. Bcl-xL inhibits the A4 channels to the same extent as the C16-Cer 
channels (Fig. 5.3C, D) indicating that Bcl-xL is not sensitive to the modification.   
 
Figure 5.3 Bax is more sensitive than Bcl-xL to changes in the amide N-H group of 
ceramide. 
A. Blocking the amide nitrogen with a methyl group prevents Bax (3.5 nM) from enhancing 
channels made by A3 (10 µg of C16-Cer and A3 were added to induce approximately 10% 
MOMP). B. Bcl-xL (0.1 µM) is approximately 50% less effective on A3 (20 µg) than C16-Cer (6 
µg); however, Bcl-xL can still cause about a 35% decrease in the permeability induced by A3 
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channels (~11% MOMP). C, D. Analog A4 contains a urea group, which increases the hydrogen-
bonding ability of the molecule. While Bax is more effective on A4 than C16-Cer, Bcl-xL is 
similarly effective on both. For these experiments, 3.5 nM Bax, 0.1µM Bcl-xL, and 10 µg of C16-
Cer and 5 µg of A4 were used to induce approximately 22% MOMP. 
 
5.4.4 The Importance of Tail Length and Apolar Bulk 
The importance of the apolar region of ceramide for Bcl-2 protein interaction was 
tested with a minimal analog, N-palmitoyl serinol (L5). It only has one aliphatic chain. 
Bax was able to interact with L5 (Fig. 5.4A) almost as well as C16-Cer. Surprisingly, Bcl-
xL was not able to inhibit these channels at all (Fig. 5.4B). Likewise, the permeability 
induced by a very short-chain ceramide analog, C2-ceramide (C2-Cer), was also not 
inhibited by Bcl-xL (Fig. 5.4C, 5.8B).  To test whether this unexpected result was due to 
kinetic delays, the added doses of the ceramides was adjusted to achieve a similar MOMP 
by C2-Cer and C16-Cer alone.  Fifteen and 30 min incubations with Bcl-xL resulted in the 
same degrees of inhibition (Fig. 5.4D).  No effect of Bcl-xL on C2-Cer was seen at either 
time point whereas the same substantial level of inhibition of C16-Cer permeabilization 
occurred at each time point.  Thus, the inability of Bcl-xL to inhibit C2-Cer channels is 




Figure 5.4 Effects of analogs with altered hydrophobic regions on the regulation by Bcl-xL 
and Bax.  A. Bax (2 nM) enhances MOMP formed by L5 (10µg), which has a truncated 
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sphingoid base (10 µg of C16-Cer was used, ~30% MOMP). B. Bcl-xL (0.4 µM) does not inhibit 
channels formed by L5 (3 µg); 7.5 µg of C16-Cer was added here (~12% MOMP). C. Varying the 
length of the N-acyl chain of ceramide reveals an optimal acyl chain length for Bcl-xL (0.4 µM) 
inhibition of ceramide channels. 10 µg of C2-Cer - C18-Cer and C18:1-Cer was used. 7.7 µg each 
C20-Cer and C24-Cer were added in a volume of 13µL. Before addition of Bcl-xL, the amount of 
ceramide or ceramide analog used induced approximately 19% MOMP. D. Analysis of the time 
dependence of Bcl-xL interaction. 6 µg of C2-Cer and 12 µg of C16-Cer in a volume of 12 µL 
were added to induce a similar level of mitochondrial permeabilization (~40%). The addition of 
0.1 µM of Bcl-xL results in 60% inhibition of C16-Cer channels but does not cause any change in 
the permeability of C2-Cer channels during the time of a typical experiment, 15 min. Increasing 
the incubation time by 15 min does not abate the inability of Bcl-xL to recognize C2-Cer 
channels. 
 
Ceramide analogs with tail lengths varying between C2-C24 were tested and the 
results show an optimal length for the acyl chain of C16, C18 and C20.  Bcl-xL is known to 
have a hydrophobic groove and perhaps the optimal hydrocarbon bulk results in optimal 
binding. The introduction of an unsaturated bond in the acyl chain at C9:C10 of C18-Cer 
(C18:1-Cer) resulted in a large drop in sensitivity to Bcl-xL inhibition.  The kink in the 
fatty acyl chain may interfere with binding to Bcl-xL, indicating a very specific 
interaction.   
These results have important implications. Various long-chain and very-long 
chain ceramides are found in the MOM and the specific N-acyl chains of the naturally 
occurring ceramides in membranes are thought to play an important physiological role 
(Megha et al., 2007; Pruett et al., 2008; Grösch et al., 2011). In fact, ceramide synthases 
show specificity for different acyl-CoA substrates (Venkataraman et al., 2002; Riebeling 
et al., 2003; Mizutani et al., 2005; Laviad et al., 2008; Menuz et al., 2009), and some 
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preferentially generate long-chain ceramides such as C16-Cer or C24-Cer (Venkataraman 
et al., 2002; Mizutani et al., 2005). In the early stages of apoptosis, cells are reported to 
generate primarily C16-Cer along with some C18-Cer and C20-Cer (Kroesen et al., 2003; 
Siskind et al., 2010). C24-Cer generation occurs at later stages (Kroesen et al., 2003).  
This fits well with our observation that Bcl-xL interacts optimally with C16-, C18-, and 
C20-Cer as those species are elevated when the fate of the cell is still being decided. 
During this initiation stage of apoptosis, before the mitochondria have become 
permeabilized, various apoptotic signals result in the elevation of ceramides. Anti-
apoptotic Bcl-2 family proteins, like Bcl-xL and Bcl-2, could prevent these higher 
ceramide levels from forming channels resulting in MOMP.  Bax activation and 
heterodimerization with Bcl-xL would relieve this inhibition and, at the same time, any 
excess Bax could favor ceramide channel formation and/or growth. Clearly these 
interactions result in many opportunities for controlling this key, decision-making step. 
Many studies have been carried out with cell permeable C2- and C6-ceramides to 
trigger apoptosis in cancer cells. It is also evident that many enzymes that metabolize 
ceramide do not recognize C2-ceramide (Wijesinghe et al., 2005; Phillips et al., 2009) 
thus allowing these molecules to act over a longer time scale.  Interestingly, the ability of 
short and long-chain ceramides to form channels is about the same and mixtures of long 
and short-chain ceramides are actually more potent (Perera et al., 2012).  Thus, it is 
possible that these short-chain ceramides may be more effective than long chain 
ceramides therapeutically in promoting apoptosis because Bcl-xL is unable to recognize 
or regulate these species while Bax retains the ability to promote channel formation by 
these ceramides.  
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5.4.5 Inhibitors provide insights into the region of Bcl-xL that binds to the ceramide 
channel 
Cells overexpressing pro-survival proteins Bcl-xL and Bcl-2 are highly resistant 
to cell death and many types of cancer indeed display this phenotype. Three known 
small-molecule inhibitors of Bcl-xL and Bcl-2 are 2-MeAA3, ABT-737, and ABT-263. 
These inhibitors bind to the hydrophobic groove on Bcl-2 and Bcl-xL (Manion et al., 
2004; Wendt et al., 2006; Siskind et al., 2008; Tse et al., 2008), effectively neutralizing 
the effects of pro-survival protein overexpression and sensitizing cells to death.  Since 
Bcl-xL interacts with the ceramide channel through the hydrophobic region, the inhibitors 
should interfere with the interaction if binding involves the hydrophobic groove.     
Results from the 2-MeAA3 experiments are shown in Figure 5.5A. Whereas the 
highest concentration of 2-MeAA3 tested (2.7 µM) had no effect on ceramide induced 
permeabilization of the MOM, Bcl-xL (0.7 µM) inhibited the ceramide induced 
permeabilization by about 50%. 2-MeAA3 produced a dose-dependent recovery of 
ceramide-induced permeabilization, indicating that 2-MeAA3 might bind to the same site 
on Bcl-xL as the ceramide channel. Unlike 2-MeAA3, ABT-737 displayed a strong 
inhibition of ceramide permeabilization at 2.5 and 5 µM whereas lower concentrations 
had either no effect or a slightly stimulatory effect on ceramide permeabilization (Fig. 
5.5B).  In the presence of 0.7 µM Bcl-xL, ABT-737 produced a dose-dependent recovery 
of ceramide permeabilization with 50% recovery at about 1 µM and complete recovery at 
2.5 µM.  A strong inhibition of ceramide channels by ABT-737 is evident at 5 µM even 
in the presence of Bcl-xL. ABT-263, the orally available analog of ABT-737, was also 
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able to cause a dose-dependent recovery of ceramide permeabilization in the presence of 
Bcl-xL but did not inhibit ceramide permeabilization at any of the concentrations tested 
when Bcl-xL was not present (Fig. 5.5C). Thus the inhibitory effects of Bcl-xL on 
ceramide channels can be reversed by the addition of Bcl-xL-targeted inhibitors that bind 
to the hydrophobic groove, suggesting competition and that the hydrophobic groove is 




Figure 5.5. The hydrophobic groove of Bcl-xL is involved in binding to ceramide channels. 
Inhibitors known to bind to the hydrophobic groove of Bcl-xL were assayed for ability to prevent 
Bcl-xL binding to ceramide channels in isolated rat liver mitochondria. A.-C. Increasing 
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concentrations of 2-methoxyantimycin A3 (2-MeAA3), ABT-737 or ABT-263 were tested with 
C16-Cer alone (10 µg) and the combination of C16-Cer and Bcl-xL (0.7µM). 
 
 
Molecular docking of ceramides and inhibitors to Bcl-xL were conducted to 
determine the lowest energy site and mode of binding on Bcl-xL. The region of lowest 
energy binding was first determined probing the whole surface of Bcl-xL and the 
hydrophobic groove was the best, or near best, scored region for all ligands tested. The 
top 10 poses for each of the ligands are shown in Fig. 5.6 and the average energy of these 
were calculated and shown as a horizontal bar.  The more negative the number the 
stronger the interaction. ABT-737 and ABT-263 had the lowest energy score, and 
therefore best binding, followed by C16-ceramide. Especially noteworthy is the weaker 
average binding of C2-ceramide as compared to C16-ceramide, consistent with the 
experimental results.  To further explore the potential interaction between Bcl-xL and 
C16-ceramide, the lowest energy pose was subjected to global system energy 
minimization to allow both the protein and the ligand to flex. These results were 





Figure 5.6 E Score 2 of ten best poses of molecular docking simulations. 
Docking simulations of Bcl-xL to either C16-Cer (C16), C2-Cer (C2), ABT-737, ABT-
263, 2-methoxyantimycin A3 (2MeAA3), or palmitoyl-serine (P-Serine) yielded structures of 
various degrees of interaction energy.  The lower the E Score, the better the interaction.  The 
average of the 10 best interacting structures (poses) for each ligand is shown as a horizontal line. 
 
One of the top 10 poses shows ceramide binding to Bcl-xL with only one chain 
(Fig. 5.7A).  When this is placed on top of a segment of the model of a ceramide channel, 
this provides mechanistic support for a hypothetical mechanism by which Bcl-xL 




Figure 5.7 Molecular structures of C16-Cer bound to Bcl-xL from docking simulations and 
possible interaction with a ceramide channel. 
A. How Bcl-xL might bind to a ceramide molecule at the end of a ceramide column that is part of 
a ceramide channel.  One of the top poses of C16-Cer bound to Bcl-xL leaves one chain free.  This 
was lined up with a segment of the proposed structure of a ceramide channel, showing how Bcl-
xL might bind to the end of one ceramide column, disrupting the column’s interaction with the 
adjacent phospholipid bilayer.  B. C16-Cer nestled in the hydrophobic grove of Bcl-xL. This is 





Molecular dynamics simulations (Anishkin et al., 2006; Samanta et al., 2011) 
indicate that the ceramide channel forms an hourglass shape in the membrane, allowing 
the channel to properly interface with the phospholipid bilayer and thus avoiding 
exposure of apolar chains to the aqueous environment (Fig. 5.9, 5.10). This results in a  
 
 
Figure 5.8 The effect of Bax and Bcl-xL on the ability to regulate channels made of 
ceramide or ceramide analogs at 37°C. These experiments were conducted in an identical 
fashion as described in the Methods section except the experiments were conducted at a constant 
temperature of 37°C. A. Bax (3.5nM) enhances ceramide channels but not those formed of A3 
(2.5µg of C16-cer and 10µg of A3 were added in a volume of 10µL). B. Bcl-xL (0.4µM) can 
inhibit channels formed of C16-cer but not C2-cer (2.5µg of C16-cer and 10µg of C2-cer were 
added in a volume of 10µL). Results from both A and B are consistent with results obtained at 





Figure 5.9 Membrane curvature depends upon the intrinsic curvature of its lipid 
components. Membrane phospholipids are shown in black and ceramide is shown in red.  A. 
Intrinsic curvature is measure of size of the hydrophilic portion of a lipid relative to the 
hydrophobic region.  Cylindrical lipids where the head group and tail region are of similar 
relative size display zero curvature as shown in the plane of the membrane.  Positive intrinsic 
curvature results when the head group of the lipid is larger than the tail region leading to the 
formation of positive curvature of the membrane. The opposite is seen for lipids with negative 
intrinsic curvature.  B. Ceramide is thought to have dual curvature; ceramide is known to have 
negative intrinsic curvature (left, top), however, rotating the molecule reveals a positive curvature 
(left, bottom). This dual curvature allows for the formation of stable ceramide channels in 
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membranes as reveled by molecular modeling studies conducted by (Anishkin et al., 2006).  
Negative curvature of ceramide allows for the formation of a cylindrical pore in the plane of the 
membrane (middle) while the positive curvature of ceramide allows for the formation of positive 
curvature perpendicular to the plane of the membrane (right). Together, these features allow for 
the formation of stable transmembrane ceramide channels in the mitochondrial outer membrane.  
This figure and the subsequent supplemental figures were made using Microsoft Powerpoint and 
Adobe Photoshop software. 
 
Figure 5.10 Cross section of a ceramide channel in the membrane. Membrane phospholipids 
are shown in black as is the surface of the membrane and ceramide is shown in red. The 
hydrophobic region is shown in tan. A. A ceramide channel is shown here in red as a cylindrical 
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channel formed by columns of ceramide. The columns are held together by a network of 
hydrogen bonds. If the channel were to have a zero curvature (as shown), or a negative curvature, 
perpendicular to the plane of the membrane, this would lead to the exposure of the apolar region 
of ceramide. This is structure is energetically unfavorable and highly unstable in an aqueous 
environment. B. Molecular modeling studies reveal that ceramide channels could form a positive 
curvature perpendicular to the plane of the membrane. This stable structure is formed by a 
distortion of both the membrane phospholipids and the ceramide molecules at the channel-
membrane interface. This low-energy compromise effectively protects the hydrophobic region. 
Any factor that influence the channel between the two states illustrated in A and B can affect the 
stability of the channel and shift the dynamic equilibrium of ceramide to ceramide in the channel 
form or ceramide in the membrane. 
 
curvature in the ceramide columns forming the channel that is positive in the direction 
normal to the plane of the membrane (Anishkin et al., 2006). This curvature reduces the 
distortion of the phospholipids in close proximity to the ceramide channel. Thus 
interfacing the ceramide molecules that would tend to have their long axis parallel with 
the membrane plane with the phospholipids whose long axis is normal to that plane 
requires a compromise distortion of both to minimize the overall energy level. This low-
energy compromise might be interfered with by the interaction with Bcl-xL.  Bcl-xL 
could bind at this interface, displacing the local phospholipids and allowing the ceramide 
column to relax by reducing the positive curvature.  Evidence from the present study 
indicates that the hydrophobic groove of Bcl-xL is interacting with the hydrophobic 
chains of the ceramide molecules in a channel, chains that are buried within the 
membrane apolar environment. This is consistent with previous results by Siskind et al. 
2008, who demonstrated that a Bcl-xL deletion mutant missing the transmembrane 
domain is unable to disassemble ceramide channels suggesting that the membrane active 
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form of Bcl-xL is required for ceramide channel regulation. Thus the binding of Bcl-xL 
to the end of one column and resulting relaxation of that column (Fig 5.11) would result 
in a mismatch with the curvature of adjacent ceramide columns and thus the generation of 
mechanical stress.  The highly hydrogen-bonded structure of the channel would result in 
the propagation of the mechanical stress to the rest of the channel (Fig. 5.12).  This high 
energy structure would then lead to the destabilization of the channel, shifting the 
dynamic equilibrium toward channel disassembly. This mechanism is consistent with 
previous results (Siskind et al., 2008) that indicate the formation of a 1:1 complex 
between Bcl-xL and the channel, requiring that the effects of this binding propagate 




Figure 5.11 Model of Bcl-xL regulation of a ceramide channel. The membrane phospholipids 
and the surface of the membrane are shown here in black, ceramide molecules and the ceramide 
163	  
	  
channel is shown here in red. The hydrophobic region is shown in tan. A. Bcl-xL binding to the 
membrane displaces the phospholipids that form a continuous surface with the ceramide channel 
and contribute to forming the curvature that stabilizes the ceramide channel. The data from the 
present study indicate that Bcl-xL interacts with the apolar  region of the ceramide channel, which 
is embedded within the membrane, and this interaction involves the hydrophobic groove of Bcl-
xL.  B. Bcl-xL may bind the apolar  region of ceramide and influence positive curvature of the 
channel, possibly reducing this curvature to a zero or to a negative curvature as seen in C. 
Reduction of this positive curvature at the site of Bcl-xL binding would result in mechanical 
stress on adjacent columns, leading to the local exposure of the hydrophobic region (as seen in 
tan). Ceramide channels are composed of ceramide columns held together by a vast network of 
hydrogen bonds. As Bcl-xL induces a local destabilizing conformational change, this mechanical 
stress is propagated throughout the channel via the hydrogen bonded network (blue arrows), 





Figure 5.12 Model of the proposed influence of Bcl-xL binding on the stability of the 
ceramide channel.  The model described in Fig. 5.11 is illustrated differently here using a 
TrueSpace (Caligari Corp.) model.  A. The hydrogen bonded network of ceramide molecules that 
compose the polar surface of the ceramide channel are shown in blue. (Also seen in Fig 5.10B) B. 
The binding of Bcl-xL (green) to the aliphatic chain(s) of the ceramide at the end of a ceramide 
column in the channel should displace the phospholipids allowing the column to relax into a 
conformation with reduced positive curvature.  However, interaction with adjacent columns 
results in a structural mismatch illustrated as a red fracture area between the ceramide channel 
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and the surrounding phospholipids.  This should destabilize the adjacent columns leading to 
channel disassembly. 
 
As for Bax, the results indicate that the chirality of the molecule’s polar region 
and specifically the accessibility of the amide N-H group are key for Bax binding. This 
indicates that Bax may also be acting at the interface of the channel and the phospholipid 
membrane where there is access to the carboxamide group. However, unlike Bcl-xL, 
ceramide binding might favor the positive curvature of the ceramide columns, stabilizing 
the channel at the channel-membrane interface. This stabilization can result in the 
enlargement of ceramide channels to an optimal size (Fig. 5.13). Again these results are 
consistent with previous findings (Ganesan et al., 2010) as the binding of Bax influences 
the ceramide channel to enlarge to a size that fits optimally with the binding site of Bax. 
Previous results also indicated that multiple Bax structures bind to a single ceramide 




Figure 5.13 Model of activated-Bax regulation of a ceramide channel. The membrane 
phospholipids and the surface of the membrane is shown here in black, ceramide molecules and 
the ceramide channel is shown here in red. The hydrophobic region is shown in tan. A. Evidence 
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from this study indicates that Bax appears to be interacting with the top of the ceramide channel, 
where there is access to the amide N-H group, at the interface of the channel and the membrane. 
Bax may promote the stable conformation of the channel at this interface, as shown in B, 
allowing the channel and the membrane to interface correctly. The stabilizing effect of Bax is 
propagated throughout the channel (blue arrows) via the hydrogen bonded network of ceramide 
columns resulting in C. Bax has also been shown to enhance ceramide channel formation and the 
stabilizing effect of Bax may also allow for the enlargement of ceramide channels to an optimal 
size as indicated in studies published by (Ganesan et al., 2010). 
 
5.4.6 Concluding remarks 
Beyond the details, it is worth noting that highly-organized lipid assemblies, 
ceramide channels in this case, take a form dictated by the properties of their monomeric 
subunits and the environment in which they exist.  However, the forms of these 
superstructures can be modified by interactions with regulating molecules, in this case 
Bcl-2 family proteins.  Thus cells can control these superstructures at various levels: by 
controlling the supply of specific monomers at the membrane or cell compartment of 
interest, by changing the lipid environment of the membrane, and by producing proteins 
(or other regulating factors) that alter the form or stability of the final structure. Perhaps, 
in thinking about lipids one must go beyond thinking about lipid phases, fluidity, and 
phase transitions. Lipids can form superstructures with unique properties and the ability 
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In this dissertation, I presented my research on the multifaceted means of 
regulation of ceramide channels. Researching ceramide channels challenges one to look 
beyond the known scientific dogmas in the field of apoptosis and to look at the world of 
lipids in a new light. The ability of lipid monomers to self assemble into large stable 
channels is a novel idea but the precise molecular means of regulation would suggest this 
is no accident.  In the field of apoptosis, the general consensus in the cell biology 
community is that Bax and/or Bak channels are the likely means of MOMP during 
apoptosis however, the role of ceramide in apoptosis has long been appreciated by those 
who study lipids. Thus, a key deficit in the understanding of the big picture of the 
apoptotic scheme is due to the lack of cross talk between these fields and the integration 
of existing knowledge.  The work presented in this dissertation seeks to bridge this gap.  
It is clear that the properties of ceramide channels are in accordance with the known 
properties of the pore formed in mitochondria to initiate apoptosis and while Bax and/or 
Bak can form channels as well, the properties of Bax channels can vary widely (see 
section 1.3.1, 1.5.2). One of the biggest challenges facing the study of ceramide channels 
is the lack of pharmacological tools to detect ceramide channel formation in vivo and 
distinguish them from Bax or Bak channels. What is evident however is that there is a 
highly specific interaction between ceramide channels and the Bcl-2 family and the onset 
of apoptosis is not simply regulated by the action of proteins, but an intricate 
manipulation of lipid species as well. Understanding this relationship is key to piecing 
together the big picture of the apoptotic program as well as for its potential impact on 
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drug design and chemotherapeutics. In this chapter, I present feasible directions to 
explore in the study of ceramide channels.  
Visualization of ceramide channels in MOM vesicles.  
 In 2008, while presenting a poster on ceramide channels at a national conference, 
one passer-by, without even stopping to examine the work, posed this question to me, 
“have ceramide channels ever been visualized?” At the time, as the man walked away, 
my only retort was to ask, “how many channels, of any kind, have?” Needless to say, 
visual evidence is invaluable and thankfully, a couple of years later, my colleagues 
Soumya Samanta and Johnny Stiban were able to visualize ceramide channels formed in 
negative stained liposomes using TEM (Samanta et al., 2011).  Using the techniques they 
developed for that study, I would suggest to try to visualize ceramide channels in MOM 
vesicles as they more closely represent the physiological mitochondrial membrane 
environment. My colleagues also found that ceramide channels formed a continuum of 
sizes with an average of 10nm.  To this regard it would be quite interesting to examine 
the effect of Bax and Bcl-xL on ceramide channel formation and size. For Bax, would the 
average ceramide channel size detected increase and would the opposite happen for Bcl-
xL? Evidence from my work on Bax and Dr. Siskind’s work on Bcl-xL would suggest 
that pretreating the vesicles with Bax or Bcl-xL before ceramide would yield the same 
results as treating them after ceramide channel formation. These suggested studies would 





Understanding membrane specificity of ceramide channels. 
 Numerous studies indicate that ceramide can be generated in a number of 
subcellular compartments; however, channel formation is restricted to mitochondrial 
outer membranes.  Ceramide channel formation can easily be demonstrated in simpler 
membrane models such as liposomes and planar phospholipid bilayer membranes. The 
problem of interest is how the lipid composition of the mitochondrial outer membrane 
contributes to ceramide channel formation and what lipid compositions are unfavorable 
to ceramide channels. These questions can be explored by employing the use of 
liposomes with various lipid compositions where ceramide channel formation can easily 
be detected spectrophotometrically by assaying for the release of fluorescently labeled 
molecules (Stiban et al., 2006).   
The effect of Mcl-1 on ceramide channels 
 As described in chapter one, Bax and Bcl-xL are just two of a plethora of Bcl-2 
family proteins that play a role in regulating the permeability of the mitochondrial outer 
membrane. Mcl-1, like Bcl-xL, is an anti-apoptotic Bcl-2 protein but there is a key 
difference between the two: their hydrophobic groove. Studies have shown that the 
hydrophobic groove of Bcl-xL is larger and more flexible than that of Mcl-1 and 
compounds that can bind well to the hydrophobic groove of Bcl-xL and Bcl-2, cannot 
bind well to the hydrophobic groove of Mcl-1 (Lee et al., 2009; Dutta et al., 2010; Liu et 
al., 2010; Acoca et al., 2011).  Many studies have indicated that both Mcl-1 and Bcl-xL 
must be inhibited to induce apoptosis, thus the search for a pan-anti-apoptotic Bcl-2 
family protein inhibitor has garnered much interest for its value to cancer therapy 
173	  
	  
(Nijhawan et al., 2003; Nguyen et al., 2007; Dutta et al., 2010; Acoca et al., 2011).  The 
effect of purified Mcl-1 protein can be tested on ceramide channels on isolated 
mitochondria. Whether Mcl-1 can or cannot interact with ceramide channels may very 
well be related to the hydrophobic groove of the protein. If Mcl-1 does bind ceramide 
channels, Obatoclax, an inhibitor that specifically binds the Mcl-1 hydrophobic groove, 
could be tested for competition with ceramide. Regardless of the results, molecular 
docking studies could be used to estimate the binding energy of ceramide to Mcl-1 and 
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